



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Wednesday, 4. June 2025

Congress Opening

Date: **04/06/2025**

Institutional

Room: **Hall A Plenary Room**

08:00-08:45 CEST

Opening Lectures

Chair:	Monica Fontana (Italy)
08:00 - 08:02	Video Vienna
08:02 - 08:07	Welcome Words Speaker: Ivan Rychlik (Czech Republic)
08:07 - 08:22	Opening Lecture
08:22 - 08:32	Abstract Submission Speaker: Ronald Gansevoort (Netherlands)
08:32 - 08:42	Personal Highlights from the program
08:42 - 08:45	Congress official opening Speaker: Roser Torra (Spain)



Discover the ERA25 Scientific Programme.
 Please note that the information below is constantly being updated.

Wednesday, 4. June 2025

CME

Date: **04/06/2025**

Kidney Transplantation

Room: **Hall B**

09:00-11:30 CEST

CME 2 - Kidney Transplantation

Chair:	Rachel Hellemans (Belgium) Christophe Mariat (France)
09:00 - 09:05	Course Introduction Speaker: Christophe Mariat (France) Co-Speaker: Rachel Hellemans / (Edegem, Belgium)
09:05 - 09:35	Nephrologists' View on Frailty and Kidney Transplantation: Results from a European Survey Speaker: Arzu Velioglu (Türkiye)
09:35 - 10:05	Aging in Chronic Kidney Disease: From Translational Basics to Clinical Practice Speaker: Peter Stenvinkel (Sweden)
10:05 - 10:20	Break
10:20 - 10:45	Should We Accept This Frail Patient for Transplant? PRO Speaker: Helen Erlandsson (Sweden)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

10:45 - 11:10	Should We Accept This Frail Patient for Transplant? CON Speaker: Amaryllis Van Craenenbroeck (Belgium)
11:10 - 11:25	Panel Discussion
11:25 - 11:30	Take home message Speaker: Rachel Hellemans (Belgium) Co-Speaker: Christophe Mariat / (Saint-Etienne, France)

Wednesday, 4. June 2025

CME

Date: **04/06/2025**

Hypertension & Diabetes

Room: **Hall C**

09:00-11:30 CEST

CME 3 - Cardio-kidney metabolic disease

Chair:	Johannes Stegbauer (Germany) Marieta P. Theodorakopoulou (Greece)
09:00 - 09:05	Course introduction Speaker: Marieta P. Theodorakopoulou (Greece)
09:05 - 09:35	What are we doing here? The mechanism behind the pleiotropic effects of GLP1 agonists effects on cardio-kidney-metabolic health Speaker: Matias Trillini (Italy)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:35 - 10:05	State of the art and future concepts to reduce atherosclerotic vascular disease in chronic kidney disease Speaker: Jennifer Lees (United Kingdom)
10:05 - 10:20	Break
10:20 - 10:45	Is a cardiologist needed for the diagnosis and management of HFpEF in every CKD patient? PRO Speaker: Katharina Andrea Schütt (Germany)
10:45 - 11:10	Is a cardiologist needed for the diagnosis and management of HFpEF in every CKD patient? CON Speaker: Shanmugakumar Chinnappa (United Kingdom)
11:10 - 11:25	Panel Discussion
11:25 - 11:30	Take home message Speaker: Marieta P. Theodorakopoulou (Greece)

Wednesday, 4. June 2025

CME

Date: **04/06/2025**

Dialysis

Room: **Hall E1**



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:00-11:30 CEST

CME 4 - Hemo and PD

Chair:	Björn Meijers (Belgium) Lily Jakulj (Netherlands)
09:00 - 09:05	Course Introduction Speaker: Björn Meijers (Belgium) Co-Speaker: Lily Jakulj / (Amsterdam, Netherlands)
09:05 - 09:35	Overview of evidence-based strategies for cardiovascular risk reduction in dialysis patients Speaker: Sandip Mitra (United Kingdom)
09:35 - 10:05	Should dialysate sodium should be high? Speaker: Manfred Hecking (Austria)
10:05 - 10:20	Break
10:20 - 10:50	What is the best dialysis strategy for which patient? HD point of view Speaker: Casper F.M. Franssen (Netherlands)
10:50 - 11:20	What is the best dialysis strategy for which patient? PD point of view Speaker: Rumezsa Kazancioglu (Türkiye)
11:20 - 11:30	Take home messages Speaker: Lily Jakulj (Netherlands)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	Co-Speaker: Björn Meijers / (Leuven, Belgium)
--	-----------------------------------------------

Wednesday, 4. June 2025

CME

Date: **04/06/2025**

AKI & Critical Care Nephrology

Room: **Hall E2**

09:00-11:30 CEST

CME 5 - Acute kidney injury

Chair:	Marlies Ostermann (United Kingdom) Joana Gameiro (Portugal)
09:00 - 09:05	Course introduction Speaker: Joana Gameiro (Portugal)
09:05 - 09:35	Prevention of peri-operative AKI: anything new on the horizon? Speaker: Stanislas Faguer (France)
09:35 - 10:05	Fluid resuscitation and decongestion in AKI Speaker: Bairbre McNicholas (Ireland)
10:05 - 10:20	Break
10:20 - 10:50	RRT in AKI: Can we be greener? Speaker: Raymond Vanholder (Belgium)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

10:50 - 11:20	<p>Post-AKI follow-up: is it possible in real life? Round Table Speaker: Nicholas Selby (United Kingdom)</p> <p>Co-Speaker: Stanislas Faguer / (Toulouse, France), Bairbre McNicholas / (Galway, Ireland)</p>
11:20 - 11:30	<p>Take home message Speaker: Marlies Ostermann (United Kingdom)</p>

Wednesday, 4. June 2025

Work Shop

Date: **04/06/2025**

Hands-On Course

Room: **Hall G1**

09:00-12:00 CEST

HC 1: Morning Workshop - Vascular Access Catheter Placement

Chair:	<p>Maurizio Gallieni (Italy)</p> <p>Kate Stevens (United Kingdom)</p>
09:00 - 09:05	<p>Introduction Speaker: Kate Stevens (United Kingdom)</p>
09:05 - 09:20	<p>Minimising catheter associated infection Speaker: Maria João Teixeira Guedes Marques (Portugal)</p>
09:20 - 09:35	<p>Kinking and Tip position Speaker: Carlo Lomonte (Italy)</p>



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:35 - 09:50	Assessment and management of central vein stenosis and atrial thrombus Speaker: Peter Thomson (United Kingdom)
09:50 - 10:05	Discussion
10:05 - 10:20	Break
10:20 - 10:35	Demonstration Tunnelled Line Insertion & Non tunnelled Line insertion Speaker: Maurizio Gallieni (Italy)
10:35 - 11:30	Practice

Wednesday, 4. June 2025

Work Shop

Date: **04/06/2025**

Hands-On Course

Room: **Hall G2**

09:00-12:00 CEST

HC 3 - Morning Workshop: Renal Biopsy Techniques

Chair:	Emily McQuarrie (United Kingdom)
--------	----------------------------------



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	Loreto Gesualdo (Italy)
09:00 - 09:05	Introduction Speaker: Emily McQuarrie (United Kingdom)
09:05 - 09:20	Indications and epidemiology of native kidney biopsy Speaker: Emily McQuarrie (United Kingdom)
09:20 - 09:35	Practical aspect of Biopsy (video)
09:35 - 09:50	Practical pathology for Biopsy (Processing of the samples and tests)
09:50 - 10:05	Complications of Kidney Biopsy Speaker: Loreto Gesualdo (Italy)
10:05 - 10:20	Break
10:20 - 10:35	US demonstration Speaker: Amit Patel (United Kingdom)
10:35 - 11:30	Biopsy demonstration and Practice



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Wednesday, 4. June 2025

Work Shop

Date: **04/06/2025**

Hands-On Course

Room: **Hall G1**

13:00-16:00 CEST

HC 2: Afternoon Workshop - Vascular Access Catheter Placement (Repeat Session)

Chair:	Maurizio Gallieni (Italy) Kate Stevens (United Kingdom)
13:00 - 13:05	Introduction Speaker: Kate Stevens (United Kingdom)
13:05 - 13:20	Minimising catheter associated infection Speaker: Maria João Teixeira Guedes Marques (Portugal)
13:20 - 13:35	Kinking and Tip position Speaker: Carlo Lomonte (Italy)
13:35 - 13:50	Assessment and management of central vein stenosis and atrial thrombus Speaker: Peter Thomson (United Kingdom)
13:50 - 14:05	Discussion



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

14:05 - 14:20	Break
14:20 - 14:35	Demonstration Tunnelled Line Insertion & Non tunnelled Line insertion Speaker: Maurizio Gallieni (Italy)
14:35 - 15:30	Practice

Wednesday, 4. June 2025

Work Shop

Date: **04/06/2025**

Hands-On Course

Room: **Hall G2**

13:00-16:00 CEST

HC 4: Afternoon Workshop - Renal Biopsy Techniques (Repeat Session)

Chair:	Emily McQuarrie (United Kingdom) Loreto Gesualdo (Italy)
13:00 - 13:05	Introduction Speaker: Emily McQuarrie (United Kingdom)
13:05 - 13:20	Indications and epidemiology of native kidney biopsy Speaker: Emily McQuarrie (United Kingdom)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

13:20 - 13:35	Practical aspect of Biopsy (video)
13:35 - 13:50	Practical pathology for Biopsy (Processing of the samples and tests)
13:50 - 14:05	Complications of Kidney Biopsy Speaker: Loreto Gesualdo (Italy)
14:05 - 14:20	Break
14:20 - 14:35	US demonstration Speaker: Amit Patel (United Kingdom)
14:35 - 15:30	Biopsy demonstration and Practice

Wednesday, 4. June 2025

CME

Date: **04/06/2025**

Miscellaneous

Room: **Hall E2**

13:30-16:00 CEST

CME 6 - Onconeurology and Electrolytes



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chair:	Clara García Carro (Spain) Jolanta Malyszko (Poland)
13:30 - 13:45	Why Onconephrology? How to start an Onconephrology clinic Speaker: Jolanta Malyszko (Poland) Co-Speaker: Clara García Carro / (Madrid, Spain)
13:45 - 14:15	Debate: Kidney biopsy versus biomarkers and new diagnostic tools in immune check point inhibitors AKI Speaker: Maria Jose Soler Romeo (Spain)
14:15 - 14:45	Debate: Kidney biopsy versus biomarkers and new diagnostic tools in immune check point inhibitors AKI Speaker: Sandra Herrmann (United States of America)
14:45 - 15:00	Break
15:00 - 15:20	Cancer and advanced CKD: screening for neoplasia in dialysis and transplant waiting list, drug dosing and inclusion in oncological RCT Speaker: Ben Sprangers (Belgium)
15:20 - 15:40	Clinical case: TMA and cancer. Questions to answer and new therapeutic approaches Speaker: Steven Grange (France)
15:40 - 15:55	Panel Discussion



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:55 - 16:00	<p>Take home message Speaker: Jolanta Malyszko (Poland)</p> <p>Co-Speaker: Clara García Carro / (Madrid, Spain)</p>
---------------	-----------------------------------------------------------------------------------------------------------------------------------------

Wednesday, 4. June 2025

CME

Date: **04/06/2025**

Miscellaneous

Room: **Hall F1**

13:30-16:00 CEST

CME 10 - Renal pathology for nephrologists

Chair:	Pablo Cannata-Ortiz (Spain) Sandrine Florquin (Netherlands)
13:30 - 13:35	<p>Course introduction</p> <p>Co-Speaker: Sandrine Florquin / (Amsterdam, Netherlands)</p>
13:35 - 14:10	<p>Complement Stains and TMA spectrum: or alternatively: pitfalls in complement stains in C3GP and TMA Speaker: Agnieszka Perkowska-Ptasinska (Poland)</p>
14:10 - 14:45	<p>Transplant Renal Pathology - Updates from the Banff 2024 meeting Speaker: Candice Roufosse (United Kingdom)</p>
14:45 - 15:05	<p>Break</p>



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:05 - 15:25	AI in Renal Pathology Speaker: Peter Boor (Germany)
15:25 - 15:45	Role of Novel Imaging techniques in renal pathology diagnosis Speaker: Paola Romagnani (Italy)
15:45 - 15:55	Panel discussion
15:55 - 16:00	Take home message Co-Speaker: Sandrine Florquin / (Amsterdam, Netherlands)

Wednesday, 4. June 2025

CME

Date: **04/06/2025**

Miscellaneous

Room: **Hall E1**

13:30-16:00 CEST

CME 9 - Artificial intelligence for Nephrologists

Chair:	Olivier Aubert (France) Claudia Torino (Italy)
13:30 - 13:35	Course introduction Speaker: Olivier Aubert (France) Co-Speaker: Claudia Torino / (Reggio Calabria, Italy)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

13:35 - 14:05	AI and Machine Learning Demystified: Essential Concepts and Practical Insights Speaker: Valentin GOUTAUDIER (France)
14:05 - 14:25	Exploring the power of AI in Nephrology: useful or dangerous? PRO Speaker: Len Usvyat (United States of America)
14:25 - 14:45	Exploring the power of AI in Nephrology: useful or dangerous? CON Speaker: Pierpaolo Maio (Italy)
14:45 - 15:00	Break
15:00 - 15:55	Test you knowledge on AI and ML - dynamic session with poll and questions
15:55 - 16:00	Take home message Speaker: Olivier Aubert (France) Co-Speaker: Claudia Torino / (Reggio Calabria, Italy)

Wednesday, 4. June 2025

CME

Date: **04/06/2025**

Chronic Kidney Disease

Room: **Hall C**

13:30-16:00 CEST



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

CME 8 - CKD MBD and nephrolithiasis: Bone and Cardiovascular health in CKD-MBD an update

Chair:	Maria Fusaro (Italy) Mathias Haarhaus (Sweden)
13:30 - 13:35	Course introduction Speaker: Mathias Haarhaus (Sweden) Co-Speaker: Maria Fusaro / (Padova, Italy)
13:35 - 14:10	It's time to be aware of the fracture burden in CKD: Nephrologist defines the fracture risk profile of your patient Speaker: Hanne Skou Jørgensen (Denmark)
14:10 - 14:45	Vertebral fractures in chronic kidney disease: how to assess them and why Speaker: Maria Fusaro (Italy)
14:45 - 15:00	Break
15:00 - 15:30	Therapy in skeletal fragility with low or high turnover: Pros & Cons Speaker: Pieter Evenepoel (Belgium)
15:30 - 15:55	Romozumab: when the statistician through numbers helps the physician Speaker: Giovanni Luigi Tripepi (Italy)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:55 - 16:00	Take home message Speaker: Mathias Haarhaus (Sweden) Co-Speaker: Maria Fusaro / (Padova, Italy)
---------------	------------------------------------------------------------------------------------------------------------------

Wednesday, 4. June 2025

CME

Date: **04/06/2025**

**Physiology, cell biology & genetic
diseases**

Room: **Hall B**

13:30-16:00 CEST

CME 7 - Genetics for nephrologists

Chair:	Roman-Ulrich Mueller (Germany) Maria Vanessa Perez Gomez (Spain)
13:30 - 13:35	Course introduction Speaker: Roman-Ulrich Mueller (Germany) Co-Speaker: Maria Vanessa Perez Gomez / (Madrid, Spain)
13:35 - 13:55	The role of genetic testing - whom do we test? PRO Speaker: Emilie Cornec-Le Gall (France)
13:55 - 14:15	The role of genetic testing - whom do we test? CON Speaker: Matias Simons (Germany)
14:15 - 14:45	Ask the Expert: What's the current consensus in Alport syndrome? A focus on diagnostic strategies. Speaker: Beata S. Lipska-Ziętkiewicz (Poland)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

14:45 - 15:00	Break
15:00 - 15:15	Implementing ADPKD guidelines in clinical practice - expert guidance through clinical case examples Speaker: Emilie Cornec-Le Gall (France)
15:15 - 15:30	RNA-therapeutics - chance and challenge in genetic kidney disease Speaker: Roman-Ulrich Mueller (Germany)
15:30 - 15:50	Panel Discussion
15:50 - 16:00	Take home message Speaker: Roman-Ulrich Mueller (Germany) Co-Speaker: Maria Vanessa Perez Gomez / (Madrid, Spain)

Wednesday, 4. June 2025

CME

Date: **04/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Hall D**

13:30-16:00 CEST

CME 1 - Primary and secondary GN, vasculitis and autoimmune diseases



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chair:	Annette Bruchfeld (Sweden) Andreas Kronbichler (Austria)
13:30 - 13:35	Course introduction Speaker: Andreas Kronbichler (Austria) Co-Speaker: Annette Bruchfeld / (Stockholm, Sweden)
13:35 - 14:10	Prons & Cons - Plasma exchange in ANCA-associated vasculitis: is there still a role? PRO Speaker: David R. W. Jayne (United Kingdom)
14:10 - 14:45	Prons & Cons - Plasma exchange in ANCA-associated vasculitis: is there still a role? CON Speaker: Silke Brix (United Kingdom)
14:45 - 15:00	Break
15:00 - 15:25	It's not all about the kidney: what the nephrologist should know about extra-renal SLE Speaker: Y.K.Onno Teng (Netherlands)
15:25 - 15:50	The use of C5 inhibition in secondary thrombotic microangiopathy Speaker: Eleni Frangou (Cyprus)
15:50 - 16:00	Take home message Speaker: Annette Bruchfeld (Sweden)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Wednesday, 4. June 2025

Symposium

Date: **04/06/2025**

Institutional

Room: **Hall D**

16:15-17:15 CEST

General Assembly

Chair:	

Wednesday, 4. June 2025

Symposium

Date: **04/06/2025**

Institutional

Room: **Hall A Plenary Room**

17:30-18:30 CEST

Welcome Ceremony

Chair:	
17:30 - 17:35	Welcome words and Presidential address Speaker: Ivan Rychlik (Czech Republic)
17:35 - 17:40	Welcome words and Presidential address (Austrian Soc. Neph.)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:40 - 17:47	Presidential address
17:47 - 17:50	Diplomas and thanks
17:50 - 18:10	ERA Awards
18:10 - 18:25	Special Closure Speaker: Rainer Oberbauer (Austria)
18:25 - 18:26	Adjourn and invitation for the reception Speaker: Monica Fontana (Italy)
18:26 - 18:27	Video Glasgow

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Hypertension & Diabetes

Room: **Hall D**

08:15-09:45 CEST

Game changers in CKD and type 2 diabetes



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chair:	William Herrington (United Kingdom) Katherine R Tuttle (United States of America)
08:15 - 08:45	An update on GLP-1RA in Diabetic Kidney Disease: from ebb to FLOW Speaker: Peter Rossing (Denmark)
08:45 - 09:15	Aldosterone pathway inhibition when treated with RASi and SGLT2i: gaining CONFIDENCE? Speaker: Paola Fioretto (Italy)
09:15 - 09:45	SGLT2 inhibition in diabetic kidney disease: what's new in the last year? Speaker: Kaitlin Mayne (United Kingdom)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Glomerular & tubulo-interstitial diseases

Room: **Hall A Plenary Room**

08:15-09:45 CEST

Game changers in Kidney Vasculitis

Chair:	Fernando Caravaca Fontan (Spain) Sarah Moran (Ireland)
08:15 - 08:45	CD19-targeting CAR T cells for ANCA vasculitis Speaker: Adrian Schreiber (Germany)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:45 - 09:15	Complement inhibitors in ANCA-Vasculitis Speaker: Andreas Kronbichler (Austria)
09:15 - 09:45	Can we optimize clinicopathologic prognostication in AAV? Speaker: Silke Brix (United Kingdom)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Dialysis

Room: **Hall B**

08:15-09:45 CEST

Prevention and treatment of infections in haemodialysis patients – a real challenge of XXI century

Chair:	Valerie A. Luyckx (Switzerland) Gaetano Alfano (Italy)
08:15 - 08:45	Viral respiratory diseases – RSV, flu and COVID19 Speaker: An De Vriese (Belgium)
08:45 - 09:15	Clostridioides difficile infection Speaker: Marcin Adamczak (Poland)
09:15 - 09:45	Bacterial endocarditis Speaker: Laura Labriola (Belgium)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

--	--

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Hall C**

08:15-09:45 CEST

Sex as a game changer in kidney diseases

Chair:	Lucia Del Vecchio (Italy) Ivan Rychlik (Czech Republic)
08:15 - 08:45	Role of estradiol in AKI Sensitivity Speaker: Andreas Linkermann (Germany)
08:45 - 09:15	Women and kidney diseases: focus on hypertensive status in pregnancy and preeclampsia. Speaker: Giorgina Piccoli (France)
09:15 - 09:45	Why are females protected from kidney injury but develop preeclampsia? Speaker: Paola Romagnani (Italy)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

**Physiology, cell biology & genetic
diseases**

Room: **Hall E1**

08:15-09:45 CEST

Game changers in genetic diseases: gene therapy

Chair:	Roman-Ulrich Mueller (Germany) Albert Ong (United Kingdom)
08:15 - 08:45	Gene therapy in nephrology and beyond
08:45 - 09:15	Gene therapy for cystinosis Speaker: Elena Levtchenko (Netherlands)
09:15 - 09:45	Gene therapy perspectives for genetic podocytopathies Speaker: Moin Saleem (United Kingdom)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

AKI & Critical Care Nephrology

Room: **Hall E2**

08:15-09:45 CEST

Game changers in AKI diagnosis: coding out the creatinine

Chair:	Bairbre McNicholas (Ireland)
--------	------------------------------



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	Nicholas Selby (United Kingdom)
08:15 - 08:45	Biomarkers vs AI Speaker: Marlies Ostermann (United Kingdom)
08:45 - 09:15	Patterns in the labs- can this tell us what we dont know Speaker: Greet De Vlieger (Belgium)
09:15 - 09:45	Alphabet soup- Unleashing the data in free text to recognise AKI Speaker: Conor Judge (Ireland)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Kidney Transplantation

Room: **Hall F1**

08:15-09:45 CEST

Game changers in organ shortage: xenotransplantation?

Chair:	Ilaria Gandolfini (Italy) Mario Schiffer (Germany)
08:15 - 08:45	Social Implication of xenotransplantation
08:45 - 09:15	What's Next in Making Xenotransplantation a Reality for Our Patients? Speaker: Vineeta Kumar (United States of America)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:15 - 09:45	Virus Safety of Xenotransplantation Speaker: Joachim Denner (Germany)

Thursday, 5. June 2025

Free Communication

Date: **05/06/2025**

Hypertension & Diabetes

Room: **Hall G2**

08:15-09:45 CEST

FC 2: More about the New Pillars of Treatment

Chair:	
08:15 - 08:37	The effect of canagliflozin dose on cardiovascular and renal outcomes in patients with type 2 diabetes and high cardiovascular risk
08:37 - 08:59	IMPACT OF DIABETES, ALBUMINURIA, ACUTE EGFR DIP, AND DISEASE SEVERITY ON THE EFFECTS OF EMPAGLIFLOZIN ON PROGRESSION OF CHRONIC KIDNEY DISEASE. Speaker: William Herrington (United Kingdom)
08:59 - 09:21	Effect of finerenone on eGFR slope across different levels of baseline albuminuria: Insights from FINEARTS-HF Speaker: Finnian R. Mc Causland (United States of America)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:21 - 09:43	Real-World Outcomes of Switching from steroidal mineralocorticoid receptor antagonists (sMRA) to Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes (T2DM): A Multicenter Study in Madrid Community.
---------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Thursday, 5. June 2025

Focused Oral

Date: **05/06/2025**

Physiology, cell biology & genetic diseases, Focused Orals

Room: **Focused Oral Room 1**

08:15-09:45 CEST

Physiology, cell biology & genetic diseases

Chair:	
	Depot-specific metabolic and thermogenic profiles in perirenal and renal sinus adipose tissue Speaker: Maria K. Svensson (Sweden)
	Development and characterization of 3D models based on Urine derived Renal Epithelial Cells Speaker: Valeria Pizzuti (Italy)
	Mechanosensitive Cation Channel Piezo1 Regulates AQP2 Expression in Collecting Ducts of the Kidney



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	A glomerulus-on-chip to study glomerular cell interactions
	Discoidin Domain-containing Receptor 2 in pericyte plays a crucial role in AKI-CKD continuum
	Cysteinyl tRNA synthetase-2 is involved in cisplatin-induced acute kidney injury
	Epigenetic and transcriptional landscape of the kidney in heart failure with preserved ejection fraction
	Mettl3-mediated m6A methylation of Ndrp1 promotes acute kidney injury sensitivity in diabetic kidney diseases
	Exploring Exosome-Mediated Effects on Renal Pathology in Anderson Fabry Disease
	The nephronophthisis protein GLIS2/NPHP7 is required for the DNA damage response in kidney tubular epithelial cells Speaker: Gisela Slaats (Netherlands)
	Primary Hyperparathyroidism induces Erythropoietin resistance through FGF23



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	<p>Establishing a co-culture system to identify key paracrine and endocrine interactions between myoblasts and osteoblasts Speaker: Limy Wong (Australia)</p>
	<p>Mitochondrial Oxidative Phosphorylation in Human Proximal Tubular Epithelial Cells Is Impaired by Iron Deficiency-Additional Report- Speaker: Toshiyuki Imasawa (Japan)</p>
	<p>MYELOID SRC-FAMILY KINASES AND THEIR ROLE IN VARIOUS FORMS OF KIDNEY INFLAMMATION Speaker: Lukács Lesinszki (Hungary)</p>
	<p>Pathological role of Neuroaminidase-1 in Nephrotic Syndrome Speaker: Xhuliana Kajana (Italy)</p>

Thursday, 5. June 2025

Free Communication

Date: **05/06/2025**

Physiology, cell biology & genetic diseases

Room: **Hall K**

08:15-09:45 CEST

FC1: Genetics of Kidney Disease: from Big Data to Small Stones

Chair:

--	--



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:15 - 08:33	Deciphering the genetic architecture of urinary stone disease using 100K Genomes Data
08:33 - 08:45	Genealogical Analysis in the Era of Big Data: Implications for Biomedical Research
08:45 - 08:57	ENHANCING DIAGNOSTIC PRECISION FOR INHERITED KIDNEY DISEASES: THE IMPORTANCE OF DATABASES. Speaker: Leonor Fayos de Arizón (Spain)
08:57 - 09:09	Urinary myeloid bodies as a biomarker for early diagnosis and monitoring of enzyme replacement therapy in Fabry disease
09:09 - 09:21	SGLT2 Inhibitors in adult patients with Alport Syndrome: a single center Italian experience
09:21 - 09:33	Genetically determined reduction of renal carbonic anhydrase 12 is associated with decreased kidney function and increased serum urate
09:33 - 09:45	Discovery of a rare vitamin D receptor defect as an inherited cause of kidney stones in Malta Speaker: Julian Delicata (Malta)



Discover the ERA25 Scientific Programme.
Please note that the information below is constantly being updated.

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Creative Labs

Room: **Hall G1**

08:15-09:45 CEST

Creative Labs 1 - Top tips for the ESENeph exam

Chair:	
08:15 - 09:45	Top tips for the ESENeph exam Speaker: Ana Carina Ferreira (Portugal)

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Focussed Oral Room 2**

08:15-09:45 CEST

Glomerular & tubulo-interstitial diseases

Chair:	
08:15 - 08:20	Long-term prognosis of lupus nephritis: comparison between pediatric, adult, and advanced age onset



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:20 - 08:25	Machine Learning-Based Plasma Proteome Signatures Including > 5,000 Protein Levels Distinguish Glomerulonephritis Subtypes
08:25 - 08:30	Predictive Value of Gd-IgA1, Poly-IgA in the Treatment of IgA Nephropathy with Targeted Release Formulation-Budesonide.
08:30 - 08:35	Sparsentan reversibly decreases mesangial IgA deposition in gddY mice; a possible role for mesangial-cell -surface autoantigen expression.
08:35 - 08:40	Targeted release budesonide (TRB) can effectively reduce proteinuria when active lesions are present in IgA Nephropathy (IgAN) patients: A multicenter study Speaker: CHRISTODOULOS KESKINIS (Greece)
08:40 - 08:45	Association of cardiovascular and renal involvement in patients with granulomatosis with polyangiitis and microscopic polyangiitis
08:45 - 08:50	Rapid diagnosis of membranous nephropathy based on serum Raman spectroscopy combined with deep learning methods
08:50 - 08:55	Using national hospital discharge data to estimate the clinical and economic hospital burden and care pathways of patients with ANCA-associated vasculitis in Italy Speaker: Federico Alberici (Italy)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:55 - 09:00	Effects of sodium-glucose cotransporter 2 inhibitors on proteinuria and kidney function in glomerulonephritis and glomerulopathy of different etiologies undergoing induction immunosuppression therapy
09:00 - 09:05	Nomogram-based prediction of tubulointerstitial lesions in lupus nephritis patients Speaker: Zishan Lin (P.R. China)
09:05 - 09:10	The impact of kidney relapse on long-term kidney function in ANCA-associated vasculitis Speaker: Lisa Uchida (United Kingdom)
09:10 - 09:15	Predictors and long-term outcomes of glucocorticoid discontinuation in an inception cohort of lupus nephritis patients with a 10-year follow-up
09:15 - 09:20	Daratumumab-based regimens vs conventional clone-directed treatment in relapsed/refractory non-amyloid monoclonal immunoglobulin related kidney disease
09:20 - 09:25	Prognostic significance of Soluble urokinase-type plasminogen activator receptor (suPAR) in patients with glomerulonephritis: Association with renal outcomes Speaker: Ji-Young Choi (Korea, Rep. of South)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:25 - 09:30	Insights into Geographic Patterns, Urban-Rural Contrasts, and Healthcare Disparities in Glomerular Disease Incidence in a Canadian Province
09:30 - 09:35	Effects of Sparsentan After Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients With IgA Nephropathy (IgAN) in the PROTECT Trial Speaker: Jürgen Floege (Germany)

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Glomerular & tubulo-interstitial diseases

Room: **Focussed Oral Room 3**

08:15-09:45 CEST

Glomerular & tubulo-interstitial diseases

Chair:	
08:15 - 08:21	Trends in Diagnosis, Renal Progression, and Therapeutic Impact on Survival in AL Amyloidosis
08:21 - 08:27	Predictors of disease activity in ANCA-associated vasculitis subtypes: A statistical and predictive analysis



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:27 - 08:33	Clinical significance of punctate podocyte IgG staining in primary diffuse podocytopathy
08:33 - 08:39	Urinary Markers of Inflammation and Damage in Anti-GBM Disease Before and After Treatment with Imlifidase
08:39 - 08:45	The clinical and histological long-term effects of two different anti-CD20 regimens in a large series of Fibrillary Glomerulonephritis Speaker: Martina Marchisio (Italy)
08:45 - 08:51	Plasma exosomal MiR-15a-5p levels are associated with SMAD7/TGFβ1 podocyte signaling pathway in lupus nephritis
08:51 - 08:57	Serum Inflammatory Biomarkers in IgA nephropathy: Insights from a Swedish Cohort with 25 years of follow-up Speaker: Jacqueline Haller (Sweden)
08:57 - 09:03	Modified NIH Activity and Chronicity Indices In IgA Nephropathy: Chronicity as a Predictor of Renal Outcomes
09:03 - 09:09	Long-term safety and efficacy of the combination of Belimumab and Rituximab in the treatment of severe and refractory SLE: a preliminary report



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:09 - 09:15	Association of Complement deposition with clinical phenotype in Lupus nephropathies (LN)
09:15 - 09:21	Kidney Injury Molecule-1 and Beta-2-microglobuline significance in lupus nephritis
09:21 - 09:27	Lupus nephritis outcomes in patients with acute kidney injury and rapidly progressive glomerulonephritis presentation - cohort of a tertiary center
09:27 - 09:33	Complement 3 (C3) Staining and Glomerular Inflammation in Immunoglobulin A Nephropathy (IgAN): Real-World Biopsy Data in the United States (US)
09:33 - 09:39	Clinical characteristics and disease progression in primary IgA nephropathy patients in the Netherlands
09:39 - 09:45	Treatment response in lupus podocytopathy: Long-term experience of a tertiary center
09:45 - 09:51	CD163+ MACROPHAGES: A PROGNOSTIC MARKER IN ANCA VASCULITIS?



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

--	--

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 4**

08:15-09:45 CEST

Chronic kidney disease

Chair:	
08:15 - 08:21	Roxadustat Treatment of Anaemia in Chronic Kidney Disease (CKD) in Real-World Clinical Practice: Observational Study Using Secondary Data from the QuANT-Registry in Germany Speaker: Frank-Peter Tillmann (Germany)
08:21 - 08:27	Evidence of impaired myocardial perfusion reserve in asymptomatic non-diabetic patients with advanced CKD Speaker: Thomas Anderton (United Kingdom)
08:27 - 08:33	Responsiveness to Roxadustat in Non-dialysis Chronic Kidney Disease Patients with Anemia by Baseline Iron Status: A Secondary Analysis of the ROXSTAR Registry
08:33 - 08:39	Explaining the gap between guidelines and practice in myocardial infarction care for people with chronic kidney disease.



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:39 - 08:45	<p>Reduced arterial stiffness in children with CKD under long-term growth hormone treatment Speaker: Stella Stabouli (Greece)</p>
08:45 - 08:51	<p>Effects of long-term GH treatment on FGF23/Klotho axis in pediatric patients with CKD Speaker: Stella Stabouli (Greece)</p>
08:51 - 08:57	<p>The kynurenine-to-tryptophan ratio (KTR) in serum is an import predictor of overall and cardiovascular mortality in CKD, independent of gut microbiome Speaker: Ward Zadora (Belgium)</p>
08:57 - 09:03	<p>Phenylacetylglutamine's role in the link between uremic toxins and cognition in chronic kidney disease: a CKD-REIN cohort study Speaker: Helene Levassort (France)</p>
09:03 - 09:09	<p>Severe chronic kidney disease increases the risk of appendicular fractures in postmenopausal women Speaker: Satu Keronen (Finland)</p>
09:09 - 09:15	<p>Modulating ER-Mitochondrial Crosstalk with Kunkuibaoshen Granules: A Novel Strategy to Combat Renal Fibrosis in CKD Speaker: Weilong Xu (P.R. China)</p>
09:15 - 09:21	<p>Dysregulation in Slc20a1/Slc20a2 Associated with Myocardial-Bone Axis in Mild Chronic Kidney Disease – Mineral and Bone Disorder: Experimental Study Speaker: Evdokia Bogdanova (Russia)</p>



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:21 - 09:27	An novel lectin-mediated sorting protocol for renal tubules as an innovative multi-purpose tool advancing kidney research
09:27 - 09:33	Annexin A13 inhibits renal fibrosis by inhibiting senescence-associated secretory phenotype in tubular epithelial cells
09:33 - 09:39	Anti-Fibrotic Profile of a Next-Generation AT2 Receptor Agonist in Human Fibrotic Kidney Tissue Speaker: Johanna Gräns (Sweden)
09:39 - 09:45	Pirfenidone, a drug intended to treat idiopathic pulmonary fibrosis, prevented CKD progression in an experimental model of hypertensive nephrosclerosis

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 5**

08:15-09:45 CEST

Chronic kidney disease

Chair:	
08:15 - 08:21	Clinical Frailty Scale, Surprise Question and one-year mortality in older patients approaching kidney failure



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:21 - 08:27	High dietary phosphate and disuse-induced bone loss blunt the acute rise in serum phosphate following an oral challenge
08:27 - 08:33	A prospective observational cohort study analysing how infertility affects quality of life of patients with and without chronic kidney disease (CKD) using the FertiQOL questionnaire Speaker: Rouvick Gama (United Kingdom)
08:33 - 08:39	The Microbiome and Its Metabolites Promote Cardiac Remodeling in Chronic Kidney Disease via the AhR-IL17A Axis
08:39 - 08:45	The Copper/Zinc balance and anemia in patients with reduced glomerular filtration rate, data from the National Health and Nutrition Examination Survey (NHANES).
08:45 - 08:51	MHR as a biomarker for kidney function decline and cardiovascular disease in a large cohort of geriatric patients.
08:51 - 08:57	Fracture incidence and risk factors in peritoneal dialysis patients
08:57 - 09:03	Bone Turnover and Bone Density in Chronic Kidney Disease: a Translational Study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:03 - 09:09	Differentially expressed Bone miRNAs in Low and High Bone Turnover in Chronic Kidney Disease: a pilot study
09:09 - 09:15	CKD-associated osteoporosis in an academic dialysis unit: a wake-up call
09:15 - 09:21	Exploring the Impact of Medication Adherence, Beliefs, Perceptions, and Psychological Factors on Blood Pressure Control in Elderly CKD Patients Speaker: Bülent Demirelli (Türkiye)
09:21 - 09:27	Desidustat in Chronic Kidney Disease Anaemia: Real-World Experience and Outcomes Speaker: Syeda Hurmath (India)
09:27 - 09:33	The relationship between the central obesity and early kidney injury in a community cohort

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Dialysis

Room: **Focussed Oral Room 6**



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:15-09:45 CEST

Dialysis

Chair:	
08:15 - 08:21	Loop Diuretics in Anuric Hemodialysis Patients: An Unexplored Avenue for Removal of ProteinBound Uremic Toxins Speaker: Didier Sánchez Ospina (Spain)
08:21 - 08:27	ROLE OF A LOW-PROTEIN DIET BASED ON ESSENTIAL AMINO ACIDS AND KETOANALOGUES IN CARDIOPROTECTION IN SHR RATS WITH RENAL DYSFUNCTION
08:27 - 08:33	Correlation between protein energy wasting and cognitive impairment in maintenance hemodialysis patients
08:33 - 08:39	Multi-Organ Ultrasound in Dialysis: A New Frontier in Blood Volume Quantification
08:39 - 08:45	Relationship between antioxidant nutrients intake and oxidative stress in patients treated with hemodialysis Speaker: Flaviu Bob (Romania)
08:45 - 08:51	Age-Related Cardiovascular Disease Burden in Dialysis: Insights from ApolloDialDb



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:51 - 08:57	Data-driven clustering of secretory bone markers to risk-stratify hemodialysis patients: Insights from a multicentric, prospective observational study Speaker: Simon Aberger (Austria)
08:57 - 09:03	Integrating Palliative Care into Nephrology: A Single-Center “action-research” process
09:03 - 09:09	Relationship between Changes in Bone Responsiveness to Parathyroid Hormone and Bone Mineral Density in Patients on Chronic Haemodialysis
09:09 - 09:15	Tenapanor administration combined with phosphate binders provides synergistic phosphate lowering effect Speaker: Hiroshi Kikuchi (Japan)
09:15 - 09:21	Effects of a group exercise program supported by audiovisual media on muscle strength of people on maintenance hemodialysis: a pilot study
09:21 - 09:27	Outcomes of Bioprosthetic and Mechanical Valve Replacement in Hemodialysis Patients
09:27 - 09:33	Impact of Atrial Fibrillation on Cardiac Remodeling in Patients on Dialysis: Insights from a Longitudinal Study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:33 - 09:39	FEASIBILITY AND SAFETY OF A GROUP EXERCISE PROGRAM SUPPORTED BY AUDIOVISUAL MEDIA DURING HEMODIALYSIS (GREXID): AN EXPERIMENTAL STUDY
09:39 - 09:45	Real-World Effectiveness of Patiromer Among Hemodialysis (HD) Patients Prescribed Various Treatment Schedules Over a One-Year Follow-Up

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Dialysis

Room: **Focussed Oral Room 7**

08:15-09:45 CEST

Dialysis

Chair:	
08:15 - 08:21	Strong-HD-VIE - Prevalence of Strongyloides stercoralis infection in hemodialysis patients in Vienna, Austria
08:21 - 08:27	Utilization of Telemedicine for Patients Receiving In-center Hemodialysis in the United States



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:27 - 08:33	Symptoms burden in Dialysis Patients: Determinants and Impact on Mortality
08:33 - 08:39	Characteristics and Outcomes of Culturally and Linguistically Diverse Patients Receiving Kidney Replacement Therapy in Australia: Insights from a Nationwide Registry Study (CALD-KF study)
08:39 - 08:45	SLEEP DISORDERS IN HEMODIALYSIS PATIENTS ENROLLED IN A TERTIARY HOSPITAL IN DAVAO CITY Speaker: Richelle May Cajoles-Pagarigan (Philippines, The)
08:45 - 08:51	Sodium Balance in Hemodialysis and Hemodiafiltration: Real-World Insights from Spanish Clinics
08:51 - 08:57	A Multidisciplinary Team Delivered Deprescribing Intervention for Patients with Chronic Kidney Disease in Qatar: A Pilot Randomized Controlled Trial
08:57 - 09:03	Effect of individualized dialysate bicarbonate concentration on patient prognosis: A multicenter retrospective study
09:03 - 09:09	Impact of dialysis initiation on drug use patterns in older patients: Results from the French national renal replacement therapy registry matched with the national health data system (SNDS)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:09 - 09:15	Greenhouse gas emissions from the special waste incineration: a comparative analysis between a large Dialysis Center and a University Hospital.
09:15 - 09:21	Impact of fluid overload changes within the first 6 months of dialysis on hospitalization during a two-year follow-up
09:21 - 09:27	Mediterranean Diet and Serum Phosphorus in hemodialysis: Beyond Food Phosphorus Content. Speaker: Inês Pastor Neto (Portugal)
09:27 - 09:33	Implementing a Clinical Governance and Performance Benchmarking Model in Dialysis: The DaVita Quality Index Experience in Brazil
09:33 - 09:39	The Impact of a Clinical Governance Program on Mortality and Hospitalization Rates in Dialysis: The DaVita Quality Index Experience in Brazil
09:39 - 09:45	Impact of haemodialysis timing before kidney transplant surgery on early postoperative outcomes



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Kidney Transplantation

Room: **Focussed Oral Room 8**

08:15-09:45 CEST

Kidney Transplantation

Chair:	
08:15 - 08:20	Prediction of BK Polyomavirus associated nephropathy by the NEPHROVIR method in kidney transplant recipients with BK Polyomavirus-DNAemia
08:20 - 08:25	IMPACT OF PROTON PUMP INHIBITOR USE ON RENAL FUNCTION IN KIDNEY TRANSPLANT RECIPIENTS: A LONGITUDINAL COHORT STUDY Speaker: Hiba Azar (Lebanon)
08:25 - 08:30	SGLT2 inhibitors Reduce the eGFR Slope in Diabetic and Non-diabetic Renal Transplant Recipients
08:30 - 08:35	Use of Radiofrequency Echographic Multi Spectrometry (REMS) and Cardio-Ankle Vascular Index (CAVI) to evaluate the effects of immunosuppressive (IS) drugs on bone and vessel disease in renal transplant (RTX) patients.



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:35 - 08:40	Long Term Monitoring of Torque Teno Virus Load for the Detection of Infections in Kidney Transplantation
08:40 - 08:45	Evaluating Causes of Diarrhea in Renal Transplant Recipients using Stool Multiplex PCR Assay and its Impact on Graft Function
08:45 - 08:50	Association of Early Post-Donation Weight Gain with Kidney Function in Obese Living Kidney Donors
08:50 - 08:55	CMV Infection in CMV-Seropositive Kidney Transplant Recipients: does pretransplant CMV IgG titer matter?
08:55 - 09:00	Graph Neural Networks in the Nephropathological Diagnosis of Antibody-Mediated Rejection (AMR)
09:00 - 09:05	Glomerulitis and interstitial fibrosis in first year kidney transplant biopsies are associated with cardiovascular risk
09:05 - 09:10	Legacy effect of pretransplant immunosuppression in kidney transplant recipients with crescentic glomerulonephritis



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:10 - 09:15	Prolonged functional warm ischaemia is associated with metabolic and protease dysregulation in DCD kidneys
09:15 - 09:20	Fluid Overload in Perioperative Kidney Transplantation: More Common Than Meets the Eye
09:20 - 09:25	Gene Expression Profiles of PBMCs in Kidney vs. Lung Recipients Prior to Extracorporeal Photopheresis: Similarities and Differences
09:25 - 09:30	Identifying risk factors for sedentarism in kidney transplantation
09:30 - 09:35	Exploring Psychological Distress and Quality of Life in Kidney Transplant Patients: A Study of Gender Differences

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Hypertension & Diabetes

Room: **Focussed Oral Room 9**

08:15-09:45 CEST

Hypertension & Diabetes



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chair:	
08:15 - 08:21	Role of Total Flavonoids of <i>Abelmoschus manihot</i> (L.) Medic in Improving Renal Fibrosis in DKD via O-GlcNAc Glycosylation and FAO Pathway Speaker: Weilong Xu (P.R. China)
08:21 - 08:27	SGLT2 and HIF-PH inhibitors restore podocyte abnormalities in diabetes
08:27 - 08:33	The Effect of SGLT2 inhibitor therapy on urinary podocyte markers in diabetic kidney disease
08:33 - 08:39	Association of Intra-individual Differences in Estimated GFR by Creatinine versus Cystatin C with Incident Hypertension and the Mediating Role of TyG
08:39 - 08:45	Impact of SGLT2 and Dual SGLT1/2 Inhibition on Salt-Sensitive Hypertension Progression in Dahl SS Rats Speaker: Alexander Staruschenko (United States of America)
08:45 - 08:51	Atypical chemokine receptor 4 is involved in blood pressure regulation and ameliorates experimental glomerulonephritis
08:51 - 08:57	Wide-proteome analysis on renal tissue samples reveals new intriguing outcomes on NA-Milan hypertensive rat strain phenotype Speaker: Luciano D'Apollito (Italy)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:57 - 09:03	The overlooked players: immunomodulatory endothelial cells in diabetic kidney disease
09:03 - 09:09	Mechanisms of GPCR19-Mediated Protection in Diabetic Kidney Disease: Regulation of Mitochondrial Homeostasis and Therapeutic Potential
09:09 - 09:15	Antagonistic DcR2 peptides ameliorate renal fibrosis by inhibiting renal tubular cells senescence in diabetic nephropathy
09:15 - 09:21	Single-cell transcription combined with spatial transcriptome reveals the role of senescent proximal tubules in the progression of diabetic nephropathy
09:21 - 09:27	Urinary and serum aminoacids may be associated to Podocyte, Proximal Tubule, and Renal Endothelial Injury in Early Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients
09:27 - 09:33	Characterization and standard of care efficacy testing in a translational mouse model of cardiovascular-kidney-metabolic syndrome



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:33 - 09:39	Exploring the Role of KDM6A as a Regulator of Proximal Tubular Epithelial Cell Dysmetabolism in Diabetic Kidney Disease
09:39 - 09:45	Oxidative status in chronic kidney disease. Effect of dialysis and kidney transplantation

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

AKI & Critical Care Nephrology

Room: **Focussed Oral Room 10**

08:15-09:45 CEST

AKI & Critical Care Nephrology

Chair:	
08:15 - 08:21	Macrophage TREM2 deficiency attenuates ischemic acute kidney injury
08:21 - 08:27	Neutrophils protect against Staphylococcus aureus-induced kidney injury in part through the release of neutrophil extracellular traps
08:27 - 08:33	Teneligliptin alleviates acute kidney injury by exerting anti-ferroptotic effects on renal tubules



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:33 - 08:39	Chemical Reprogramming of Macrophages to Facilitate Renal Repair After AKI
08:39 - 08:45	The Contribution of Epigenetic Factors to CRS3 Development Induced by AKI: Role of Methyltransferase SET7
08:45 - 08:51	Extracorporeal hemoadsorption therapy in the treatment of sepsis induced by Gram-negative bacteria: in vitro assessment of two new sorbent cartridges
08:51 - 08:57	The Role of Foxp2 in Kidney Ischemia-Reperfusion Injury
08:57 - 09:03	Endotoxin and cytokines removal with new microporous (CA) sorbent prototypes
09:03 - 09:09	Circular RNA circAASS inhibits renal fibrosis post AKI by modulating mitophagy and mitochondrial biogenesis in tubular epithelial cell
09:09 - 09:15	Intravital ATP imaging reveals unexpected associations between proximal tubular ATP levels and ischemia reperfusion injury severities in aged mice



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:15 - 09:21	An ultrasmall ruthenium-based nanoparticle to protect acute kidney injury and promote renal repair
09:21 - 09:27	Engineering Primed Extracellular Vesicles with Enhanced Anti-inflammatory Properties and ROS-Responsive Drug Delivery for AKI Treatment
09:27 - 09:33	The short and long-term accuracy of Urinary C-C Motif Chemokine-14 in an ICU Population Speaker: Michael Strader (Ireland)
09:33 - 09:39	Evaluating Middle Cut-Off Membranes in Renal Support – Potential for Enhanced Cytokine Removal Speaker: Stine Koball (Germany)

Thursday, 5. June 2025

e-Poster

Date: **05/06/2025**

Miscellaneous

Room: **XWall 5 Haydn The Creation**

09:45-11:15 CEST

E-Posters

Chair:

--	--



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	The Kidney Failure Risk Equation in IgA nephropathy: External validation and model update
09:45 - 09:45	Variability and severity of HIF-PHIs' adverse events in CKD population
09:45 - 09:45	Efficacy of Ginger on Lipid Profile and Fasting Blood Glucose in Diabetic Patients Undergoing Peritoneal Dialysis: A Systematic Review & Meta-Analysis Speaker: Zeyad Elariny (Egypt)
09:45 - 09:45	The Impact of Low-Intensity Exercise on Glycemic Control and Cardiovascular Risk in Diabetic Patients with Chronic Kidney Disease
09:45 - 09:45	Impact of load and movement on arteriovenous fistula flow
09:45 - 09:45	AvacoStar, a real-world evidence study of avacopan in ANCA-associated vasculitis – baseline characteristics of initial patients
09:45 - 09:45	Skeletal Muscle Density measured in L3 computerized tomography is a prognostic marker in patients initiating hemodialysis.



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Comparative Analysis of Predictive Criteria for Unassisted Maturation of AVF Using Post-Operative Ultrasound Measurement: UAB vs NKF-KDOQI
09:45 - 09:45	Effectiveness of a Boosting mRNA COVID-19 Vaccine Dose among Hemodialysis Patients during the Omicron Era
09:45 - 09:45	Omentum wrapping of peritoneal dialysis catheter and peritoneal inflammation
09:45 - 09:45	Weekly Patterns of Emergency Department Visits, Hospitalizations, and Mortality in Patients With End-Stage Kidney Disease: A Korean Nationwide Registry Analysis
09:45 - 09:45	Online Patient Education Improves Understanding of IgAN Speaker: Amy Larkin (United States of America)
09:45 - 09:45	Effects of FGF23 on renal inflammation in an experimental model of diet-induced obesity: influence of sex.
09:45 - 09:45	The evolution of consultation practices with general practitioners and nephrologists for patients with CKD before and after the COVID-19 pandemic in France



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Association of SLC13A2 genotypes with the risk of kidney function decline in patients with nephrolithiasis in Ukraine Speaker: Natalia Stepanova (Ukraine)
09:45 - 09:45	Ileum Delivery of Budesonide by 3D Micro-structure Design for the Treatment of IgA Nephropathy
09:45 - 09:45	INNOVATIVE DEVELOPMENT OF ARTIFICIAL INTELLIGENCE IMAGE IDENTIFICATION PLATFORM FOR PERITONEAL DIALYSIS CATHETER EXIT
09:45 - 09:45	INShore: Phase III, Multicentre, Randomised, Open-Label Study of Efficacy and Safety of Obinutuzumab vs MMF in Patients With Childhood-Onset Idiopathic Nephrotic Syndrome
09:45 - 09:45	The effect of Pravastatin on Insulin Resistance in patients with CKD stage 1-3. A randomized, placebo-controlled cross over trial Speaker: Mai-Britt Skadborg (Denmark)
09:45 - 09:45	EFFECTS OF OBINUTUZUMAB ON URINARY RENAL BIOMARKERS IN LUPUS NEPHRITIS: A POST HOC EXPLORATORY ANALYSIS OF THE PHASE II NOBILITY STUDY
09:45 - 09:45	Advancing Coaching and Telehealth for CKD Care: The ACT-CKD Cohort Study Protocol



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Diet-induced kidney protection - a translational research approach
09:45 - 09:45	Comparison of simulated dialysis efficacy and actual dialysis efficacy of hemodialysis patients.
09:45 - 09:45	Sex differences in the risk of bladder cancer among kidney transplant recipients and patients with kidney failure receiving hemodialysis Speaker: Chan-Young Jung (Korea, Rep. of South)
09:45 - 09:45	Shifts in Acute Kidney Injury Trends Post-Alert System Implementation: A Comprehensive Analysis
09:45 - 09:45	Effective muscle index based on muscle mass and quality to diagnose sarcopenia and predict renal survival in CKD patients Speaker: Yukari Mae (Japan)
09:45 - 09:45	Can creatinine muscle index be a biomarker for diagnosing sarcopenia and predicting renal prognosis in CKD patients? Speaker: Natsuki Yamakawa (Japan)
09:45 - 09:45	Parathyroid Hormone Levels, Rather Than Calcium or Phosphate, as Independent Predictor of Ischemic Heart Disease in CKD stages 3-5 Non-Dialysis Patients: A Retrospective Cohort Study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Hypomagnesemia-induced Proximal Tubular Injury and Nephrocalcinosis in Rats: Insights into FHHNC Pathophysiology Speaker: Takamasa Iwakura (Japan)
09:45 - 09:45	Deletion of hypoxia-inducible factors in erythroid progenitor cells does not significantly impair erythropoiesis Speaker: PEI-ZHEN TSAI (Taiwan, R.O.C.)
09:45 - 09:45	Success of Online, Interactive, Case-Based CME at Improving Nephrologists' Competence and Confidence Related to DD-CKD-Anemia Diagnosis and Management
09:45 - 09:45	Diabetic nephropathy evaluation in a non-genotypic animal model of type 2 diabetes
09:45 - 09:45	Assessment of Frailty and Sarcopenia in Kidney Transplant Patients
09:45 - 09:45	Association Between Skeletal Muscle Mass and Bone Mineral Density in Kidney Transplant Recipients: A Retrospective Cohort Study Speaker: Morikuni Nishihira (Japan)
09:45 - 09:45	COMPARISON OF THYMOGLOBULIN® VS GRAFALON® AS INDUCTION TREATMENT IN KIDNEY TRANSPLANTATION WITH MAASTRICHT TYPE III DONOR



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	BENEFITS OF PHYSICAL ACTIVITY FOR ORGAN TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW OF MEDICAL PUBLICATIONS Speaker: Michel Baujard (France)
09:45 - 09:45	Regulation of Renal Fibrosis via the RAGE Pathway by miR-214 and Host ncRNA in Diabetic Kidney Disease Speaker: Shinji Hagiwara (Japan)
09:45 - 09:45	Effect of rabbit anti-thymocyte globulin (rATG) induction in ABO-incompatible (ABOi) kidney transplantation: Single center retrospective cohort study
09:45 - 09:45	The final hit-A case of IgA nephropathy with pembrolizumab Speaker: Sandipan Shringi (United States of America)
09:45 - 09:45	Zileuton attenuates acute kidney injury in a glycerol-induced rhabdomyolysis by regulating myeloid-derived suppressor cells in mice.
09:45 - 09:45	Post-transplantation management of calcium and parathyroid hormone levels and its association with kidney graft survival and fibrosis
09:45 - 09:45	Genetic Insights into Renal Diseases in Armenian Children



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	A case of MPO-ANCA positive dense deposit disease (DDD) with normal C3 levels presenting with end-stage renal disease (ESRD) at admission
09:45 - 09:45	Erythropoiesis-Stimulating Agent Hyporesponsiveness and Malignancy Development in non-Dialysis-Dependent CKD Patients: A Prospective Cohort Study Speaker: Nobuhiro Hashimoto (Japan)
09:45 - 09:45	Exploring Differences in Cognitive and Behavioral Outcomes of Home-Based Self-Care Retraining in Peritoneal Dialysis Patients Speaker: Woan-Jean Lin (Taiwan, R.O.C.)
09:45 - 09:45	Prevalence of Functional Iron Deficiency and Its Impact on Mortality in Hemodialysis Patients in Hatay
09:45 - 09:45	Cancer screening examination can decrease the death with the functioning graft after living donor kidney transplantation Speaker: Takahisa Hiramitsu (Japan)
09:45 - 09:45	Effect of Serum Albumin Levels at The Time of Peritoneal Dialysis Initiation on Technique Survival Period and Outcome
09:45 - 09:45	C3 Glomerulonephropathy Overlaps Hereditary Nephritis



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Sarcopenia, Frailty, and Malnutrition in Hemodialysis Patients: An Emerging Clinical Challenge
09:45 - 09:45	Preserving Dialysis Continuity: The Efficacy of the Peri-Patch Device in Catheter Salvage
09:45 - 09:45	Inhibition of Histone deacetylase 6 restores kidney fibrosis in a mouse model of unilateral ureteral obstruction Speaker: Ting-Yu Wu (Taiwan, R.O.C.)
09:45 - 09:45	A Murine Model of Peritoneal Fibrosis in Adenine-Induced Chronic Kidney Disease Speaker: Yi-Ting Wu (Taiwan, R.O.C.)
09:45 - 09:45	Comparative Prognostic Value of Glomerular Filtration Rate, Serum Cystatin C, Beta-2-Microglobulin and Albuminuria for Death and Chronic Kidney Disease Progression
09:45 - 09:45	Relationship between vascular biomarkers, NT-proBNP and renal function in chronic kidney disease, IgA nephropathy Speaker: Balázs Sági (Hungary)
09:45 - 09:45	An Atypical Case of Atypical HUS Speaker: Shannon Wong (Canada)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Association between peritoneal uric acid clearance, inflammation, and peritoneal membrane function in normouricemic patients undergoing peritoneal dialysis Speaker: Natalia Stepanova (Ukraine)
09:45 - 09:45	Pathogen Distribution and Clinical Outcomes of aHUS Patients on Peritoneal Dialysis
09:45 - 09:45	Prognostic value of the red blood cell distribution width-to-albumin ratio in scrub typhus-associated acute kidney injury Speaker: A Young Cho (Korea, Rep. of South)
09:45 - 09:45	Consideration of the amount of serum ferritin required to increase hemoglobin
09:45 - 09:45	The active ingredient in the Nuphar Lutea plant, 6,6'-Dihydroxythiobinupharidine (DTBN) ameliorates inflammation and anaemia in a mouse model of CKD
09:45 - 09:45	Investigate the effect of retinoid X receptor in renal tubular cell senescence Speaker: Wu Meng-Hsuan (Taiwan, R.O.C.)
09:45 - 09:45	Case Series of Posterior Reversible Encephalopathy Syndrome (PRES) with Diverse Etiologies



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Protective effects of TRIM33 via inflammasome suppression on ischemia-reperfusion injury-induced kidney fibrosis in mice
09:45 - 09:45	Limitations of Urine Dipstick Testing in Early Diagnosis of Diabetic Kidney Disease (DKD) and the Necessity of Measuring Urinary Albumin-to-Creatinine Ratio (UACR)
09:45 - 09:45	Impact of nutritional and inflammatory conditions on kidney outcomes and mortality in individuals with diabetes
09:45 - 09:45	Metabolome-wide Mendelian Randomization Reveals Causal Effects of Betaine and N-acetylmethionine on Impairment of Renal Function
09:45 - 09:45	Low serum Na-Cl difference level before alkali therapy is an independent predictor of rapid renal deterioration in CKDG3b-G5 patients with hyperkalemic metabolic acidosis Speaker: Shuzo Kaneko (Japan)
09:45 - 09:45	Association of Combined Hypomagnesemia and Hypouricemia With Mortality Risk in Hemodialysis Patients: A Cohort Study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Collagen 1a1 Depletion in Podocytes Increases Proteinuria Speaker: chingchun Yang (Taiwan, R.O.C.)
09:45 - 09:45	Real-world practice of palliative care for advanced cancer in patients on maintenance hemodialysis.
09:45 - 09:45	From hospital acute kidney failure to chronic renal replacement therapy: a complex patient journey in a public health system.
09:45 - 09:45	THE INCREASE IN THE LEVEL EXPRESSION OF THE PDL1 AND FOXP3 GENES IN KIDNEY TRANSPLANT RECIPIENTS WITH EXTRACORPOREAL PHOTOPHERESIS
09:45 - 09:45	LONG-TERM CONSEQUENCES OF COVID-19 FOR THE KIDNEYS: A CONTROLLED COMPLICATION OR A TIME BOMB?
09:45 - 09:45	Factors Influencing Rapid eGFR Decline in Outpatients: A Retrospective Cohort Study
09:45 - 09:45	Elucidating the Underlying Molecular Mechanisms of Shenshuai Ling Formulation in Enhancing Autophagy and Suppressing Apoptosis to Mitigate Adenine-Induced Renal Fibrosis in mice



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Evaluation of Sequential Romosozumab-Denosumab Therapy for Osteoporosis in Maintenance Hemodialysis Patients. Speaker: Rie Kiyosumi (Japan)
09:45 - 09:45	Effects of healthcare quality on renal outcomes in early-stage chronic kidney disease patients: a nationwide cohort study Speaker: Hon-Yen Wu (Taiwan, R.O.C.)
09:45 - 09:45	Clinical and laboratory manifestations of kidney damage in various types of ANCA-associated vasculitis
09:45 - 09:45	Correlation between proteinuria and soluble IL-33 receptor levels in kidney transplant recipients
09:45 - 09:45	Association of POCUS and biomarkers of congestion in cardiorenal syndrome in a monographic nephrology consultation
09:45 - 09:45	Hemodialysis in Focus: Patient Survival Through the Lens of Time and Hazard Factors.
09:45 - 09:45	The effect of Valsartan on portal and systemic hemodynamics and on renal function in liver cirrhosis



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	ESTIMATION OF ALLERGY FREQUENCY WITH TRYPTASE IN HEMODIALYSIS PATIENTS
09:45 - 09:45	Efficacy and Safety of Telitacicept in IgA Nephropathy: A Preliminary Report of the Large Single-center Observational Study
09:45 - 09:45	Comparative Performance of the New-Generation Large Language Model o1 pro and the Established Model GPT-4 on Japanese Nephrology Board Renewal Questions
09:45 - 09:45	Continuous Renal Replacement Therapy in Octogenarian and Nonagenarian AKI Patients: Short- and Long-Term Outcomes by Age Group
09:45 - 09:45	Proximal Tubular Multiciliated Cells as Prognostic Markers in Glomerular Diseases Speaker: Chun Soo Lim (Korea, Rep. of South)
09:45 - 09:45	interaction of Sleep Obstructive Apnea and Hyperuricemia on Albuminuria in General Population
09:45 - 09:45	Serum Chloride Concentration and Progression to Impaired Kidney Function in General Population



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Psychological Symptoms among Hemodialysis Patients in Thailand and Their Impact on Health-Status
09:45 - 09:45	Altered Mental Status in Patients Undergoing 5-Fluorouracil Based Chemotherapy: Think of the Zebras
09:45 - 09:45	Clinical implications of diabetic retinopathy as a predictor of the severity of diabetic kidney injury and systemic inflammation in patient with type 2 diabetes mellitus: Focusing on a histologically confirmed diabetic nephropathy
09:45 - 09:45	Chronic kidney disease specific astrocyte is related with cognitive function
09:45 - 09:45	Co-exposure of Environmental DEHP and Melamine Increases Adverse Kidney Outcomes in Patients with Early Chronic Kidney Disease – A Prospective Cohort Study
09:45 - 09:45	Establishment of urine-derived tubuloid system from pediatric leukemia patients on methotrexate treatment
09:45 - 09:45	Outcomes of medical and surgical peritoneal dialysis catheter insertion: a single centre experience Speaker: Leanne Stannard (United Kingdom)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Kidney transplantation outcomes of racial minority groups in a Central European setting: a retrospective cohort study
09:45 - 09:45	Monocyte-to-Lymphocyte Ratio Changes and Mortality in AKI Patients on CRRT
09:45 - 09:45	Pericytes Mediate Renal Recovery after Acute Kidney Injury through CXCL12 Speaker: YU-HAN SHAO (Taiwan, R.O.C.)
09:45 - 09:45	The Association Between Residual Urine Output and Quality of Life in Hemodialysis Patients Speaker: Hyun Lee Ko (Korea, Rep. of South)
09:45 - 09:45	Inhibition of histone 3 lysine 9 trimethylation improves kidney fibrosis in a mouse model of unilateral ureteral obstruction Speaker: CHIA CHI WU (Taiwan, R.O.C.)
09:45 - 09:45	Association between Blood Pressure and Chronic Kidney Disease Progression in Patients with Advanced Chronic Kidney Disease: Findings from CRIC and KNOW-CKD Study
09:45 - 09:45	Regulatory T cells: a promising therapeutic strategy for AKI Speaker: Federica Petrillo (United Kingdom)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	case report : what is the impact of plasmapheresis in polyarteritis nodosa associated with HBV ?
09:45 - 09:45	Histological analyses of kidney lesion in IgA model mice induced by nasal treatment of Porphyromonas gingivalis
09:45 - 09:45	40-year renal survival rate in patients with IgA nephropathy: Analysis of 1,121 patients at a single center Speaker: Takayuki Fujii (Japan)
09:45 - 09:45	Tamoxifen induces antioxidants to attenuate ischemia-reperfusion renal injury
09:45 - 09:45	Depressive mood and cognitive dysfunction to predict renal outcome and mortality in elderly patients
09:45 - 09:45	Functional impairment as a Predictor of Renal Outcomes and Mortality in Elderly Patients
09:45 - 09:45	Long-term follow-up study for Japanese patients with renal hypouricemia



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Latent Tuberculosis in advanced chronic kidney disease- single centre experience in the UK
09:45 - 09:45	Risk factors and long-term outcomes in a prospective acute kidney injury cohort in Korea
09:45 - 09:45	Telitacicept therapy for IgA nephropathy : A case series
09:45 - 09:45	Cardiovascular Risk in Systemic Lupus Erythematosus With and Without Lupus Nephritis: A cross-sectional comparative study
09:45 - 09:45	Association between Haemodialysis Access Tape and Mortality
09:45 - 09:45	Dextran sulfate sodium-induced colitis causes production of degalactosylated mucosal IgA and glomerular IgA-IgG deposition in HIGA mice
09:45 - 09:45	IMPROVING HEMODIALYSIS CARE FOR THE POPULATION IN UZBEKISTAN



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Short-term effect of finerenone on albuminuria and potassium levels in patients with diabetic kidney disease: analysis in real clinical practice.
09:45 - 09:45	Arteriovenous Fistula for Haemodialysis as a Predictor of the Heart Failure in Kidney Transplant Recipients
09:45 - 09:45	Effect of erythropoiesis-stimulating agent types on malignancy in hemodialysis patients
09:45 - 09:45	Association of albuminuria and POCUS in cardiorenal syndrome in a monographic nephrology consultation
09:45 - 09:45	Association between ultrafiltration variability and clinical outcomes in patients undergoing hemodialysis
09:45 - 09:45	Nutritional status: The Silent Risk of Falls in Hemodialysis Patients
09:45 - 09:45	Circulating extracellular vesicles: a mediator of renal tubular oxidative stress, mitochondrial Ca²⁺ overload and SIRT1/PGCα axis suppression in obesity



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Artificial Intelligence in the Identification of Key Metabolites Associated with Diabetic Kidney Disease
09:45 - 09:45	Real-World Use of HIF-PH Inhibitors and ESAs in Non-Dialysis-Dependent CKD with Anemia: Insights from a Japanese Database study
09:45 - 09:45	Association of Time-updated Body Mass Index with the Initiation of Kidney Replacement Therapy in Patients with Chronic Kidney Disease: Results from the KNOW-CKD Study
09:45 - 09:45	Efficacy and safety of telitaccept in patients with class III- V lupus nephritis: a real-world retrospective cohort study
09:45 - 09:45	The Impact of Intradialytic Physical Activity on Inflammatory Markers in Patients with Diabetes Mellitus
09:45 - 09:45	The prognostic significance of the Birmingham Vasculitis Activity Score on the Outcome of ANCA- Associated Vasculitis Speaker: Saimir Seferi (Albania)
09:45 - 09:45	IgA expressed by glomerular mesangial cells is involved in the pathogenesis of IgA nephropathy



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Association between pretransplant dialysis modality and long-term graft outcomes
09:45 - 09:45	Population-Based Analysis of Metabolic-Associated Steatotic Liver Disease as a Risk Factor for End-Stage Kidney Disease in Chronic Kidney Disease Patients
09:45 - 09:45	Ca-sensing receptor agonists can improve taste sensitivity in hemodialysis patients.
09:45 - 09:45	A Pharmacogenetic and Body Weight-Informed Predictive Model for Tacrolimus Dosing in Taiwanese Kidney Transplant Recipients
09:45 - 09:45	UTILITY OF MULTI-SEGMENTAL BIOIMPEDANCE FOR THE DIAGNOSIS OF SARCOPENIA AND SARCOPENIC OBESITY IN DIALYSIS
09:45 - 09:45	Analysis of the Survival Rate of Patients on Kidney Replacement Therapy in a Large City: A Multicenter Prospective Cohort Observational Study
09:45 - 09:45	Low Handgrip Strength predicts long term mortality in patients treated with Hemodialysis Speaker: Orit Kliuk Ben-bassat (Israel)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Prognostic indicators after treatment in IgA nephropathy.
09:45 - 09:45	Development of new method for continuous kidney replacement therapy weaning Speaker: Won Min Hwang (Korea, Rep. of South)
09:45 - 09:45	Association Between Acid-Base Disorders at Dialysis Initiation and Mortality: A Multicenter Prospective Cohort Study in Japan
09:45 - 09:45	Structured Post-AKI Follow-Up: A Nurse-Led Kidney Health Check Model for Improved Pharmacological Interventions and secondary prevention
09:45 - 09:45	Urinary exosome miRNAs as biomarkers associated with proteinuria and eGFR in lupus nephritis
09:45 - 09:45	Sleep Disorders And Sleep Quality Among Hemodialysis Patients In A Tertiary Hospital In Valenzuela, Philippines: A One Center Cross Sectional Study Speaker: Geraldine Jettee Gales-Villar (Philippines, The)
09:45 - 09:45	Evaluating the real-world efficacy and safety of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease – A single center long-term observation



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Association of Serum Selenium and Zinc Levels with Anemia Parameters and ESA Response in Different Dialysis Modalities
09:45 - 09:45	SARC-F Questionnaire as a Screening Tool for Identifying Hemodialysis Patients at High Risk of Falls and Fractures Speaker: Minoru Ito (Japan)
09:45 - 09:45	Inhibiting progression of abdominal aortic calcification by vitamin K2 in dialysis patients.
09:45 - 09:45	Cost-effectiveness analysis of voclosporin vs mycophenolate or belimumab in the treatment of patients with lupus nephritis from the Spanish National Healthcare System perspective
09:45 - 09:45	The Influence of Vitamin D on Quality of Life in Patients with Lupus Nephritis
09:45 - 09:45	CHRONIC KIDNEY DISEASE PROGRESSION ASSESSMENT ON THE BASIS OF COMPLEX TREATMENT
09:45 - 09:45	Renal replacement therapy is not associated with increased mortality in patients with sepsis and acute kidney injury in the intensive care unit



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Longitudinal follow-up of Health-related Quality of Life indicators in glomerulonephritis treated with immunosuppressants
09:45 - 09:45	KIDNEY TRANSPLANTATION AND FUNCTIONAL STATE OF THE PARATHYROID GLANDS
09:45 - 09:45	The association of sodium-glucose transporter 2 inhibitor prescription and incident chronic kidney disease in a multi-ethnic Asian population: a retrospective cohort study using Singhealth Diabetes Registry
09:45 - 09:45	Pilot Results from Evaluation of Autosomal Dominant Polycystic Kidney Disease Diagnosis Impact on the Patients' Quality of Life Speaker: Niloufar Ebrahimi (United States of America)
09:45 - 09:45	OUTCOME OF THE PERITONEAL DIALYSIS PROGRAM IN PATIENTS WITH HEART FAILURE
09:45 - 09:45	Single-cell RNA sequencing reveals immune landscape and cellular dynamics in peritoneal dialysis effluent



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	EFFICACY AND SAFETY OF A NOVEL ANTI-CD20 AGENT RIPERTAMAB IN TREATMENT OF PRIMARY MEMBRANOUS NEPHROPATHY : A MULTI-CENTER, RETROSPECTIVE STUDY IN CHINA
09:45 - 09:45	Urinary microcholesterol and progression of chronic kidney disease
09:45 - 09:45	Development of the Nephrotic Syndrome Symptom and Impact Patient Reported Outcome (NephroSSI-PRO) Measure for Use in Adults and Adolescents with Primary Glomerulopathies
09:45 - 09:45	Therapeutic Potential of Propylparaben in Modulating Pathophysiological Features of Fabry Nephropathy
09:45 - 09:45	Denosumab versus Bisphosphonates for Medication-Related Osteonecrosis of the Jaw and Recurrent Clinical Fractures among Japanese Patients on Haemodialysis: A Target Trial Emulation
09:45 - 09:45	Efficacy and Safety of Telitacicept in IgA Nephropathy and IgA Vasculitis Nephropathy in Children: A Retrospective Single-Center Study
09:45 - 09:45	Transcriptional Intermediary Factor 1γ Ameliorates Kidney Fibrosis by Enhancing Irisin Levels in Skeletal Muscle of db/db Mice Speaker: Hyun-Jung Kim (Korea, Rep. of South)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Effectiveness of Chronic Kidney Disease Education in Patients with Advanced Stages: A Retrospective Study
09:45 - 09:45	The Effect of Vitamin D on Pro-inflammatory Cytokines in Patients with Lupus Nephritis
09:45 - 09:45	Albuminuria and Coronary Artery Calcium in a General Japanese Population
09:45 - 09:45	Breaking Barriers in Nephroprotection for Advanced Chronic Kidney Disease: SGLT2 Inhibitors in the Treatment of CKD Stage 4-5 Speaker: Lida Rodas (Spain)
09:45 - 09:45	"Pink Cocaine" (TUSI): A New Cause of Acute Kidney Injury?
09:45 - 09:45	The dialysis quality parameters as predictors of symptom burden in cluster analysis
09:45 - 09:45	Characteristics of Patients with a Diagnosis of De Novo Polycystic Kidney Disease



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Development and Validation of Deep-Learning Model for Diagnosing Systemic Acidemia From the Electrocardiograms.
09:45 - 09:45	Serum β2-microglobulin is independently associated with left ventricular mass index in patients with stage 5 chronic kidney disease not undergoing dialysis
09:45 - 09:45	The occurrence of CKD in the Aral Sea region
09:45 - 09:45	Timing of Transition to Peritoneal Dialysis (PD) and Its Impact on Bacteremia Risk in PD Patients Speaker: Sara-Jane Chan (Singapore)
09:45 - 09:45	THE ROLE OF MOLECULAR GENETICS IN THE ETIOLOGICAL DIAGNOSIS OF MICROSCOPIC HEMATURIA
09:45 - 09:45	CYSTIC KIDNEY DISEASE IN X-LINKED ALPORT SYNDROME CHILDREN
09:45 - 09:45	Non-invasive detection of calcineurin inhibitor toxicity using urinary mRNA expression in kidney transplant recipients
09:45 - 09:45	Association between estimated glomerular filtration rate and mortality in elder population



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	The effect of endogenous serotonin on vitamin K metabolism and vitamin K-dependent bone mineralization in an experimental model of chronic kidney disease in rats. Speaker: Krystyna Pawlak (Poland)
09:45 - 09:45	The treatment with β-blockers reduced IL-6 and MMP-2/TIMP-2 system in patients with chronic kidney disease on conservative treatment.
09:45 - 09:45	ANTIHYPERTENSIVE THERAPY IMPROVES CARDIOVASCULAR OUTCOMES IN PATIENTS ON HEMODIALYSIS: AN UPDATED META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
09:45 - 09:45	AMBULATORY PULSE WAVE VELOCITY AS A PREDICTOR OF ALL-CAUSE DEATH RISK IN PATIENTS RECEIVING PERITONEAL DIALYSIS: A PROSPECTIVE OBSERVATIONAL STUDY
09:45 - 09:45	Safety of Continued Belatacept Treatment After Kidney Graft Rejection
09:45 - 09:45	Evaluating Serum Alkaline Phosphatase Trajectories for Fracture Risk Prediction in Hemodialysis Patients



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Revisiting Frequent Premature Atrial Contractions and Cerebrovascular Events in Non-Dialysis CKD patients
09:45 - 09:45	Observation of the therapeutic effect of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in patients with non-diabetic CKD Speaker: Fang Li (P.R. China)
09:45 - 09:45	Association Between CKD-MBD and Mortality, Cardiovascular Events, and Fractures in Peritoneal Dialysis Patients
09:45 - 09:45	Dickkopf-3 (DKK3) and the progression of diabetic kidney disease in primary health care
09:45 - 09:45	Cancer Mortality in Patients with Kidney Failure: Insights from the Korea Clinical Data Utilization Network (K-CURE) Database
09:45 - 09:45	High-sensitivity C-reactive protein levels and mortality, cardiovascular events, and adverse kidney outcomes in non-dialysis-dependent CKD patients
09:45 - 09:45	HIV-associated nephropathy in a patient with undetectable viral load: a case report



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Machine learning analysis of clinical determinants affecting gut microbiota in hemodialysis patients: a longitudinal study
09:45 - 09:45	The utility of Anifrolumab in Patients with Class III or IV Lupus Nephritis – the single center experience.
09:45 - 09:45	The Relationship Between Serum Uric Acid Levels and Arteriovenous Fistula Thrombosis in Hemodialysis Patients
09:45 - 09:45	Impact of Dapagliflozin on the Kidney Failure Risk Equation (KFRE) in Patients with Stage G4 Chronic Kidney Disease
09:45 - 09:45	PREVENTION OF RENAL FIBROSIS WITH ALLOGENEIC PERINATAL STEM CELLS - A LONG-TERM PRECLINICAL MODEL OF KIDNEY INJURY
09:45 - 09:45	The role of neutrophil extracellular traps in the animal model crystal-induced chronic kidney disease
09:45 - 09:45	Efficacy and Safety of Dapagliflozin in Patients with Stage G4 Chronic Kidney Disease



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Evaluation of the Impact of COVID-19 Vaccines on Renal Function in Chronic Kidney Disease (CKD) Patients
09:45 - 09:45	Dietary Management Strategies for Koreans with Chronic Kidney Disease: A Nutrient Intake Analysis Based on Korea National Health and Nutrition Examination Survey (KNHANES)
09:45 - 09:45	Effect of genotype on renal outcome among the patients with inherited cystic kidney disease Speaker: Yun Kyu Oh (Korea, Rep. of South)
09:45 - 09:45	Persistent higher trajectories of waist-to-hip ratio are associated with greater risk of cardio-renal outcomes: results from the KNOW-CKD study
09:45 - 09:45	Trajectories of serum total carbon dioxide and the risk of cardio-renal outcomes in chronic kidney disease: Results from the KNOW-CKD Study
09:45 - 09:45	Prevalence and Trends of Cardiovascular-Kidney-Metabolic (CKM) Syndrome Among Korean Adults, 2013-2022
09:45 - 09:45	Fibroblast-Macrophage Dynamics and Midkine Signaling in ischemic induced renal fibrosis. Speaker: Sunhwa Lee (Korea, Rep. of South)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Phospholipase A2 Receptor Antibody IgG and IgG4 Subclass by TRFIA Improves Sensitivity and Specificity in the Diagnosis of Primary Membranous Nephropathy
09:45 - 09:45	Prospective Controlled Trial of the Effects of Different Renal Biopsy Needle Sizes on the Number of Glomeruli Collected and their Associated Complications
09:45 - 09:45	Causal Association Between Constipation and Chronic Kidney Disease: A Two-Sample Mendelian Randomization Analysis
09:45 - 09:45	Atopic dermatitis-like chronic inflammation may be associated with kidney inflammation
09:45 - 09:45	Comparative study of safety of cuffed tunnelled catheter on patients on dual anti-platelets compared with standard indications.
09:45 - 09:45	Telitaccept followed by Rituximab in highly active SLE:two successful cases
09:45 - 09:45	Development of a Predictive Model for Nafamostat Mesylate Dosing in Hemodialysis



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	The urinary proteome as a window to the transition from AKI to CKD after repeated acute kidney injuries
09:45 - 09:45	Trandolapril attenuates renal fibrosis in rats with a dual-injury model of kidney disease progression.
09:45 - 09:45	Trends in dialysis population in Albania over the last 5 years: rising age and increased mortality among Diabetic patients Speaker: Fjona Nasto (Albania)
09:45 - 09:45	Clinical Efficacy and Safety of Telitacicept in the Treatment of Renal Involvement in Primary Sjögren's Syndrome: A Report of 4 Cases
09:45 - 09:45	Rate of HMGR gene methylation in diabetic patients on hemodialysis
09:45 - 09:45	Cognitive Impairment and Associated Factors in Patients Undergoing Hemodialysis
09:45 - 09:45	2-y crovalimab paroxysmal nocturnal haemoglobinuria (PNH) data for fatigue, a relevant symptom in atypical haemolytic uraemic syndrome (aHUS) and PNH



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Late Relapse of ANCA Associated Vasculitis presenting as obstructive nephropathy due to retroperitoneal fibrosis
09:45 - 09:45	HNF4a Drives Metabolic Reprogramming in Podocytes through ChREBP/SREBP-Mediated Pathway and Promotes Cell Cycle Progression
09:45 - 09:45	The importance of anti-AT1R antibodies in patients with diabetic nephropathy
09:45 - 09:45	Trends and associations between decreased estimated glomerular filtration rate, metabolic syndrome, and non-alcoholic fatty liver disease in children and adolescents: a 15-Year data analysis
09:45 - 09:45	Efficacy of Rituximab-based Regimen in the Treatment of Obese Patients with Membranous Nephropathy
09:45 - 09:45	Survival and care trajectory of kidney graft patients after age 65 : Let's look at the cardiovascular comorbidities rather than age



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	ALOX5 Regulates Renal Fibrosis Through Modulation of Matrix Remodeling and Inflammatory Responses
09:45 - 09:45	Modeling ischemia-reperfusion injury in kidney organoids.
09:45 - 09:45	A comparison of the effectiveness of corticosteroids or telitacicept management alone in patients with IgA nephropathy: a retrospective observational study
09:45 - 09:45	1111MicrosoftInternetExplorer402DocumentNotSpecified7.8 ?Normal0 Prospective Validation of Multiple Deep Learning Model Assisted Diagnostic Program for Glomerular Diseases Using Immunofluorescence Images
09:45 - 09:45	Rituximab Based Regimen is Safe and Effective for Primary Membranous Nephropathy Patients presented with Nephrotic Syndrome and Advanced Renal Dysfunction
09:45 - 09:45	Analysis of the skeletal muscle index in hemodialysis patients over 80 years old
09:45 - 09:45	PREECLAMPSIA IN WOMEN WITH CRONIC KIDNEY DISEASE: FEATURES OF BLOOD COAGULATION FUNCTION



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Consumption of low-calorie sweeteners exacerbates the progression from acute kidney injury to chronic kidney disease and renal fibrosis
09:45 - 09:45	prevalence and characteristics of headache in chronic hemodialysis patients
09:45 - 09:45	Predicting long-term benefits of improvements in estimated glomerular filtration rate (eGFR) with iptacopan on delaying kidney failure in Complement 3 Glomerulopathy (C3G)
09:45 - 09:45	Arterial hypertension and markers of cardiovascular complications after kidney transplantation
09:45 - 09:45	Prognostic value of urinary periostin in the frequent primary glomerulopathies of the adult.
09:45 - 09:45	Angiotensin II induces mitochondrial oxidative stress in podocyte
09:45 - 09:45	Exploring the association between non-alcoholic fatty liver disease and chronic kidney disease: Insights from NHANES 1999-2016 Speaker: Yaerim Kim (Korea, Rep. of South)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	The Impact of Adolescent Smoking Initiation on the Risk of End-Stage Kidney Disease: A Nationwide Cohort Study
09:45 - 09:45	Chronic kidney disease is a major risk factor for mortality in triglyceride deposit cardiomyopathy patients
09:45 - 09:45	Biomarkers for Predicting the Efficacy of Immunosuppressive Therapy in IgA Nephropathy: The Role of serum MCP-1 and TGF-β
09:45 - 09:45	Long-term treatment with medium cut-off dialyzer increase muscle mass in hemodialysis patients
09:45 - 09:45	Anemia as a predictor of peritoneal dialysis withdrawal in stable peritoneal dialysis patients
09:45 - 09:45	Prognostic value of Glasgow Prognostic Score and its derived scores in patients undergoing hemodialysis
09:45 - 09:45	Osteoactivin levels are correlated with eGFR and proteinuria in diabetic kidney disease.



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Severity of preeclampsia and fetal complications- potential association with serum albumin levels?
09:45 - 09:45	END-STAGE KIDNEY DISEASE IN PEOPLE WITH ANCA-ASSOCIATED VASCULITIS: A SYSTEMATIC REVIEW OF OUTCOMES Speaker: Andreas Kronbichler (Austria)
09:45 - 09:45	Is urgent start peritoneal dialysis after percutaneous PD catheter placement by a nephrologist safe?
09:45 - 09:45	Comparison study of Human resourced ellipsoid method vs kidney volumetry using artificial intelligence in Polycystic kidney disease
09:45 - 09:45	Dialysate leaks in peritoneal dialysis patients – a retrospective review
09:45 - 09:45	SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Solid Organ Tumor: A Retrospective Observational Study on Safety and Tolerability
09:45 - 09:45	Complications Associated with Tunneled Hemodialysis Catheters: A Retrospective Study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Advanced kidney models to better understand tacrolimus-induced nephrotoxicity Speaker: Kate Liang (Netherlands)
09:45 - 09:45	Adult stem cell-derived kidney organoids (tubuloids) to model renal ciliopathies Speaker: Gisela Slaats (Netherlands)
09:45 - 09:45	Predictive Value of the ATRIA Score for Contrast-Induced Nephropathy in Patients Undergoing Primary Percutaneous Coronary Intervention for Non-ST-Segment Elevation Myocardial Infarction
09:45 - 09:45	Changes in Serum Bisphenol S (BPS) Concentrations in Dialysis Patients: Impact of Switching from Hemodialysis (HD) to On-line Hemodiafiltration (OHDF) and Changing the Dialysis Membrane from Polyethersulfone (PES) to Polysulfone (PS).
09:45 - 09:45	Urinary excretion of TNF-α and IL-9 in patients treated with immune checkpoint inhibitors. Potential application in the subclinical renal damage diagnosis.
09:45 - 09:45	Interplay between polymorphism in the EDNRA gene and endothelin-1 concentration in the blood of patients with chronic kidney disease



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Green Tea Polyphenol Sandwich-assisted Construction of Endothelial Biomimetic Coatings with HA Platform and NO Release for Hemodialysis Access Stents to Prevent Thrombosis and Restenosis
09:45 - 09:45	The effect of Pravastatin on Insulin Resistance in kidney transplant recipients. A randomized, placebo-controlled cross over trial Speaker: Mai-Britt Skadborg (Denmark)
09:45 - 09:45	Real-life analysis of a monocentric cohort of IgA nephropathy patients
09:45 - 09:45	Differences in chronic kidney disease management based on identification and diagnosis in a population-based observational study Speaker: Dan Henrohn (Sweden)
09:45 - 09:45	Renal Involvement in Sjögren's Syndrome: A Clinical and Biological Analysis
09:45 - 09:45	CKD with hyperuricemia vs CKD with wide plasma uric acid fluctuations --- two different types of CKD both with rapid eGFR decline
09:45 - 09:45	Role of urinary biomarkers in the diagnosis of kidney damage due to immune checkpoint inhibitors



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Predictive Factors for Hospitalizations: Comparison Between Incremental Hemodialysis and Conventional Hemodialysis Speaker: Nouha Ben Mahmoud (Tunisia)
09:45 - 09:45	The effect of homocysteine correction on the quality of life in CKD patients
09:45 - 09:45	Improvement in Uncomfortable Dialysis-Related Symptoms Such as Daytime Itching, Nighttime Itching, Restless Legs and Leg Muscle Cramps by Switching from HD to OHDF Through Enhanced Removal Efficacy of Medium-Molecular-Weight Substances.
09:45 - 09:45	IMPORTANCE OF INTRINSIC MEMBRANE DYSFUNCTION AS A PREDICTOR OF SURVIVAL IN PERITONEAL DIALYSIS
09:45 - 09:45	Eculizumab for Treatment-Resistant Lupus - A Friend or Foe? A Case Report
09:45 - 09:45	Benefits of Exercise in Octogenarians on Hemodialysis Speaker: Lida Rodas (Spain)
09:45 - 09:45	¿What Changes Can the Use of the IEXPAC Tool Induce in the Nurse Consultation for Advanced Chronic Kidney Disease? Speaker: Sergi Aragó Sorrosal (Spain)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Kidney disease spectrum in patients with haematological malignancies.
09:45 - 09:45	Treatment outcomes of liver cyst infection in patients with autosomal dominant polycystic kidney disease.
09:45 - 09:45	Subclinical Renal Tubular Dysfunction in Postmenopausal Women Exposed to Low-Level Environmental Cadmium
09:45 - 09:45	ANALYSIS OF PRIMARY SURVIVAL AND QUALITY INDICATORS OF NATIVE ARTERIOVENOUS FISTULAS PERFORMED DURING THE PERIOD 2020 – 2023.
09:45 - 09:45	Ultrafiltration pattern in Automated Peritoneal Dialysis
09:45 - 09:45	“Use a machine learning model that estimates survival curves to identify patients at high risk of rapid progression of chronic kidney disease.”
09:45 - 09:45	Resistin: a potential predictor of adverse outcomes in chronic kidney disease?



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	ORIGIN 3 Study Design: A Global, Randomized, Controlled, Phase 3 Study of Atacicept in IgA Nephropathy
09:45 - 09:45	Colocalization of complement C3 and IgA in glomerular immune-complex deposits of patients with IgA nephropathy correlates with the Oxford classification MEST-C scores
09:45 - 09:45	DMX-200 is effective in reducing urine monocyte chemoattractant protein 1 (MCP-1) levels in patients with FSGS without affecting plasma MCP-1 concentration
09:45 - 09:45	DMX-200 does not induce a haemodynamic effect or an acute change in GFR and has a strong cardiovascular safety profile.
09:45 - 09:45	Necrotizing histiocytic lymphadenitis (Kikuchi-Fujimoto disease): About a case
09:45 - 09:45	Real-world outcomes of belimumab in systemic lupus erythematosus and lupus nephritis.
09:45 - 09:45	Immune complex made by immunoglobulin A and Cnm Protein expressing in Streptococcus mutans might induce IgA nephropathy



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	like kidney lesion.
09:45 - 09:45	Pilot Insights from an Online Survey Study Interpreting Clinical Trials Outcome; Nephrologist Recall vs. Artificial Intelligence Speaker: Niloufar Ebrahimi (United States of America)
09:45 - 09:45	ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgA Nephropathy
09:45 - 09:45	Nephrotic Syndrome that Changed the Course of Chronic myeloid leukemia Treatment
09:45 - 09:45	The association of cognitive dysfunction with markers of oxidative stress and vitamin K deficiency in Chronic Kidney Disease patients
09:45 - 09:45	Atypical familial Mediterranean fever presenting AA amyloidosis
09:45 - 09:45	Comparison of β-blocker with other anti-hypertensive drugs in patients with chronic kidney disease in Korea: A National Health Insurance Data
09:45 - 09:45	Evaluation of embelin alone and its combination with metformin on diabetic nephropathy.



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Assessment of the Combined Antiurolithiatic Properties of Tribulus terrestris Fruit Extract in Conjunction with Selected Indian Medicinal Plants.
09:45 - 09:45	Urinary NGAL as a potential Biomarker to detect subclinical AKI post Fundus Fluorescein Angiography
09:45 - 09:45	The influence of antibodies against angiotensin II type-1 receptor to kidney allograft function and their association to alloimmune sensitization
09:45 - 09:45	Interdialytic weight gain and cardiac geometry in hemodialysis patients
09:45 - 09:45	Severe Hyperkalaemia: A Retrospective Study of Clinical Characteristics, Aetiology, and Management. Speaker: Louise Dervan (Ireland)
09:45 - 09:45	Prognostic Factors of Renal Survival in ANCA-Associated Vasculitis: A Retrospective Cohort Study from the Nephrology department of Monastir



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	The effect of xCT modulation on ROS levels in a unilateral ureteral obstruction model
09:45 - 09:45	Investigation of the gastrointestinal tract with capsule endoscopy in patients undergoing renal replacement therapies
09:45 - 09:45	Axillary loop arteriovenous grafts as a rescue from vascular access failure: Long-term results at a single facility
09:45 - 09:45	Efficacy Evaluation of Telitacicept in IgA Nephropathy: a real-world study Speaker: Ying Fan (P.R. China)
09:45 - 09:45	A case report of a concurrent axonal neuropathy and focal segmental glomerulosclerosis treated with ocrelizumab and plasma exchange.
09:45 - 09:45	Trends of Occurrence and Mortality in Dialysis Requiring Acute Kidney Injury
09:45 - 09:45	REMISSION RATES OF IMMUNOTHERAPY WITH ANTI-CD20 MONOCLONAL ANTIBODY (RITUXIMAB) IN PATIENTS WITH MEMBRANOUS NEPHROPATHY



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Hyperkalemia: Treatment and Associated costs in Argentina
09:45 - 09:45	Minimal changes disease in patients over 60 years of age
09:45 - 09:45	URINARY METABOLOMICS EVALUATION IN SENSITIZED KIDNEY TRANSPLANT RECIPIENTS
09:45 - 09:45	Percutaneous native kidney biopsy performed by Nephrologists: Safety, desmopressin use and complications.
09:45 - 09:45	SEARCH Project: Early diagnosis of chronic kidney disease in Argentina. Initial Results
09:45 - 09:45	Urinary CXCL16 correlates with renal function and proteinuria in diabetic chronic kidney disease
09:45 - 09:45	Differences in expression dynamics and renoprotective effects between Klotho delivery using mRNA-LNP and AAV
09:45 - 09:45	Percutaneous kidney biopsy and the histopathologic patterns of kidney diseases in children



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	A Novel Peritoneal Dialysis Catheter Insertion Technique to Reduce Catheter Migration
09:45 - 09:45	Venous Excess Ultrasound Score and Acute Kidney Injury in patients with decompensated heart failure
09:45 - 09:45	Temporal trends in acute kidney injury-related mortality across 43 countries, 1996-2021, with projections up to 2050: a global time series analysis and modelling study
09:45 - 09:45	Efficacy and Safety of Paediatric Continuous Veno-Venous Hemodialysis (CVVHD) with MultiFiltratePRO: A Prospective Multicenter Study
09:45 - 09:45	Maribavir Treatment in Resistant/Refractory Cytomegalovirus Infection Among Kidney Transplant Recipients: A Real-World Experience
09:45 - 09:45	Prognostic value of triglyceride glucose (TyG) index in population with chronic kidney disease



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Machine Learning Approach Using CT-Based Morphological Features for Evaluating Acute Kidney Injury Severity
09:45 - 09:45	Clinical Implications of the Triglyceride-Glucose Index in Hemodialysis Patients: A Multicenter Prospective Cohort Study
09:45 - 09:45	Hepatitis, acute kidney injury and myositis due to atorvastatin
09:45 - 09:45	NEOPLASMS IN PATIENTS WITH RENAL SUBSTITUTE THERAPY AND EVALUATION OF THE USE OF CHECK POINT INHIBITORS IN THIS POPULATION
09:45 - 09:45	Nephrology and Primary Care: Integrated Care Program for Chronic Kidney Disease
09:45 - 09:45	Risk Factors associated with acute kidney injury during the postpartum period Speaker: Tehir Mohamed Cherif (Algeria)
09:45 - 09:45	Von Willebrand Factor as a Predictor of Acute Kidney Injury and Hemodialysis Requirement in Severe Leptospirosis: A Prospective Cohort Study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Association of ACE and IL-1B gene polymorphisms with erythropoietin resistance in dialysis patients with anemia
09:45 - 09:45	Histological and evolutionary profile of hypertension in patients with lupus nephropathy
09:45 - 09:45	1 year follow up of bone density markers in patients dialyzed with a citric acid-vitC containing dialysate versus acetate dialysate.
09:45 - 09:45	Effect of increasing age on pre-renal AKI incidence and severity in dehydrated and normohydrated rats
09:45 - 09:45	Dehydration and hypertension differently prime intrinsic and pre-renal AKI
09:45 - 09:45	Outcomes of Sirolimus-Coated Balloon Angioplasty for Arteriovenous Fistula Stenosis: A Prospective Registry Analysis from a Single Center
09:45 - 09:45	Serum acrolein as a potential biomarker of aortic stiffness in patients with non-dialysis chronic kidney disease stage 3 to 5



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	THE INFLUENCE OF ANEMIA ON QUALITY OF LIFE OF PATIENTS ON HEMODIALYSIS AND PERITONEAL DIALYSIS Speaker: Gergana Todorova (Bulgaria)
09:45 - 09:45	A case of membranous nephropathy that reached remission with SGLT2 inhibitor alone
09:45 - 09:45	Contrast Media in Hospitalized Patients with Acute Kidney Injury- Renal and Clinical Outcomes.
09:45 - 09:45	Dynamic Changes in Renal Hyperfiltration and Influences on Cardiovascular Events, Kidney Disease Progression, and Mortality: a nationwide prospective cohort study
09:45 - 09:45	Beyond the Kidney: Unconventional Roles of Indoxyl Sulfate in Modulating Purinergic Receptors, Transporters, and Cytokines in Mouse Aorta
09:45 - 09:45	Investigating AKI in ICU Trauma Patients: Incidence, Risk Profiles, and Outcome Implications
09:45 - 09:45	From Covid to GEPA: A systematic Vasculitis with Unexpected IgA Deposits



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	COGNITIVE FUNCTIONS IN MULTYMORBIDITY PATIENTS WITH ATRIAL FIBRILLATION DEPENDING ON THE PRESENCE OF CONCOMITANT CHRONIC KIDNEY DISEASE STAGES 3A, 3B AND 4 Speaker: Svetlana Litvinova (Russia)
09:45 - 09:45	Is hyponatremia at the beginning of peritoneal dialysis relevant?
09:45 - 09:45	Valuing overhydration in stable, non-dialysis stage 4 and 5 kidney disease patients.
09:45 - 09:45	Three years of kidney transplantation in the Yaounde General Hospital, Cameroon
09:45 - 09:45	Proteinuria in Deceased Kidney Transplant Donors for Prediction of Chronic Lesions in Pre- Transplant Biopsies – a prospective multi-center study
09:45 - 09:45	Cardioprotective effect of a Low-Protein Diet in Patients with Type 2 Diabetes and Chronic Kidney Disease stages 3-4
09:45 - 09:45	Effect of Low-Dose Tenapanol on Inflammation in Hemodialysis Patients



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Unveiling the Role of Peroxiredoxins 1-5 as Markers in Early Diagnosis and Monitoring of IgA Nephropathy, Membranous Nephropathy and Lupus Nephritis.
09:45 - 09:45	MALIGNANT TUMORS OF THE URINARY BLADDER AND BALKAN ENDEMIC NEPHROPATHY - 70 YEARS AFTER
09:45 - 09:45	BRIGHT-HD - Brazil Research Investigation on public Health Gain comparing survival between hemodialysis and hemodiafiltration
09:45 - 09:45	Glyoxylic acid induce crystalline nephropathy and Hair-Straightening Products : A case report
09:45 - 09:45	EVALUATION OF OUTCOMES AND CHALLENGES IN ARTERIOVENOUS FISTULAS AS HEMODIALYSIS ACCESS IN PEDIATRIC PATIENTS
09:45 - 09:45	Complication of Self-Catheterization in a Kidney Transplant Recipient : Psoas Abscess
09:45 - 09:45	Assay validation and quantification of new urinary kidney safety biomarker candidates for the detection of glomerular injury



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Hereditary Minimal change disease (MCD) : About Three Cases reports
09:45 - 09:45	Estimated Glomerular Filtration Rate in Pediatric Neurogenic Bladder Patients using cystatin C and creatinine based CKiD and EKFC equations – usefulness of cystatin C
09:45 - 09:45	Cardiac involvement in monoclonal gammopathies : A single center experience
09:45 - 09:45	Experience in a single center with standard treatment of Lupus Nephritis.
09:45 - 09:45	Nodular Glomerulosclerosis Complicating MIDD: Report of 2 Cases in Young Patients
09:45 - 09:45	Hungry bone syndrome (HBS) as an outcome of Parathyroidectomy as a Treatment of Hyperparathyroidism in a third level hospital in a medium-income country
09:45 - 09:45	Evolution of renal function in patients with long-term mechanical circulatory support



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:45 - 09:45	Predicting ICU Outcomes in Trauma Patients: The Prognostic Value of SOFA Score and AKI Severity
09:45 - 09:45	IMPACT OF MEDIUM CUT-OFF DIALYZER MEMBRANE AND DIETARY MODIFICATION ON SERUM P-CRESYL SULFATE AND INDOXYL SULFATE LEVELS: A RANDOMIZED CONTROLLED TRIAL
09:45 - 09:45	Prognostic factors for cardiovascular events in pauci-immune glomerulonephritis: a retrospective cohort study
09:45 - 09:45	Prevalence of hyperuricemia among patients undergoing hemodialysis
09:45 - 09:45	Supply of probiotics with L. Rhamnosus and B. Longum Evaluation of the improvement of uremic gastrointestinal symptoms in patients aged 30 to 70 years, with hemodialysis treatment at the SENETO clinic, for 1 to 120 days.
09:45 - 09:45	Association of Post-Transplant Apolipoprotein A-1 Levels with Cardiovascular Events and Graft Loss in Kidney Transplant Recipients: Results from the KOTRY Study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Kidney Transplantation

Room: **Focussed Oral Room 8**

11:15-12:30 CEST

Kidney Transplantation

Chair:	
11:15 - 11:21	Monkeypox Infection in Kidney Transplant Recipients: A Systematic Review Speaker: Henry H L Wu (Australia)
11:21 - 11:27	Assessing urinary exfoliated proximal tubule cell multispectral autofluorescence to differentiate between causes of post-transplant graft dysfunction Speaker: Henry H L Wu (Australia)
11:27 - 11:33	ASSOCIATION OF HLA SYSTEM ALLELES WITH THE OCCURRENCE OF IgA NEPHROPATHY AND ITS RECURRENCE AFTER KIDNEY TRANSPLANTATION Speaker: Ivana Dedinska (Slovakia)
11:33 - 11:39	Clinical Experience with Extracorporeal Photopheresis in BK Virus-Associated Nephropathy Speaker: Víctor Joaquín Escudero Saiz (Spain)
11:39 - 11:45	The multi-omic analysis identified CHI3L1 as a potential mediator of immune system deregulation in kidney transplant patients with chronic antibody-mediated rejection



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:45 - 11:51	Immunosuppressive treatment with two drugs (tacrolimus and prednisone) in older adult kidney transplant recipients.
11:51 - 11:57	DELISTING STRATEGY IN HIGHLY SENSITISED PATIENTS WITH PERFORMED DSA Speaker: José Manuel Amaro (Spain)
11:57 - 12:03	TRENDS IN CREATININE AND BLOOD PRESSURE AFTER STENT IMPLANTATION IN PATIENTS WITH SIGNIFICANT STENOSIS OF THE RENAL ARTERIES AFTER KIDNEY TRANSPLANTATION
12:03 - 12:09	Quantifying Donor-Derived Cell-Free DNA for Monitoring Kidney Transplant Recipients: a Head-to-Head Comparison of NGS and ddPCR Assays Speaker: Louise Benning (Germany)
12:09 - 12:15	Hemodynamic Impacts of Kidney Donation on the Abdominal Aorta: A Computational Fluid Dynamics Study
12:15 - 12:21	Unveiling Donor-Originated BKPyV Viremia in kidney transplant recipients Speaker: Wouter Moest (Netherlands)
12:21 - 12:27	FACTORS ASSOCIATED WITH EARLY MORTALITY IN KIDNEY TRANSPLANT RECIPIENTS =70 YEARS OLD



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

12:27 - 12:33	Haemophagocytic histiolymplocytis after solid organ transplantation: preliminary data from a cohort study

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

AKI & Critical Care Nephrology

Room: **Focussed Oral Room 10**

11:15-12:30 CEST

AKI & Critical Care Nephrology

Chair:	
11:15 - 11:21	Health inequalities and outcomes following acute kidney injury: a systematic review & meta-analyses of observational studies
11:21 - 11:27	Neutrophil Gelatinase-Associated Lipocalin (NGAL) for the assessment of persistent renal dysfunction after acute kidney injury Speaker: Yacov Shacham (Israel)
11:27 - 11:33	Is Acute Hemodialysis Precluded in the Oldest-Old Patients?



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:33 - 11:39	Audit of the Clinical Implementation of Urinary NGAL in the Diagnostic Work-up of Acute Kidney Injury at an Irish Hospital Speaker: Michael Strader (Ireland)
11:39 - 11:45	Acute Kidney Injury in Acute Heart Failure patients undergoing aggressive diuresis and its impact on short term outcome Speaker: Anil Jhajhria (India)
11:45 - 11:51	Kidney injury post Covid-19 - a nationwide Swedish register study
11:51 - 11:57	Prognostic value of changes in the serum indoxyl sulfate concentration in septic-shock-associated AKI: the Tox-AKI cohort study. Speaker: Dimitri Titeca-Beauport (France)
11:57 - 12:03	Acute Kidney Injury in the Very Elderly: Evolving Times, Evolving Epidemiology in an aging society Speaker: Pasquale Esposito (Italy)
12:03 - 12:09	Malaria is the leading cause of Acute Kidney Injury in paediatric patients in Nigeria. Evidence from a Point-of-Care Creatinine Study in a Nigerian Primary Health Care Centre
12:09 - 12:15	Kidney involvement in severe Legionnaire's disease in intensive care Speaker: Mickaël Bobot (France)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

12:15 - 12:21	Association between baseline serum creatinine/cystatin C (SCr/CYS) ratio and adverse events in patients receiving cisplatin or carboplatin: a prospective cohort study Speaker: Meghan Sise (United States of America)
12:21 - 12:27	Association between new-onset proteinuria during hospitalization and cardiovascular mortality among patients with atherosclerotic cardiovascular disease

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Hypertension & Diabetes

Room: **Focussed Oral Room 9**

11:15-12:30 CEST

Hypertension & Diabetes

Chair:	
11:15 - 11:21	Angiotensin Dysregulation in Patients with Arterial Aneurysms
11:21 - 11:27	Predicting the risk of and days without albuminuria in patients with diabetes mellitus: a development and validation study Speaker: Roemer Janse (Netherlands)
11:27 - 11:33	Impact of Glycemic Variability on Mortality Risk in Patients with Diabetes and End-Stage Kidney Disease Undergoing Maintenance Dialysis



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:33 - 11:39	The impact of Metformin on CKD Progression and Mortality in Diabetic Patients using SGLT2 inhibitors – a real world cohort study Speaker: Timna Agur (Israel)
11:39 - 11:45	Sex differences in ambulatory central blood pressure and arterial stiffness in hemodialysis patients.
11:45 - 11:51	Glucagon-like Peptide-1 Receptor Agonists and the Risk of Emergency Department Visits and Hospitalization in Patients Across the Spectrum of Kidney Disease Speaker: Kevin Yau (Canada)
11:51 - 11:57	Heterogeneity in characteristics of target population and definitions of renal outcome on evaluating the renoprotective effect of GLP-1RA in patients with diabetes: a systematic review and meta-analysis of observational studies versus randomized controlled trials Speaker: Xiaoyu Wu (P.R. China)
11:57 - 12:03	Renal perfusion assessment by magnetic resonance imaging in patients with diabetic cardiac autonomic neuropathy
12:03 - 12:09	Trends in the global, regional, and national burden of diabetic kidney disease from 1990 to 2021: A systematic analysis of the Global Burden of Disease Study 2021



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

12:09 - 12:15	Early Dynamic Identification of Glomerular Hyperfiltration is Associated with Chronic Kidney Disease in Type 2 Diabetes
12:15 - 12:21	The association between oxidative balance score and its combination with advanced lung cancer inflammation index and risks of chronic kidney disease in hypertension: NHANES 1999-2018 Speaker: Xuejing CHEN (P.R. China)
12:21 - 12:27	Association of glomerular hyperfiltration with mortality in stroke: an analysis using pooled individual patient data from the MICON multi-centre collaboration

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Dialysis

Room: **Focussed Oral Room 7**

11:15-12:30 CEST

Dialysis

Chair:	
11:15 - 11:21	Projections of infection-related cost savings associated with treating CKD associated pruritus (CKD-aP) with difelikefalin in five European countries through the combination of clinical trial data and real-world evidence



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:21 - 11:27	External validation of existing mortality prediction models for patients entering kidney replacement therapy
11:27 - 11:33	Physical Performance Outperforms Uremic Toxins in Predicting 10-Year Mortality in Dialysis Patients
11:33 - 11:39	Dynamic impact of the COVID-19 pandemic on Health-related Quality of Life and Symptom Burden in Dutch Dialysis patients Speaker: Pim Bouwmans (Netherlands)
11:39 - 11:45	Dialysate bicarbonate concentration is associated with an increased risk of cardiac arrhythmias in individuals receiving haemodialysis: results from a Danish multicentre cohort study (the CADDY study) Speaker: Dea Kofod (Denmark)
11:45 - 11:51	Health status in different subgroups of people receiving hemodiafiltration versus hemodialysis for renal replacement therapy: a subgroup analysis of the CONVINCe randomized controlled trial Speaker: Krister Cromm (Germany)
11:51 - 11:57	“Six hours per day” sedentarism: a strong risk factor in dialysis patients
11:57 - 12:03	Arterial oxygen saturation trajectory during hemodialysis: an indication of bio-incompatibility?



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

12:03 - 12:09	Green Dialysis? Identifying Carbon Footprint Hotspots in a Hemodialysis Center in Poland Speaker: Zuzanna Jakubowska (Poland)
12:09 - 12:15	RECOGNITION OF END OF LIFE IN PATIENTS WITH CHRONIC HEMODIALYSIS IN LAZIO AND USE OF PALIATIVE CARE: A REGISTRY STUDY
12:15 - 12:21	Non-Conventional Nutritional Parameters, Including Adipokines and Extracellular Water (ECW), in the First Three Years following Renal Replacement Therapy (RRT): Association with Long-Term Mortality in an End Stage Kidney Disease (ESKD) Cohort
12:21 - 12:27	Predicting Mortality in Unplanned Hemodialysis
12:27 - 12:33	Comparison of Survival Between Hemodialysis and Peritoneal Dialysis in Patients Aged \geq80 Years: A Propensity Score Matched Analysis of a large Catalonia Registry cohort.

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Dialysis

Room: **Focussed Oral Room 6**

11:15-12:30 CEST

Dialysis

Chair:	Robert Ekart (Slovenia)
11:15 - 11:20	A Bleeding Concern: Incidence of Major Gastrointestinal Bleeding in Dialysis
11:20 - 11:25	“When it’s bad, it can be debilitating”. A mixed-methods analysis of Chronic Kidney Disease Associated Pruritus in Irish dialysis patients Speaker: Lisa Mellon (Ireland)
11:25 - 11:30	Development and External Validation of a Machine Learning Model for Cardiac Valve Calcification Early Screening in Dialysis Patients: A Multicenter Study
11:30 - 11:35	The ameliorative effects of oral tacrolimus on treatment-resistant pruritus through interleukin 13 signaling pathways in hemodialysis patients: A double-blind, randomized, placebo-controlled trial
11:35 - 11:40	Nutritional issues among hemodialysis patients - Deficiency and Excess Body Mass
11:40 - 11:45	Comparative analysis of blood metals and trace elements in Egyptian hemodialysis patients and their relatives in the same



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	geographical area
11:45 - 11:50	Association of physical function and fear of falling with the number of falls over a 12-month period in patients on hemodialysis
11:50 - 11:55	Association of physical function with chronic pain and sleep quality in patients on hemodialysis
11:55 - 12:00	Management of Resistant Hyperphosphatemia in Maintenance Hemodialysis (MHD) patients - Role of Sucroferric Oxyhydroxide (SFO): A prospective study Speaker: Luvdeep Dogra (India)
12:00 - 12:05	Effect of Bisphenols on Genomic Damage in Patients with Chronic Kidney Disease on Hemodialysis
12:05 - 12:10	STUDY OF INTRADIALYSIS PHYSICAL ACTIVITY AND QUALITY OF LIFE IN PATIENTS ON HEMODIALYSIS
12:10 - 12:15	Development of Depression and Anxiety Symptoms in Chronic Hemodialysis Patients During "Sword of Iron" War



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

12:15 - 12:20	Comparison and validation of two laboratory platforms for peritoneal NGAL in PD patients with and without peritonitis.
---------------	-------------------------------------------------------------------------------------------------------------------------------

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 5**

11:15-12:30 CEST

Chronic kidney disease

Chair:	
11:15 - 11:21	Kidney function and the metabolome in the general population Speaker: Maria K. Svensson (Sweden)
11:21 - 11:27	Gender disparities in CKD before and after referral to nephrology Speaker: Frida Welander (Sweden)
11:27 - 11:33	Unraveling the Biology of Adversity: Proteomic and Metabolomic Insights into Socioeconomic Disparities in Kidney Disease
11:33 - 11:39	Improving and personalizing nephrology care with the use of outcome data: examples of national and regional initiatives in the Netherlands.



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:39 - 11:45	Sex-specific temporal relationship between common comorbidity patterns and subsequent risk of chronic kidney disease Speaker: Chunyang Li (P.R. China)
11:45 - 11:51	Discordant results between creatinine- and cystatin C-based equations for estimating glomerular filtration rate: the equation matters Speaker: Pierre Delanaye (Belgium)
11:51 - 11:57	Disease trajectory leading to cause of death among patients with chronic kidney disease Speaker: Chunyang Li (P.R. China)
11:57 - 12:03	Genetic screens of imaging-derived kidney volumes identify genes linked to kidney function Speaker: Sara Monteiro-Martins (Germany)
12:03 - 12:09	Risk of end-stage kidney disease, death and suicide attempts in men and women with migraine treated with topiramate Speaker: Jean Michel Halimi (France)
12:09 - 12:15	Evaluating the Impact of AI-Driven Interventions on Hospital Admissions in End-Stage Kidney Disease (ESKD) Patients Using Medicare and EMR Data.
12:15 - 12:21	Baseline analysis of the patterns of CKD care in an Implementation Trial using Future Health Today in Primary Care



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

12:21 - 12:27	Management and Treatment of Chronic Kidney Disease in the Danish Lolland-Falster Health Study: Focus on Renoprotection and Cardiovascular Disease Prevention

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 4**

11:15-12:30 CEST

Chronic kidney disease

Chair:	
11:15 - 11:21	FEATURES OF POST-COVID KIDNEY DAMAGE IN CHILDREN
11:21 - 11:27	PF4 derived from endothelial cells induces vascular smooth muscle cells calcification via the CXCR3-PERK signaling
11:27 - 11:33	METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IN ADVANCED CHRONIC KIDNEY DISEASE: IMPACT ON PATIENT SURVIVAL.



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:33 - 11:39	NA
11:39 - 11:45	Progression of Cardiac Remodelling and Dysfunction is accompanied by altered metabolic profile in Chronic Kidney Disease Speaker: Juliana Boukhaled (France)
11:45 - 11:51	Serum Zinc Concentration and Long-Term Mortality in CKD Patients: Insights from NHANES (2011-2016) Speaker: Lan Ye (P.R. China)
11:51 - 11:57	Serum Resistin and Other Predictors of CIMT and Cardiovascular Events in Chronic Kidney Disease
11:57 - 12:03	Prognostic Value of N-terminal Prohormone B-type Natriuretic Peptide Modified by Renal Function in Patients with Acute Heart Failure Speaker: Rui Zhu (P.R. China)
12:03 - 12:09	Exploratory study on bone microarchitecture in post-mortem specimens of various skeletal sites from dialysis-dependent patients
12:09 - 12:15	Promising Anemia Related Inhibitors of Vascular Calcification in Chronic Kidney Disease. Data from Systematic Review.



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

12:15 - 12:21	PROGNOSTIC SIGNIFICANCE OF CORONARY ARTERY CALCIFICATION AND EPICARDIAL FAT IN POLYMORBID PATIENTS
12:21 - 12:27	Homocitrulline is associated with cardiovascular outcomes in non-dialysis patients with chronic kidney disease Speaker: Solene Laville (France)

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Glomerular & tubulo-interstitial diseases

Room: **Focussed Oral Room 3**

11:15-12:30 CEST

Glomerular & tubulo-interstitial diseases

Chair:	
11:15 - 11:21	Hereditary Transthyretin Amyloidosis (ATTRv): finerenone along the spectrum of kidney and heart disease
11:21 - 11:27	Health related Quality of Life in Patients with Lupus Nephritis: A Cross-Sectional Survey based Study
11:27 - 11:33	Real-world utility of the International IgA Nephropathy Prediction Tool in a tertiary referral centre of Nephrology



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:33 - 11:39	Clinicopathological correlation of interstitial inflammation in Diabetic Nephropathy: A cross-sectional study
11:39 - 11:45	Full recovery from lupus nephritis with no signs of CKD. Focused analysis
11:45 - 11:51	Multi-Center study of Anti-Nephrin Antibodies in Minimal Change Disease and Focal Segmental Glomerulosclerosis
11:51 - 11:57	BACTERIAL DIVERSITY OF THE GENITAL TRACT IN LUPUS NEPHRITIS PATIENTS. A PILOT MICROBIOME ANALYSIS
11:57 - 12:03	A study of calcineurin inhibitors in comparison with intravenous cyclophosphamide for initial induction treatment of lupus nephritis class ?, IV, ? in Chinese children
12:03 - 12:09	Obinutuzumab in Steroid-Resistant Podocytopathies
12:09 - 12:15	LUPUS NEPHRITIS TREATED WITH BELIMUMAB. EXPERIENCE IN CANARY ISLANDS. Speaker: GERMAN PEREZ SUAREZ (Spain)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

12:15 - 12:21	Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome
12:21 - 12:27	Diagnostic Gaps in C3G and ic-MPGN: Findings of the CompCure Study Cohort Speaker: Giulia Bassanese (Germany)
12:27 - 12:33	Predicting disease progression in IgA Nephropathy Portuguese patients: the role of inflammation and vascular damage markers beyond the IgAN PT.

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Glomerular & tubulo-interstitial diseases

Room: **Focussed Oral Room 2**

11:15-12:30 CEST

Glomerular & tubulo-interstitial diseases

Chair:	
11:15 - 11:21	Association between relapse and long-term kidney outcomes in IgA nephropathy



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:21 - 11:27	Loin pain in adults with IgA nephropathy: Insights from qualitative interviews with patients, families, and healthcare professionals Speaker: Kristina Newman (United Kingdom)
11:27 - 11:33	Clinical and biological characteristics predictive of immune checkpoint inhibitors-induced acute tubulo-interstitial nephritis
11:33 - 11:39	Cancer Incidence and Risk Factors in PLA2R-associated Membranous Nephropathy
11:39 - 11:45	Metabolic disease assessment and control among adults diagnosed with severe podocytopathies
11:45 - 11:51	What characteristics are associated with a positive genetic study in patients suspected of Alport Syndrome?
11:51 - 11:57	Anti-Phospholipase A2 Receptor Antibody IgG4-to-IgG Ratio Predicts Remission of PLA2R-Associated Primary Membranous Nephropathy
11:57 - 12:03	Association of magnesium depletion score with kidney stones in patients with gout



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

12:03 - 12:09	Time to diagnosis in patients with rare kidney diseases: Findings from the European Rare Kidney Disease Registry
12:09 - 12:15	Long-Term Outcomes in IgA Nephropathy: Findings from the ERKNet Patient Registry (ERKReg)
12:15 - 12:21	THE EFFECT OF IMMUNOSUPPRESSION BASED ON CORTICOSTEROIDS ON ARTERIAL STIFFNESS IN PATIENTS WITH GLOMERULONEPHRITIS
12:21 - 12:27	Long-term outcomes of patients developing acute kidney injury after CAR-T cell therapy for relapsed/refractory hematological malignancies
12:27 - 12:33	Characterizing IgAN and assessing the role of International IgAN Prediction Tool in our population

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Creative Labs

Room: **Hall G1**

11:15-12:30 CEST



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Creative Labs II - How to use stories/narratives to improve scientific communication

Chair:	
11:15 - 12:30	How to use stories/narratives to improve scientific communication Speaker: Andrej Skoberne (Slovenia)

Thursday, 5. June 2025

Free Communication

Date: **05/06/2025**

Kidney Transplantation

Room: **Hall F1**

11:15-12:30 CEST

FC 6: Kidney Transplantation: Epidemiological Insights

Chair:	
11:15 - 11:27	Integrating Pathomic and Clinical Data from Kidney Deceased Donors to Enhance Graft Function Prediction and Reduce Organ Discard: The ComPrePS Assessment Tool
11:27 - 11:39	Access to waitlisting & kidney transplantation for patients with incident kidney failure in Australia and the United Kingdom – a binational comparative analysis Speaker: Lachlan McMichael (Australia)
11:39 - 11:51	Is Living Kidney Donation with Expanded Criteria Safe for the Donor? Long-Term Follow-Up from the Catalan Registry



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:51 - 12:03	Trends in all-cause and cause-specific mortality in adult first kidney transplant recipients with and without diabetes as cause of kidney failure: an ERA Registry study
12:03 - 12:15	Recurrence of IgA nephropathy in a large multicenter cohort of kidney transplant recipients (DIVAT)
12:15 - 12:27	Changes in Cerebral Blood Flow and Cognitive Function Before and One Year After Kidney Transplantation: The VINTAGE Study

Thursday, 5. June 2025

Free Communication

Date: **05/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Hall E2**

11:15-12:30 CEST

FC 5: About ANCA and SLE Associated Glomerulonephritis

Chair:	
11:15 - 11:27	Early-onset Lupus Nephritis: insights into clinical, laboratory and prognostic characteristics of monogenic forms Speaker: Giulia Palazzini (Italy)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:27 - 11:39	Predictors and long-term impact of sustained complete renal response in lupus nephritis patients over a 10-year follow up
11:39 - 11:51	Persistent Isolated Low C3 (PILC3) predicts long-term eGFR decline in lupus nephritis: a linear projection of total eGFR slopes from BLISS-LN trial data.
11:51 - 12:03	Baseline C3 levels improves the predictive capacity of ANCA kidney risk score in patients with ANCA-associated vasculitis
12:03 - 12:15	3-months short course of avacopan in ANCA vasculitis with severe clinical involvement. A real-life experience.
12:15 - 12:27	Quality, power and fragility of randomised controlled trials in ANCA-associated vasculitis Speaker: Vanja Ivkovic (Sweden)

Thursday, 5. June 2025

Free Communication

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Hall K**

11:15-12:30 CEST



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

FC 7: CKD and Public Health: Part 2

Chair:	
11:15 - 11:27	Frailty, Sarcopenia and Mortality Risk in Patients with Chronic Kidney Disease: A Nationally Representative Analysis Speaker: Changyuan Yang (Netherlands)
11:27 - 11:39	Evaluating KDIGO and KidneyintelX.dkd for Risk Stratification in Diabetic Kidney Disease: Insights from CANVAS and CREDENCE
11:39 - 11:51	Guideline-based management of chronic kidney disease and associated risk of cardio-renal outcomes Speaker: Ellen Linnea Freese Ballegaard (Denmark)
11:51 - 12:03	What is the mortality of older adults opting for dialysis or conservative care, stratified by eligibility for dialysis?
12:03 - 12:15	A Patient-Level Simulation Study Assessing the Clinical, Economic, and Environmental Burden of Chronic Kidney Disease in the Netherlands
12:15 - 12:27	Evaluating the Clinical and Economic Impact of SGLT-2 Inhibitors for CKD Management in the UK: Insights from the IMPACT CKD Microsimulation Model.



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

--	--

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

**Physiology, cell biology & genetic
diseases, Focussed Orals**

Room: **Focussed Oral Room 1**

11:15-12:30 CEST

Physiology, cell biology & genetic diseases

Chair:	
11:15 - 11:21	Serum Metabolic Profiling Analysis of Gitelman Syndrome by Untargeted Metabolomics
11:21 - 11:27	Identification and characterization of genetic founder effects in Chuxiong-Yi populations with extremely high local incidence of Gitelman syndrome
11:27 - 11:33	EXOME SEQUENCING IN PATIENTS WITH MEDULLARY SPONGE KIDNEY
11:33 - 11:39	A phase 4 study to evaluate the safety and tolerability of higher infusion rates of agalsidase beta to shorten the infusion duration in Fabry disease – Preliminary data Speaker: Maryam Banikazemi (United States of America)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:39 - 11:45	Not a cluster of grapes, but bananas: Cord-like three-dimensional structure of cysts in ADPKD supports tubular obstruction hypothesis
11:45 - 11:51	Safety and efficacy of Tolvaptan in real-world high-risk patients with ADPKD – A Single Center Experience
11:51 - 11:57	Mitochondrial translation reveals a therapeutic vulnerability in Autosomal Dominant Polycystic Kidney Disease
11:57 - 12:03	Genetic Fingerprinting of Inflammation in Anderson-Fabry Disease: The Role of NLRP3 Polymorphisms
12:03 - 12:09	Genotyping and phenotyping early and very early Autosomal Dominant Polycystic Kidney Disease onset
12:09 - 12:15	Detecting MUC1 VNTR variants using VNtyper in Irish patients
12:15 - 12:21	APPLICATION OF MOLECULAR GENETIC METHODS IN THE DIAGNOSIS OF RENAL TUBERCULOSIS
12:21 - 12:27	Pathway Analysis of Cosmic Kidney Disease: Just how bad does spaceflight get?



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

--	--

Thursday, 5. June 2025

Free Communication

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Hall G2**

11:15-12:30 CEST

FC 8: More about SGLT2 inhibitors

Chair:	
11:15 - 11:27	SGLT2 inhibition triggers aestivation-like metabolic switches for water conservation in patients with heart failure - results from Dapa-Shuttle1, a randomized, placebo-controlled trial
11:27 - 11:39	Cellular mediators involved in the nephroprotective mechanisms of Dapagliflozin: a study on human renal tubular cells Speaker: Elisa Russo (Italy)
11:39 - 11:51	Impact of Dapagliflozin on bone mineral metabolism in Non-diabetic Patients with Chronic Kidney Disease, Randomized, Double Blinded, Placebo controlled Trial Speaker: Mohamed Elshayeb (Egypt)
11:51 - 12:03	Vicadrostat with and without empagliflozin reduces albuminuria across KDIGO risk class in chronic kidney disease Speaker: Katherine R Tuttle (United States of America)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

12:03 - 12:15	Effect of SGLT2 Inhibitor (Dapagliflozin) on Aortic Calcification in Non-Diabetic CKD Patients: A randomized controlled study. Speaker: Mostafa Gamal (Egypt)
12:15 - 12:27	Outcomes of Canagliflozin in Patients with Type 2 Diabetes with and without Progressive Renal Function Decline: Insights from the CREDENCE Trial

Thursday, 5. June 2025

Free Communication

Date: **05/06/2025**

AKI & Critical Care Nephrology

Room: **Hall E1**

11:15-12:30 CEST

FC 4: The Basics of Acute Kidney Injury

Chair:	
11:15 - 11:27	Flow-cytometric quantification of urine kidney epithelial cells specifically reflects tubular damage in acute kidney diseases
11:27 - 11:39	Urinary CXCL9 in immune checkpoint inhibitor-associated acute interstitial nephritis (ICI-AIN) Speaker: Meghan Sise (United States of America)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:39 - 11:51	Ti@Mn Nanozymes as Nanotherapeutic Agents for ROS Scavenging and Inflammation Reduction in Acute Kidney Injury
11:51 - 12:03	Autophagy-associated FIP200 protects renal tubules against apoptosis following renal ischemia-reperfusion injury
12:03 - 12:15	Pharmacokinetics, Pharmacodynamics and Safety of TIN816 in Patients With Sepsis-Associated Acute Kidney Injury: Results From a Randomized Phase 2a Study Speaker: Patrick Murray (Ireland)
12:15 - 12:27	Examining variations in adherence to guideline-recommended post-acute kidney injury care in UK primary care

Thursday, 5. June 2025

Free Communication

Date: **05/06/2025**

Dialysis

Room: **Hall C**

11:15-12:30 CEST

FC 3: Hemodialysis: Epidemiological Insights

Chair:	
11:15 - 11:27	Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: Observations in a Large U.S. Hemodialysis Cohort Speaker: Andrea Nandorine Ban (United States of America)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:27 - 11:39	Which patients benefit most from hemodiafiltration compared with hemodialysis: prediction of the individualized treatment effects
11:39 - 11:51	Delivered Hemodialysis Treatment Time and Mortality Risk: A Retrospective Analysis
11:51 - 12:03	Analysis of Characteristics of Blood Glucose Fluctuations and Risk Factors for Hypoglycemia in Older Adult Patients with Diabetes Undergoing Maintenance Hemodialysis: A Multicenter Observational Study
12:03 - 12:15	Associations Between Sodium Gradients and All-Cause Mortality in Maintenance Hemodialysis Patients Speaker: Karin Bergling (United States of America)
12:15 - 12:27	Impact of Phase Angle on Mortality in Hemodialysis Patients

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Physiology, cell biology & genetic diseases

Room: **Hall B**



Discover the ERA25 Scientific Programme.
Please note that the information below is constantly being updated.

11:15-12:30 CEST

Toward novel therapies for kidney genetic disorders?

Chair:	Alessandra Boletta (Italy) Jan Halbritter (Germany)
11:15 - 11:40	First in class compounds to treat NPH Speaker: Sophie Saunier (France)
11:40 - 12:05	Exon skipping as novel therapies in genetic disorders Speaker: John Sayer (United Kingdom)
12:05 - 12:30	Chaperone therapies in inherited kidney diseases: a way to go? Speaker: Eric Olinger (Belgium)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

AKI & Critical Care Nephrology

Room: **Hall D**

11:15-12:30 CEST

Effect of AKI and other Organs

Chair:	Z. Serhan Tuglular (Türkiye) Michael Joannidis (Austria)
--------	-------------------------------------------------------------



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:15 - 11:40	AKI and ARDS Speaker: Celine Monard (France)
11:40 - 12:05	AKI and Cardiogenic shock Speaker: Melanie Meersch (Germany)
12:05 - 12:30	AKI and distant organ dysfunction Speaker: Ryo Matsuura (United States of America)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Institutional

Room: **Hall A Plenary Room**

11:15-12:30 CEST

Cutting-Edge Clinical Trials and Future Perspectives in Nephrology

Chair:	

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Institutional

Room: **The Square**



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

11:30-12:30 CEST

Pro & Cons: Organ donation after assisted suicide/euthanasia

Chair:	Jadranka Buturovic-Ponikvar (Slovenia)
11:30 - 11:35	Introduction Speaker: Jadranka Buturovic-Ponikvar (Slovenia)
11:35 - 11:50	Short contribution Speaker: Roos Marsman (Netherlands)
11:50 - 12:05	Outline the ethics issues Speaker: Simon Sawhney (United Kingdom)
12:05 - 12:20	Patient's perspective Speaker: Daniel Gallego Zurro (Spain)

Thursday, 5. June 2025

Plenary Lecture

Date: **05/06/2025**

Institutional

Room: **Hall A Plenary Room**

14:15-15:00 CEST

Plenary Lecture 1

Chair:	Giuseppe Grandaliano (Italy)
--------	------------------------------



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	Kathrin Eller (Austria)
14:20 - 15:00	APOL1 and precision nephrology Speaker: Adriana Hung (United States of America)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Glomerular & tubulo-interstitial diseases

Room: **Hall A Plenary Room**

15:00-16:15 CEST

Game changers in diagnosis and treatment of complement-mediated kidney disease

Chair:	Tobias B. Huber (Germany) Kathrin Eller (Austria)
15:00 - 15:25	Biomarkers of complement: how to diagnose a complementopathy Speaker: Sophie Chauvet (France)
15:25 - 15:50	Monoclonal, Genetic and Autoimmune: the different etiologies of C3G Speaker: Montserrat Mercedes Diaz Encarnacion (Spain)
15:50 - 16:15	Why we need so many different drugs for complement inhibition? Speaker: Fadi Fakhouri (Switzerland)



Discover the ERA25 Scientific Programme.
Please note that the information below is constantly being updated.

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Institutional

Room: **Hall D**

15:00-16:15 CEST

Nephrology breakthroughs: editors' panel on innovation

Chair:	Hans-Joachim Anders (Germany) Jürgen Floege (Germany)
15:00 - 15:05	Introduction Speaker: Julie Ingelfinger (United States of America)
15:05 - 15:20	CKD Speaker: Christoph Wanner (Germany)
15:20 - 15:35	Glomerular disease Speaker: Kate Stevens (United Kingdom)
15:35 - 15:50	Dialysis Speaker: Valerie A. Luyckx (Switzerland)
15:50 - 16:05	Transplantation Speaker: Georg A. Böhmig (Austria)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:05 - 16:15	Concluding remarks Speaker: Julie Ingelfinger (United States of America)
---------------	------------------------------------------------------------------------------------

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Hall B**

15:00-16:15 CEST

CKD in the elderly

Chair:	Mustafa Arici (Türkiye) Halima Resic (Bosnia and Herzegovina)
15:00 - 15:25	Healthy ageing and the kidney: Lessons from centenarians Speaker: Motoko Yanagita (Japan)
15:25 - 15:50	The burden of CKD in aging societies Speaker: Kitty J Jager (Netherlands)
15:50 - 16:15	Aging Societies: Insights, Interventions, and Nephrology Challenges Speaker: Danilo Fliser (Germany)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Dialysis

Room: **Hall E1**

15:00-16:15 CEST

Artificial intelligence and home dialysis

Chair:	Christian Combe (France) Ana Carina Ferreira (Portugal)
15:00 - 15:25	Can artificial intelligence predict dialysis adequacy and dialysis access complications more accurately? Speaker: Adrian Covic (Romania)
15:25 - 15:50	Public policy and home dialysis utilization Speaker: Rajnish Mehrotra (United States of America)
15:50 - 16:15	Effect of Remote and Virtual Technology on Home Dialysis Speaker: SABRINA MILAN MANANI (Italy)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

**Physiology, cell biology & genetic
diseases**

Room: **Hall C**

15:00-16:15 CEST

Standing between rare and common



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chair:	Roser Torra (Spain) Giovambattista Capasso (Italy)
15:00 - 15:25	COL4A3 / 4 pathogenic variants: disease or risk factor? Speaker: Nine Knoers (Netherlands)
15:25 - 15:50	Common variants effect on rare diseases Speaker: Krzysztof Kiryluk (United States of America)
15:50 - 16:15	Genetic forms of hypomagnesemia Speaker: Karl Peter Schlingmann (Germany)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Kidney Transplantation

Room: **Hall F1**

15:00-16:15 CEST

Tolerance induction - a game changing innovation

Chair:	Helen Erlandsson (Sweden) Rainer Oberbauer (Austria)
15:00 - 15:25	It takes two: combining bone marrow and Tregs Speaker: Thomas Wekerle (Austria)
15:25 - 15:50	How far can CARs go? Speaker: Ilse Gille (Netherlands)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:50 - 16:15	Donor modified immune cells Speaker: Christian Morath (Germany)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Hypertension & Diabetes

Room: **Hall E2**

15:00-16:15 CEST

Emerging concepts on pathophysiology of hypertension

Chair:	Marieta P. Theodorakopoulou (Greece) Carmine Zoccali (Italy)
15:00 - 15:25	Kidney meets aging: is chronodisruption a concept relevant to hypertension and CKD? Speaker: Alberto Ortiz Arduán (Spain)
15:25 - 15:50	Potassium regulation and BP levels: a new road for treatment? Speaker: Liffert Vogt (Netherlands)
15:50 - 16:15	Autonomic nervous system dysfunction in CKD and ESKD Speaker: Konstantina Dipla (Greece)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Institutional

Room: **The Square**

15:00-16:15 CEST

Learn by Practice: Weight loss for CKD: are GLP-1 receptor agonists the solution for all patients?

Chair:	Pantelis Sarafidis (Greece)
15:00 - 15:37	Case 1: A patient with type 2 DM, HbA1c of 7.4%, BMI of 27 kg/m², and a UACR of 300 mg/g Speaker: Beatriz Fernandez Fernandez (Spain)
15:37 - 16:14	Case 2: A non-diabetic patient with presumed secondary FSGS, BMI of 34 kg/m² and a UACR of 2 g/g Speaker: Carla Maria Avesani (Sweden)

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Focussed Oral Room 2**

15:00-16:15 CEST

Glomerular & tubulo-interstitial diseases

Chair:	
--------	--



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:00 - 15:06	Validation and clinical application of the Vasculitis quality of life (VASQLIFE) survey: An AAV-Specific Patient-Reported Outcome Measure for use in routine clinic practice Speaker: Lauren Floyd (United Kingdom)
15:06 - 15:12	PREDICTING KIDNEY OUTCOMES IN ANCA VASCULITIS: WHICH HISTOLOGICAL SCORES SHOULD WE USE?
15:12 - 15:18	Chronic Kidney Disease in Sjögren's Syndrome: Key Predictive Factors Revealed in a 133-Patient Cohort
15:18 - 15:24	Insights into Early Crescentic Glomerulonephritis via Single-Nuclei Sequencing
15:24 - 15:30	Long-term patients and kidney prognosis of pure membranous compared to mixed lupus nephritis: an Italian multicenter study of 195 patients Speaker: Martina Uzzo (Italy)
15:30 - 15:36	Evaluation of the proposed clinical and histological prognostic scores in patients with ANCA-associated vasculitis: A single-center retrospective study
15:36 - 15:42	Plasma endothelial biomarkers in relation to albuminuria, kidney function and CKD progression in IgA-nephropathy Speaker: Karin Bergen (Sweden)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:42 - 15:48	Neutrophils Ferroptosis restrict Treg activity through metabolic reprogramming in systemic lupus erythematosus
15:48 - 15:54	Cardiac autonomic dysfunction and arterial stiffness in patients with sustained remission of ANCA-associated vasculitis
15:54 - 16:00	Hemorrhagic stroke as an uncommon complication of granulomatosis with polyangiitis
16:00 - 16:06	Cardiorenal outcomes and long-term kidney function decline in IgA Nephropathy compared with chronic kidney disease patients with and without diabetes - FinnGen study Speaker: Matti Sentürk (Finland)
16:06 - 16:12	Anti-drug antibodies are common in Membranous Nephropathy and affect response to rituximab: a multicenter study Speaker: Micaela Anna Casiraghi (Italy)

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 3**

15:00-16:15 CEST



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chronic kidney disease

Chair:	Alejandro Chade (United States of America)
15:00 - 15:06	Aryl hydrocarbon receptor promotes renal fibrosis via accelerating cell senescence in tubular epithelial cells Speaker: Qian Ren (P.R. China)
15:06 - 15:12	In-vitro effect of cholecalciferol on immune and vascular function in chronic kidney disease
15:12 - 15:18	The DNA Methyltransferase Inhibitor 5-Azacytidine Alleviates Podocyte Injury By Reversing DNA Hypermethylation-Mediated Inhibition of INSR In Podocytes Of Diabetic db/db Mice
15:18 - 15:24	A new calcimimetic inhibiting vascular calcification: the endogenous VIF peptide Speaker: Sofia de la Puente Secades (Germany)
15:24 - 15:30	Intestinal microbiota prevents worsening of sepsis-related outcomes in chronic kidney disease
15:30 - 15:36	Blockade of Translocator Protein Ameliorates Intrarenal Lipid Accumulation and Kidney Injury in Obesity-induced Chronic Kidney Disease



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:36 - 15:42	Uremic toxin receptor AhR promotes renal fatty acid synthesis and fibrosis via accelerating ubiquitin degradation of NR1D1
15:42 - 15:48	A new model of CKD in naturally aged swine Speaker: Alejandro Chade (United States of America)
15:48 - 15:54	Intra-coronary VEGF therapy rescues cardiac VEGF signaling and improves cardiac function in experimental CKD-HFpEF Speaker: Alejandro Chade (United States of America)
15:54 - 16:00	Interferon regulatory factor 5 in myeloid cells promotes obstructive nephropathy-induced renal fibrosis in vivo
16:00 - 16:06	Sweat-Based Protocols for Reliable Determination of Creatine and Cystatin-C in Chronic Kidney Disease
16:06 - 16:12	The role of uremic toxins and inflammation in eryptosis and renal anemia among dialysis patients.

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chronic Kidney Disease

Room: **Focussed Oral Room 4**

15:00-16:15 CEST

Chronic kidney disease

Chair:	
15:00 - 15:06	Underestimate of the diagnosis and treatment of chronic kidney disease for in-hospital cardiovascular disease patients—A nationwide cross-section study in China
15:06 - 15:12	Impact of Cardiorenal Unit Management on Care Outcomes: The Role of Heart Failure Therapy Optimization. Speaker: Ana María García Girón (Spain)
15:12 - 15:18	Impact of Kidney Transplantation on Chronic Kidney Disease-Associated Pruritus
15:18 - 15:24	Renin-angiotensin-aldosterone system inhibitor utilization and hyperkalemia in patients with chronic kidney disease – Results from ZORA China
15:24 - 15:30	Tumor Necrosis Factor alpha and high phosphate increase platelet adhesion, by modifying endothelial anti-thrombotic properties Speaker: Paola Ciceri (Italy)
15:30 - 15:36	High glucose worsens calcium deposition and osteoblastic differentiation induced by high phosphate treatment in human



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	<p>aortic endothelial cells Speaker: Paola Ciceri (Italy)</p>
15:36 - 15:42	<p>The impact of comorbid type 2 diabetes on the prevalence of chronic kidney disease-associated pruritus and its effects on quality of life: Data from the CENSUS-EU study. Speaker: James Burton (United Kingdom)</p>
15:42 - 15:48	<p>Hemoglobin increases faster at high altitude in CKD patients treated with SGLT2 inhibitors: the SGaLTitude study Speaker: Mabel Aoun (France)</p>
15:48 - 15:54	<p>Time in target range of systolic blood pressure and cardiovascular disease in patients with chronic kidney disease: A Korean nationwide cohort study</p>
15:54 - 16:00	<p>Causal assessment of CKD-MBD phenotypes and CKD progression through a g-formula analysis – Insights from the EQUAL Study</p>
16:00 - 16:06	<p>Understanding cardiovascular benefits of finerenone: the role of central arterial stiffness Speaker: Nejc Piko (Slovenia)</p>
16:06 - 16:12	<p>PREDICTIVE ABILITY OF CAROTID INTIMA MEDIA THICKNESS FOR CARDIOVASCULAR EVENTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS : INDIAN COHORT</p>



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

--	--

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Dialysis, Focussed Orals

Room: **Focussed Oral Room 5**

15:00-16:15 CEST

Dialysis

Chair:	
15:00 - 15:06	Insights into the Itching Burden Experience of Patients with Hemodialysis-Associated Pruritus: A Social Media Listening Study
15:06 - 15:12	Long-term efficacy and impact on quality of life of difelikefalin treatment in haemodialysed patients with moderate-to-severe chronic kidney disease associated pruritus
15:12 - 15:18	Lung Ultrasound Guided Management of Pulmonary Congestion in Hemodialysis: A Multi-center Randomized Controlled Trial Speaker: Kaysi Saleh (Belgium)
15:18 - 15:24	Pleural effusions among patients on maintenance hemodialysis patients
15:24 - 15:30	Calciphylaxis: a qualitative study of patient experiences Speaker: Sharon Huish (United Kingdom)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:30 - 15:36	Upacicalcet Preserves Albumin Levels in Hemodialysis Patients with Secondary Hyperparathyroidism: A Post-hoc Analysis of a Randomized Trial
15:36 - 15:42	Large Language Models for Algorithm-Based Management of Bone Mineral Disorders in Patients with Hemodialysis Speaker: Karin Bergling (United States of America)
15:42 - 15:48	The Impact of Serum Uromodulin on Aortic Arch Vascular Calcification in Hemodialysis Patients Speaker: Tetsuya Ogawa (Japan)
15:48 - 15:54	Effectiveness of microwave ablation in the treatment of non-primary hyperparathyroidism in dialysis patients Speaker: Mahmud Islam (Türkiye)
15:54 - 16:00	Efficacy of Vitamin C Supplementation in Patients Undergoing Hemodiafiltration: A Comparison Between Oral and Intravenous Administration
16:00 - 16:06	Trajectories of Muscle Mass Changes in Hemodialysis Patients: A Two-Year Prospective Cohort Study Analyzing Clinical Factors
16:06 - 16:12	Ultrafiltration rate and interleukin-6 levels are independent predictors of erythropoietin resistance in chronic hemodialysis



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	<p>patients Speaker: Luís Belo (Portugal)</p>
--	-------------------------------------------------------------------

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Dialysis

Room: **Focussed Oral Room 6**

15:00-16:15 CEST

Dialysis

Chair:	
15:00 - 15:06	Comparative effectiveness of etelcalcetide versus cinacalcet for the treatment of secondary hyperparathyroidism in patients in haemodialysis: a population-based study in Lazio, Italy
15:06 - 15:12	European Hemoglobin Target Range Supported when Assessing Association between Observed Hemoglobin and All-Cause Mortality in Hemodialysis Patients Treated with Erythropoietin Stimulating Agents
15:12 - 15:18	Two Decades of Dialysis in 41 Countries: the new MONitoring Dialysis Outcomes (MONDO) initiative dataset
15:18 - 15:24	Ultrasound for Median Nerve Evaluation in Dialysis Patients: A Reliable Tool for Detecting Carpal Tunnel Syndrome



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	Speaker: Vladimir Veselinov (Serbia)
15:24 - 15:30	Haemodialysis patients and nephrology health care professionals from Ireland exhibit concordance with the hierarchy of biomedical and patient related outcome measures proposed by the SONG-HD consortium: A single centre study
15:30 - 15:36	Novel biomarkers for cardiac evaluation in obese and non-obese hemodialysis patients
15:36 - 15:42	CORRELATION BETWEEN RIGHT VENTRICLE DIASTOLIC FUNCTION AND SYSTEMIC VENOUS CONGESTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON RENAL REPLACEMENT THERAPY AND HEMODIALYSIS Speaker: Gerardo Medina García (Mexico)
15:42 - 15:48	Roles of antiHLA antibodies in the onset of MACE in a population of patients on dialysis and on the waiting list for kidney transplant. A retrospective single-center study
15:48 - 15:54	MALNUTRITION IS PREVALENT IN DALMATIAN HEMODIALYSIS PATIENTS Speaker: Josipa Radić (Croatia)
15:54 - 16:00	A randomized clinical trial on the effect of PEGylated granulocyte-colony stimulating factor on antibody response in hemodialysis patients who had not responded to routine hepatitis B virus vaccine



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:00 - 16:06	BEHAVIOR OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION DURING THE DIALYSIS SESSION Speaker: Ana Alicia Astroña Rojas (Spain)
16:06 - 16:12	CELL-FREE PLASMA DNA (cfDNA) IN PERITONITIS IS ORIGINATED FROM APOPTOTIC EVENTS AND CASPASE-3 ACTIVATION

Thursday, 5. June 2025

Free Communication

Date: **05/06/2025**

Dialysis

Room: **Hall G2**

15:00-16:15 CEST

FC 11: Highs and Lows: The Hemodialysis Rollercoaster

Chair:	
15:00 - 15:12	A novel system to continuously estimate blood pressure in real time during haemodialysis: comparison against standard brachial cuff blood pressures. Speaker: Daniela Viramontes Hörner (United Kingdom)
15:12 - 15:24	Plasma endothelin-1 concentration before hemodialysis is related to the direction of blood pressure changes during hemodialysis
15:24 - 15:36	Intradialytic blood pressure dynamics in a large U.S. hemodialysis population: Unexpected rates of intradialytic hypotension and



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	<p>hypertension Speaker: Andrea Nandorine Ban (United States of America)</p>
15:36 - 15:48	<p>Therapeutic Approach to the Management of Intradialytic Complications: From Combating Hypoxemia to Improving Hemodialysis Tolerance</p>
15:48 - 16:00	<p>Prognostic significance of visit-to-visit ultrafiltration volume variability in hemodialysis patients Speaker: Botond Szabolcs Csiky (Hungary)</p>
16:00 - 16:12	<p>Coexistence of malnutrition and sarcopenia and its impact on mortality in patients on hemodialysis: Results from the SARC-HD Study</p>

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Physiology, cell biology & genetic diseases, Focussed Orals

Room: **Focussed Oral Room 1**

15:00-16:15 CEST

Physiology, cell biology & genetic diseases

Chair:	
15:00 - 15:06	<p>Population modelling depicts the mutational burden of NPHS2 (podocin) nephropathy and reveals an undiagnosed later onset</p>



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	<p>genetic cohort Speaker: Wen Ding (United Kingdom)</p>
15:06 - 15:12	<p>WHOLE EXOME SEQUENCING ANALYSIS IN PATIENTS WITH LOIN PAIN HEMATURIA SYNDROME VS. ISOLATED HEMATURIA</p>
15:12 - 15:18	<p>A novel CT -based radiomics approach for kidney function evaluation in ADPKD Speaker: Luca Calvaruso (Italy)</p>
15:18 - 15:24	<p>Kidney involvement in MELAS/MIDD syndrome: a multicentric description of 104 patients.</p>
15:24 - 15:30	<p>Renal uric acid microcrystals drive hyperinflammation, cystogenesis and disease progression in ADPKD</p>
15:30 - 15:36	<p>Diffusion tensor imaging for tissue characterization and risk stratification in atypical ADPKD patients</p>
15:36 - 15:42	<p>Inhibition of c-Maf and Chemokine receptors prevents the progression of Fabry Disease nephropathy Speaker: Yuta Mitsuishi (Japan)</p>
15:42 - 15:48	<p>Kidney volume based on multi-dimensional orthogonal ultrasound measurements is more accurate than kidney length in evaluation of</p>



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	kidney growth in paediatric ADPKD
15:48 - 15:54	Association of Renal Diameters with ADPKD Gene Variants: Focus on PKD2 Truncating Mutations Speaker: Giulia Condello (Italy)
15:54 - 16:00	Evaluation of eGFR slope and ht-TKV After One Year of Treatment with Dapagliflozin in ADPKD Patients: A Retrospective Case Series Analysis Speaker: Giulia Condello (Italy)
16:00 - 16:06	Genotype and phenotype in autosomal dominant tubulointerstitial kidney disease: a case series Speaker: Diana Silvia Zilisteanu (Romania)
16:06 - 16:12	Kidney Involvement in Non-MELAS/MIDD Mitochondrial Diseases: A Report on 58 Patients.

Thursday, 5. June 2025

Free Communication

Date: **05/06/2025**

Physiology, cell biology & genetic diseases

Room: **Hall K**

15:00-16:15 CEST

FC 9: ADPKD: Finding Mechanisms of Disease and Treatment



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chair:	
15:00 - 15:12	PCK1 loss contributes to kidney disease progression by altering mitochondrial fitness through its cataplerotic function
15:12 - 15:24	Monoallelic IFT172 Variants as a Genetic Contributor to the ADPKD Spectrum
15:24 - 15:36	Genetic heterogeneity of ADPKD: A total of 21 different genes identified in a population-based ADPKD cohort
15:36 - 15:48	Deep phenotyping predicts genotype and refines prognosis in lower risk ADPKD genotypes Speaker: Eugene Chen (United Kingdom)
15:48 - 16:00	Exploring the Role of Polygenic Risk Scores in Aneurysm Risk Among ADPKD Patients – A Collaborative Study
16:00 - 16:12	A novel monoclonal antibody against PAPP-A significantly inhibits disease progression in three mouse models of autosomal dominant polycystic kidney disease Speaker: Georgios Koukos (United States of America)

Thursday, 5. June 2025



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Free Communication

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Hall G1**

15:00-16:15 CEST

FC 10: The Basics of Chronic Kidney Disease

Chair:	
15:00 - 15:12	Mesangial cell injury-aggravated CKD in Jak2-mutated myeloproliferative neoplasms Speaker: Florian Siegerist (Germany)
15:12 - 15:24	COLLAGEN TYPE IV ALPHA-1 (CO4A1) IS NECESSARY FOR GLOMERULAR REGENERATION THROUGH PAX2 REGULATION
15:24 - 15:36	Impaired renal progenitor regeneration and polyploid tubular cell progression underlie physiological kidney tubule aging Speaker: Elena Lazzeri (Italy)
15:36 - 15:48	Activation of the TGF-β2-TβRIII Signaling Pathway in Glomerular Endothelial Cells during the Progression of Diabetic Kidney Disease
15:48 - 16:00	Chemokine Ligand 14 Acts as a Pro-Fibrotic Stimulus in Chronic Kidney Disease Progression through Regulation of the GATA2 Transcription Factor Speaker: Sunhwa Lee (Korea, Rep. of South)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:00 - 16:12	Sustained activation of the PI3K/Akt/mTOR pathway in proximal tubular cells promotes tubular albuminuria by decreasing the expression of endocytic receptors
---------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Dialysis

Room: **Focussed Oral Room 7**

15:00-16:15 CEST

Dialysis

Chair:	
15:00 - 15:06	First-In-Human Trial to Evaluate the Safety and Efficacy of Neokidney, a New Portable Hemodialysis Device
15:06 - 15:12	Heparin use on hemodialysis – influencing factors
15:12 - 15:18	Impact of Adipose Tissue on Estimating Extracellular Resistance in Hemodialysis Patients Using a Two-Compartment Model
15:18 - 15:24	The Choice of Anti-Inflammatory Influences the Elimination of Protein-Bound Uremic Toxins Speaker: Víctor Joaquín Escudero Saiz (Spain)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:24 - 15:30	Effects of super high-flux vitamin E-coated and medium cut-off dialyzers on uremic toxins removal and biocompatibility: the E-FLUX randomized controlled study Speaker: mohamed belmouaz (France)
15:30 - 15:36	Removal of Middle Molecules With Hemoadsorption plus Hemodiafiltration in Kidney Failure Patients
15:36 - 15:42	A single-centre service evaluation of patient-centred twice-weekly dialysis delivery
15:42 - 15:48	Dialysis Less Frequently in the Elderly: The D-LITE Pilot Trial Speaker: Christine A. White (Canada)
15:48 - 15:54	A randomized prospective crossover study on the effects of medium cut-off membranes on FGF-23 and inflammatory mediators in patients receiving regular haemodialysis
15:54 - 16:00	Intradialytic Exercise Modulates Vascular Biomarkers in CKD: Implications for Cardiovascular Health in Hemodiafiltration Patients
16:00 - 16:06	Fluid management in hemodialysis based on apparative methods and patient-reported outcome measures: A quality improvement project



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:06 - 16:12	EFFICIENCY AND SAFETY OF EXPANDED (HDx) AND HIGH-FLUX HEMODIALYSIS IN THE ERA OF GREEN DIALYSIS

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Hypertension & Diabetes

Room: **Focussed Oral Room 9**

15:00-16:15 CEST

Hypertension & Diabetes

Chair:	
15:00 - 15:06	Study of renal blood flow and severity of coronary atherosclerosis in patients with ischemic heart disease who underwent myocardial revascularization
15:06 - 15:12	STROMAL CELL-DERIVED FACTOR-1, P-SELECTIN, AND ADVANCED OXIDATION PROTEIN PRODUCTS MAY BE ASSOCIATED WITH CEREBRAL VESSELS IN NORMOALBUMINURIC DIABETIC KIDNEY DISEASE
15:12 - 15:18	REAL-LIFE STUDY OF FINERENONE, EFFICACY AND SAFETY ASSESSMENT



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:18 - 15:24	Role of ACE2 in the prediction of preeclampsia
15:24 - 15:30	Prevalence of Hypertensive Disorders of Pregnancy and Predictors of Adverse Outcomes: 5-year Retrospective Review in a Tertiary Referral Center Speaker: Vincent Anthony Tang (Philippines, The)
15:30 - 15:36	Clinical Significance of Proteinuria Burden at Serial Health Screenings in Patients with Diabetes Mellitus - A Nationwide Cohort Study
15:36 - 15:42	The association between hemoglobin A1c and complications among individuals with diabetes and severe chronic kidney disease Speaker: Dea Kofod (Denmark)
15:42 - 15:48	Incremental hemodialysis with tight control of overhydration as an option for pregnant woman in RRT Speaker: Rita Santarsiere (Italy)
15:48 - 15:54	Sex related disparities in the management of Diabetic Kidney Disease: A Retrospective Analysis in a Health Region
15:54 - 16:00	Eosinophilic Infiltration in Biopsies of Patients with Diabetic Nephropathy. Speaker: Jorge Torres Ortiz (Spain)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:00 - 16:06	Pregnancy, primary aldosteronism and renal tubular disorders: A systematic review of the utility of amiloride in pregnancy
16:06 - 16:12	Childhood Takayasu arteritis: a multicentre retrospective cohort study Speaker: Katrina Evers (Switzerland)

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

AKI & Critical Care Nephrology

Room: **Focussed Oral Room 8**

15:00-16:15 CEST

AKI & Critical Care Nephrology

Chair:	
15:00 - 15:06	Role of Roxadustat for Prevention of Severe Contrast-induced Acute Kidney Injury in Rats
15:06 - 15:12	Tubular epithelial cells are the primary source of Flt3L in acute kidney injury, independent of immune cells Speaker: Na Li (P.R. China)
15:12 - 15:18	Conventional amphotericin B versus liposomal amphotericin B: effects of treatment with dapagliflozin on kidney function and hemodynamics Speaker: Mariana Moura Nascimento (Brazil)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:18 - 15:24	Plasma extracellular cold-inducible RNA-binding protein (eCIRP) is associated with acute kidney injury in patients after cardiac arrest
15:24 - 15:30	Exploring the physiopathological role of labile iron in acute kidney injury: A model of porcine polymicrobial septic shock
15:30 - 15:36	Defective Autophagy Drives Ferroptosis via Mitochondrial ROS in Diabetic Kidney Disease. Speaker: Sho Matsui (Japan)
15:36 - 15:42	Activated HIF-1α accelerates tubular repair in Acute kidney injury via cell proliferation Speaker: Yoshifumi Kurosaki (Japan)
15:42 - 15:48	ALOX5 activation promotes ferroptosis in renal ischemia-reperfusion injury
15:48 - 15:54	TREM2 macrophages ameliorate the transition from acute kidney injury to chronic kidney disease via a PI3K/AKT Signalling Pathway
15:54 - 16:00	Insulin-like growth factor-binding protein is upregulated after acute kidney injury in those with major adverse kidney events at day 90



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:00 - 16:06	Kidney injury released circulating acetylated HMGB1 is a pathogenic factor in the development of acute lung injury Speaker: Rui Zeng (P.R. China)
16:06 - 16:12	Heat acclimation protects against acute kidney injury in mice with heat stroke by inhibiting ferroptosis through activation of mitophagy

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

AKI & Critical Care Nephrology

Room: **Focussed Oral Room 10**

15:00-16:15 CEST

AKI & Critical Care Nephrology

Chair:	
15:00 - 15:06	Quality of Life after Acute Kidney Injury, Not Just an Acute Problem
15:06 - 15:12	Glomerular Filtration Rate and Albuminuria Predicts Outcomes in Patients with Acute Kidney Disease Speaker: SZU-YU PAN (Taiwan, R.O.C.)
15:12 - 15:18	Acute Kidney Injury in Critically Ill Cancer Patients: Risk Factors and Impact on Survival



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:18 - 15:24	Pre-operative CKD Stages IIIb-IV in Renal Cancer Surgery: Are AKI and ESRD Inevitable? Insights from Real-Life experience
15:24 - 15:30	The impact of acute kidney injury in rhabdomyolysis: renal outcomes and mortality
15:30 - 15:36	Impact of Sodium-Glucose Cotransporter-2 inhibitors on Outcomes in Patients with Type 1 Diabetes with Acute Kidney Disease
15:36 - 15:42	Global Trends and Adverse Events of SGLT2 Inhibitor Use in Acute Kidney Disease Speaker: Chih-Ning Chen (Taiwan, R.O.C.)
15:42 - 15:48	Clinicopathological Features and Outcomes of Acute Kidney Injury in Patients Undergoing Diagnostic Native Kidney Biopsy
15:48 - 15:54	Pseudo-AKI in Ribociclib-treated patients: insights from the PAKY STUDY
15:54 - 16:00	KIDNEY FUNCTION ASSOCIATED WITH MORTALITY IN HANTAVIRUS INFECTION: A COHORT STUDY IN BRAZIL



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:00 - 16:06	Association between admission serum phosphate level and in-hospital acute kidney injury Speaker: Youjun Xu (P.R. China)
16:06 - 16:12	Differences Between Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rate and Association with Postoperative Complications in a Mixed Surgical Population: A Cohort Study of the UK Biobank

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 10**

16:30-18:00 CEST

Chronic kidney disease

Chair:	
16:30 - 16:36	Psychosocial factors and risk of chronic kidney disease: a prospective cohort analysis in UK Biobank
16:36 - 16:42	Exploring Sex-Based Variations in Prescription Patterns and Adverse Drug Reactions in Chronic Kidney Disease Speaker: Solene Laville (France)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:42 - 16:48	<p>Association Between the Number of Parity and the Prevalence of Chronic Kidney Disease: A Cross-Sectional Study Using KoGES-HEXA Data</p> <p>Speaker: Ha-Eun Lee (Korea, Rep. of South)</p>
16:48 - 16:54	<p>Trend of major cardiovascular events and bleeding in patients with advanced chronic kidney disease: a nationwide study</p>
16:54 - 17:00	<p>Physical function clusters in an Australian outpatient kidney care clinic</p>
17:00 - 17:06	<p>Hypocalcemia and other bone and mineral disorders associated with denosumab across the spectrum of kidney function: the Stockholm CREATinine Measurements (SCREAM) project</p> <p>Speaker: Ruowei Xiao (P.R. China)</p>
17:06 - 17:12	<p>Age and Kidney Failure Etiology: Global Profiles in ApolloDialDb</p>
17:12 - 17:18	<p>Iohexol Clearance, but not estimated GFR, reveals a steeper GFR decline in persons with prediabetes. -A population-based study-</p> <p>Speaker: Toralf Melsom (Norway)</p>
17:18 - 17:24	<p>Serum interleukin-8 concentrations, associated factors, and associated cardiovascular risk in patients with moderate-to-advanced chronic kidney disease</p> <p>Speaker: Maxime Pluquet (France)</p>



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:24 - 17:30	Do Lifestyle Interventions Including Exercise Using Digital Apps and Medical Services Reduce CKD Progression? - A Systematic Review and Meta-Analysis –
17:30 - 17:36	Promoting Gender Balance in Nephrology: Insights from a Pilot Survey by the Women of ERA Task Force Speaker: Olga Balafa (Greece)
17:36 - 17:42	CREATIVE (Comparison of Renal Estimation Approaches Through Investigating Various Equations): A Comprehensive Evaluation of eGFR Methods in CKD Staging and Management
17:42 - 17:48	Renal multiparametric MRI detects changes in renal blood flow and microstructure related to macroalbuminuria in Stage 3 Diabetic Kidney Disease patients
17:48 - 17:54	Hyperkalaemia Prevalence and Risk Factors in Chronic Kidney Disease and Heart Failure: Insights from iCaReMe Registry Middle East and Africa Cohort
17:54 - 18:00	Impact of Potassium Binders on RASi Continuation and Outcomes in Patients with CKD and Heart Failure: A Swedish National Cohort Study (DEMONSTRATE) Speaker: Hans Furuland (Sweden)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Thursday, 5. June 2025

Free Communication

Date: **05/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Hall G2**

16:30-18:00 CEST

FC 13: The Basics of Glomerular- and Tubular Disease

Chair:	
16:30 - 16:48	Outcomes of Covid-19 Vaccine-Associated Glomerular Diseases (CVAGD)
16:48 - 17:00	NOX2-independent NETosis enriched in oxidized mitochondrial DNA via cGAS/STING pathway as a therapeutic target for inflamed acute kidney injury in chronic granulomatous disease mice Speaker: Tetsuya Abe (Japan)
17:00 - 17:12	NPT2b Deficiency Mitigates Tubulointerstitial Fibrosis via Mitochondrial Restoration and Suppression of Partial Epithelial-Mesenchymal Transition in Renal Tubular Cells Speaker: Tzu-Ming Jao (Taiwan, R.O.C.)
17:12 - 17:24	Immune Phenotyping of Checkpoint Inhibitor-Induced Acute Interstitial Nephritis Uncovers Distinct Profiles Associated with Clinico-biological Features, treatment Response and outcome
17:24 - 17:36	High-resolution nanoliquid chromatography-mass spectrometry of circulating IgA1 glycosylation provides novel insight in the



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	pathogenesis of IgA nephropathy.
17:36 - 17:48	Glomerulonephritis-induced changes in epithelial lipid composition reveal a signature of prominent proximal tubules metabolic switch Speaker: Pierre-Louis Tharaux (France)
17:48 - 18:00	Single urinary extracellular vesicle proteome analysis reveals CD35 as novel biomarkers of Sepsis-associated acute kidney injury

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 9**

16:30-18:00 CEST

Chronic kidney disease

Chair:	
16:30 - 16:36	Re-defining carboplatin dosage using eGFR-CR-CYS compared to Cockcroft Gault and impact on platinum-associated adverse events Speaker: Meghan Sise (United States of America)
16:36 - 16:42	Impact of Geriatric Nutritional Risk Index on Renal Function in Elderly Chronic Kidney Disease Patients Treated with SGLT2 Inhibitors



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:42 - 16:48	Associations between modifiable medical, behavioral and sociopsychological factors with the risk of dementia in chronic kidney disease
16:48 - 16:54	FREQUENCY OF RETINOPATHY IN CHILDREN WITH KIDNEY DISEASE: A CLINICAL AND EPIDEMIOLOGICAL ANALYSIS
16:54 - 17:00	Disease Burden of Chronic Kidney Disease Attributable to Modifiable Risk Factors: Findings from the Global Burden of Disease Study 2021
17:00 - 17:06	Kidney Function and Acute Severe Infection: Observational and Mendelian Randomization Analyses
17:06 - 17:12	Burden of pruritus in older CKD stage 4-5 patients: 7-year follow-up of the EQUAL study Speaker: Enise Çelebi (Netherlands)
17:12 - 17:18	Persistent effects of territorial and gender inequalities on the care trajectory of dialysis patients: access to transplantation and CKD-related mortality before and after transplantation.
17:18 - 17:24	Changes in nutritional intakes over time and subsequent risk of CKD progression - The CKD-REIN cohort study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	Speaker: Sandra Wagner (France)
17:24 - 17:30	Proteinuria in preeclampsia and later maternal kidney and cardiovascular disease: a population-based cohort study
17:30 - 17:36	Application of estimated glomerular filtration rate equations in patients with neurogenic lower urinary tract dysfunction
17:36 - 17:42	Dose-response analysis of serum uric acid levels and the risk of developing chronic kidney disease in patients with gout
17:42 - 17:48	Association between Furosemide and Serum Uremic Toxins Levels in Patients with Chronic Kidney Disease
17:48 - 17:54	Artificial Intelligence in the Prediction of Congenital Urological Anomalies from Perinatal Characteristics
17:54 - 18:00	Prediction of chronic kidney disease using multidimensional data and foundation model

Thursday, 5. June 2025



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Focussed Oral

Date: **05/06/2025**

Dialysis

Room: **Focussed Oral Room 7**

16:30-18:00 CEST

Dialysis

Chair:	
16:30 - 16:36	Tryptophan metabolites clearance by hemodialysis and hemodiafiltration: an influence of comorbidities Speaker: Izabela Zakrocka (Poland)
16:36 - 16:42	Monitoring of Anti-Xa Activity of Enoxaparin in Hemodialysis Speaker: Habib BENDANI (Algeria)
16:42 - 16:48	ON-LINE HAEMODIAFILTRATION AND EXPANDED HAEMODIALYSIS: REAL-LIFE COMPARISON OF MEDIUM-SIZED URAEMIC TOXIN REMOVAL
16:48 - 16:54	Online prediction of dialysis adequacy failure in hemodialysis Speaker: Andreas Maierhofer (Germany)
16:54 - 17:00	Protein-Bound Uremic Toxins Removal with Post-Dilutional Hemodiafiltration with High Convective Volume: A Transversal Study from Hospital Clinic Barcelona Speaker: Víctor Joaquín Escudero Saiz (Spain)
17:00 - 17:06	Green Nephrology by Low Convection Volume Replacement in Post-dilution Online Hemodiafiltration



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:06 - 17:12	The role of therapeutic plasma exchange in hypertriglyceridemia induced pancreatitis: single-centre experience Speaker: Nejc Piko (Slovenia)
17:12 - 17:18	Intermediate monocyte and platelet activation within the extracorporeal hemodialysis circuit: novel tools assessing HD-induced thrombo-inflammation Speaker: Florine Janssens (Belgium)
17:18 - 17:24	Switching from hemodialysis to high-volume hemodiafiltration does not require adjustment of dialysate sodium in clinical practice Speaker: Malte Gross (Germany)
17:24 - 17:30	Volume status in haemodialysis patients at extreme body habitus
17:30 - 17:36	Incremental hemodialysis: A single center experience from Singapore Speaker: Mahesh Ekanayaka (Singapore)
17:36 - 17:42	Inpatient Relationship Between Plasma Refill and Ultrafiltration: Is It More Linear Than We Think?
17:42 - 17:48	EXPANDED HEMODIALYSIS VS. ONLINE HEMODIAFILTRATION: COMPARISON OF MOM CONTROL, ANEMIA, AND MOLECULAR CLEARANCE OVER 4 YEARS OF FOLLOW-UP. ARE THERE DIFFERENCES?



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	Speaker: Antonio Luis García Herrera (Spain)
17:48 - 17:54	Dialyzer data sheets revisited: the need for more information
17:54 - 18:00	Overhydration and time to recovery after hemodialysis treatment before and after the introduction of a new routine for adjusting target weight (Recova-Recovery)

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Kidney Transplantation , Focussed Orals

Room: **Focussed Oral Room 8**

16:30-18:00 CEST

Kidney Transplantation

Chair:	
16:30 - 16:36	Time trends in European paediatric kidney transplantation: an ESPN/ERA Registry study Speaker: Iris R Montez de Sousa (Netherlands)
16:36 - 16:42	Frequency, Risk Factors and Long-term Outcomes of Erythrocytosis in Kidney Transplant Patients



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:42 - 16:48	Graft Survival in Kidney Transplantation: A Comparative Analysis of IgA Nephropathy vs non-IgAN kidney disease and the Impact of Recurrent IgAN
16:48 - 16:54	Impact of diabetes and low age- and sex-specific eGFR on post-transplant kidney function recovery in living kidney donors
16:54 - 17:00	Vitamin K dependent proteins and bone quality in the first year after kidney transplantation
17:00 - 17:06	Glomerular Morphometric Feature Machine Learning-Driven Analysis of Deceased Donor Procurement Biopsies: The ComPrePS Assessment Tool
17:06 - 17:12	Categorical state sequence analysis to identify pre - transplantation care trajectories among chronic kidney disease patients in France
17:12 - 17:18	Association between sex and hospitalisation during the period prior to kidney transplantation in France
17:18 - 17:24	GlycA and all-cause mortality in kidney transplant recipients: Results of the TransplantLines Biobank and Cohort Study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:24 - 17:30	Single vs. repeated measurements of 24-hour urinary potassium excretion and long-term outcomes after kidney transplantation
17:30 - 17:36	Carboxyhemoglobin, Smoking Exposure, and Mortality in Kidney Transplant Recipients
17:36 - 17:42	Posttransplant Malignancies in Kidney Transplant Recipients - A single center Experience
17:42 - 17:48	SGLT2 Inhibitors in Kidney Transplant Recipients: Renal, Cardiovascular and Safety Outcomes: A Narrative Review
17:48 - 17:54	SAFETY AND EFFICACY OF SGLT2i IN NON-DIABETIC KIDNEY TRANSPLANT RECIPIENTS
17:54 - 18:00	Basiliximab versus anti-thymocyte immunoglobulin: renal and infectious outcomes in kidney transplant recipients
18:00 - 18:06	Beyond DSAs: Unraveling the Complexities of Antibody-Mediated Rejection in Kidney Transplants



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

--	--

Thursday, 5. June 2025

Free Communication

Date: **05/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Hall K**

16:30-18:00 CEST

FC 12: Of Membranous Nephropathy and Other Rare Diseases

Chair:	
16:30 - 16:48	New therapies for membranous nephropathy
16:48 - 17:00	Effectiveness and Remission Predictors of Obinutuzumab in Primary Membranous Nephropathy
17:00 - 17:12	Serum C3 levels are associated with glomerulosclerosis in membranous nephropathy and ANCA associated vasculitis Speaker: Martina Tedesco (Italy)
17:12 - 17:24	Kidney outcomes and effects of proteinuria in Alport Syndrome: a longitudinal analysis of 1175 patients from the UK National Registry of Rare Kidney Diseases (RaDaR) Speaker: Katie Wong (United Kingdom)
17:24 - 17:36	Development of a multiple biomarker model to predict the tubulointerstitial fibrosis area in patients with primary IgA



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	Nephropathy
17:36 - 17:48	Proteinuria as a clinical trial endpoint in focal segmental glomerulosclerosis: Validation of PARASOL findings in RaDaR Speaker: Daniel P. Gale (United Kingdom)
17:48 - 18:00	Stopping Eculizumab Treatment Safely in Atypical HUS: A Multicentre, Open-Label, Prospective, Single-Arm Trial of the Safety and Impact of Eculizumab Withdrawal

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Creative Labs

Room: **Hall G1**

16:30-18:00 CEST

Creative Labs III - the optimal diet for CKD patients and Kidney Transplant Recipients

Chair:	
16:30 - 18:00	the optimal diet for CKD patients and Kidney Transplant Recipients Speaker: Stephan J. L. Bakker (Netherlands)

Thursday, 5. June 2025



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Focussed Oral

Date: **05/06/2025**

**Glomerular & tubulo-interstitial
diseases, Focussed Orals**

Room: **Focussed Oral Room 1**

16:30-18:00 CEST

Glomerular & tubulo-interstitial diseases

Chair:	
16:30 - 16:35	Can we diagnose diabetes-related kidney disease without kidney biopsy using proteomics? Speaker: Sang Heon Song (Korea, Rep. of South)
16:35 - 16:40	Stratification of IgA nephropathy using similarity network fusion: clinical, biochemical, and biopsy-based clusters with prognostic implications.
16:40 - 16:45	The dual role of hyperuricemia and hyperglycemia in mice with CKD Speaker: Li Li (Germany)
16:45 - 16:50	Unsupervised Deep Learning Approach for Kidney Pathology Image Analysis and Clinical Correlation in Glomerulonephritis
16:50 - 16:55	Trametinib ameliorated Adriamycin-induced podocyte injury through METTL3 modified m6A RCAN1 mRNA methylation



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:55 - 17:00	The effects of early or late Empagliflozin, Liraglutide & combined therapy on the α-Klotho/Autophagy pathway in renal and pancreatic-β cells in diabetic db/db mice model.
17:00 - 17:05	IgA nephropathy with membranoproliferative pattern and resistance to immunosuppressive therapy in patients with cofactor I pathogenic variant.
17:05 - 17:10	Single-cell transcriptome combined with spatial transcriptome reveals molecular characteristics of human glomerular endothelial cells.
17:10 - 17:15	Differential Impacts of APRIL and APRIL/BAFF Inhibition on Immune Populations: Implications for IgAN Treatment and Protective Immunity Speaker: Kirk J. Rowley (United States of America)
17:15 - 17:20	Urinary Acidification and Pharmacological Inhibition of anionic transporters reduce the Severity of Experimental Vancomycin-Induced Acute Kidney Injury
17:20 - 17:25	Mesangioproliferative activity of IgA1-IgG immune complexes in IgA nephropathy requires complement C3 and can be inhibited by a broad-spectrum kinase inhibitor



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:25 - 17:30	Progressive predominant tubular damage through constitutive activation of the NF-κB pathway in renin lineage cells
17:30 - 17:35	PRIMARY RENAL BILATERAL DIFFUSE LARGE B CELL LYMPHOMA: A CASE REPORT.
17:35 - 17:40	Single-nucleus multi-omic profiling identified different extent of podocyte injury and podocyte-parietal epithelial cell communication in podocytopathy
17:40 - 17:45	Exploring the mechanism and clinical validation of mitochondrial dynamics-related genes in membranous nephropathy based on Mendelian randomization study and bioinformatics analysis
17:45 - 17:50	Role of the Wieslab test in identifying the hyperactivation of the complement lectin pathway and its application in membranous nephropathy

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Dialysis

Room: **Focussed Oral Room 6**

16:30-18:00 CEST



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Dialysis

Chair:	
16:30 - 16:36	“Bringing the world in” – experiences of an art programme in renal dialysis units
16:36 - 16:42	Oral Health Care among Dialysis Patients in France and impact on Survival Speaker: Cécile Couchoud (France)
16:42 - 16:48	Trying to Reduce Unnecessary Carbon in Haemodialysis (TRUNC-HD) – a regional sustainability quality improvement project
16:48 - 16:54	Global home medication practices in dialysis patients – applying NDC-to-ATC mapping
16:54 - 17:00	First 100 Patients Undergoing Nocturnal Every-Other-Day Online Hemodiafiltration: Clinical Outcomes and Patient and Technique Survival Speaker: Víctor Joaquín Escudero Saiz (Spain)
17:00 - 17:06	Recurrence of CKD-associated pruritus after discontinuation of long-term difelikefalin: a national real-life study.



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:06 - 17:12	AI-Powered Identification of UFR-Sensitive and Insensitive Patients to Mitigate Intradialytic Hypotension
17:12 - 17:18	Incidence of Occult Hepatitis B Infection Among Dialysis Cohort in Malaysia Speaker: Xin Yi Jolynne Tan (United Kingdom)
17:18 - 17:24	ASSESSMENT OF HEALTH-RELATED OF QUALITY-OF-LIFE IN HEMODIALYSIS PATIENTS IN COLOMBIA.
17:24 - 17:30	Exploring Intradialytic Symptoms, Post-Dialysis Recovery, and Quality of Life in Haemodialysis Patients: Insights from a Taiwan Cohort
17:30 - 17:36	Primary Hyperoxaluria: A Collaboration Project Among Hemodialysis Centers for Screening Patients with Chronic Kidney Disease of Unclear Diagnosis
17:36 - 17:42	SEVERE MENTAL ILLNESS AND END-STAGE CHRONIC KIDNEY DISEASE WITH AGGRESSIVE OR ANTI-TREATMENT BEHAVIOUR: A RETROSPECTIVE NATIONAL COHORT STUDY
17:42 - 17:48	Understanding the challenges nephrologists face in managing patients with severe mental illness and chronic kidney disease



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:48 - 17:54	LACE-HD for prediction of 30 days re-hospitalization risk in patients on maintenance Hemodialysis, Diaverum Saudi Arabia experience
17:54 - 18:00	Predictive Value of Galectin-3 for Acute Heart Failure and Mortality in New Hemodialysis Patients: A Prospective Cohort Study

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Dialysis

Room: **Focussed Oral Room 5**

16:30-18:00 CEST

Dialysis

Chair:	
16:30 - 16:36	Low Gla Rich Protein Serum Levels are associated with increased Left Ventricle Hypertrophy And Pulse Pressure In Peritoneal Dialysis Patients
16:36 - 16:42	ASSESSMENT OF ARSENIC TOXICITY IN CIGARETTE SMOKERS HEMODIALYSIS PATIENTS, ITS CORRELATION WITH ANEMIA AND METABOLIC BONE DISEASE AND EVALUATION OF THE ROLE OF HIGH FLUX HEMODIALYSIS IN ARSENIC CLEARANCE



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:42 - 16:48	THE EFFECT OF LOW DIALYSATE SODIUM CONCENTRATION ON AMBULATORY AORTIC BLOOD PRESSURE AND ARTERIAL STIFFNESS IN PATIENTS WITH INTRADIALYTIC HYPERTENSION: A RANDOMIZED CROSSOVER STUDY
16:48 - 16:54	ASSOCIATION OF DIALYSIS SHIFT WITH MORNING SURGE IN BLOOD PRESSURE AND DIPPING PATTERN
16:54 - 17:00	Effect of Dapagliflozin in Patients with End-Stage Renal Disease on Hemodialysis Speaker: Jaime Hernán Merino (Spain)
17:00 - 17:06	The role of Intravenous Etelcalcitide in Haemodialysis Patients with mid-range serum Parathyroid Hormone levels. Speaker: Shilpa Vijayasrinivasan (United Kingdom)
17:06 - 17:12	Improvement of serum calcification propensity in dialysis patients: Comparison between low-flux and medium cut-off dialyzers
17:12 - 17:18	CONTROL OF VASCULAR RISK FACTORS AMONG PATIENTS WITH STAGE 5D CHRONIC KIDNEY DISEASE IN SPAIN. PRELIMINARY RESULTS OF THE "OBJETIVO EN EL PUNTO DE MIRA" (OPM) STUDY
17:18 - 17:24	Oral Nutritional Support of Hemodialysis Patients: an intradialytic meal model intake and adherence analysis



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:24 - 17:30	Implementation fidelity of a pharmacist-led intervention program to improve hyperphosphatemia in Dutch hemodialysis patients
17:30 - 17:36	Advanced Analysis of High-Frequency Intradialytic Data Using Artificial Intelligence Speaker: Sheng-Han Yueh (United States of America)
17:36 - 17:42	Novel AI-Based Recipe Recommendation System for Dialysis Patients Using Retrieval-Augmented Generation Speaker: Sheng-Han Yueh (United States of America)
17:42 - 17:48	Evaluating ChatGPT for Dietary Support: Photo-Based Ingredient Recognition for Dialysis Patients Speaker: Sheng-Han Yueh (United States of America)
17:48 - 17:54	The diagnosis of T-score based osteoporosis in patients undergoing hemodialysis treatment is a particular challenge: a multiple bone site approach
17:54 - 18:00	SCLEROSTIN AND BONE MORPHOGENETIC PROTEIN-7 (BMP-7) IN HAEMODIALYSIS (HD) PATIENTS AND THEIR CORRELATION WITH CALCIUM AND PHOSPHORUS METABOLISM



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 4**

16:30-18:00 CEST

Chronic kidney disease

Chair:	
16:30 - 16:36	The shadow of renal dysfunction on guideline-directed medical therapy in HFrEF: insights from a cardio-nephrology perspective in Eastern Europe
16:36 - 16:42	Association of parathyroid hormone and alkaline phosphatase with fracture risk in patients with chronic kidney disease not on dialysis Speaker: Caroline sophie hjelm Pichat (Denmark)
16:42 - 16:48	Clinical characteristics and Healthcare Resource Utilization, and Costs associated in Patients with Diagnosed and Undetected hyperkalemia: IBERIK+ Study
16:48 - 16:54	Senescence: a translational perspective for uremic cardiomyopathy
16:54 - 17:00	Assessment of safety from a European difelikefalin managed access programme



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:00 - 17:06	Impact of Renal Impairment on Cardiac Fibrosis and Inflammation in Stage 3 Diabetic Kidney Disease patients: Insights from Cardiac MRI and serum Biomarkers
17:06 - 17:12	A Retrospective, Multicenter Study on the Efficacy and Safety of Desidustat in Chronic Kidney Disease-Induced Anemia
17:12 - 17:18	The association of malondialdehyde, catalase and superoxide dismutase with kidney function and vitamin K status in chronic kidney disease
17:18 - 17:24	Impact of Body Mass Index (BMI) on Renal Function Decline in High-Risk Renal Cell Carcinoma: Implications for First-Line Systemic Therapy Eligibility
17:24 - 17:30	SGLT2 Inhibitors Awaken the Norns: Unraveling Novel Erythropoietic Mechanisms in Diabetic Nephropathy
17:30 - 17:36	Between the Rhythm and the Function: Atrial Fibrillation in Chronic Kidney Disease Speaker: Ana Rita Almeida (Portugal)
17:36 - 17:42	COGNITIVE FUNCTIONS IN ELDERLY AND SENILE PATIENTS WITH ARTERIAL HYPERTENSION, DEPENDING ON THE PRESENCE OF CONCOMITANT CHRONIC KIDNEY DISEASE STAGE 3A AND 3B



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	Speaker: Kantemir Dzamikhov (Russia)
17:42 - 17:48	The association of dephosphorylated, uncarboxylated Matrix Gla Protein with vascular calcification and oxidative stress in Chronic Kindey Disease patients
17:48 - 17:54	Evaluating the association between iron deficiency status and outcomes in patients with non-dialysis dependent chronic kidney disease Speaker: Hannah O'Keeffe (United Kingdom)

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 3**

16:30-18:00 CEST

Chronic kidney disease

Chair:	Vaibhav Tiwari (India)
16:30 - 16:36	Minimally invasive percutaneous intrarenal inoculation of extracellular vesicles (EV), derived from mesenchymal stem cells (MSC), as a therapeutic strategy for experimental chronic kidney disease
16:36 - 16:42	Mesenchymal stem cells (MSC) delivered directly into the kidney through a minimally invasive percutaneous ultrasound-guided



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	technique: A new therapeutic approach to abrogate CKD progression
16:42 - 16:48	ITGA6 as a Potential Therapeutic Target for Inhibiting the Progression of Diabetic nephropathy
16:48 - 16:54	Biosensors for measuring cystatin c, creatinine and urea in human sweat
16:54 - 17:00	Tubule-specific cyclin-dependent kinase 12 knockdown promotes fatty acid oxidation disorder by down-regulating PPAR? in chronic kidney disease
17:00 - 17:06	Sex-specific metabolic dysfunction and reduced lifespan induced by long-term and low-dose dietary phosphorus loading in mice Speaker: Ayumi Matsumoto (Japan)
17:06 - 17:12	A novel cardiovascular-kidney-metabolic syndrome mouse model with inducible HFrEF and atherosclerosis
17:12 - 17:18	Fetuin-A supplementation as a key treatment strategy to mitigate acute kidney injury and prevent its progression to chronic disease



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:18 - 17:24	Polypliod tubular cells drive functional recovery after nephron mass loss and can be employed to determine likelihood of CKD progression
17:24 - 17:30	A pregnancy reduces kidney lifespan in Col4a3^{-/-} mice with Alport Nephropathy. Impact of a renoprotective triple combination therapy on maternal kidney outcomes. Speaker: Liang Chang (Germany)
17:30 - 17:36	Exogenous α-Klotho Supplementation Significantly Prolongs Survival in a Mouse Model of Alport Syndrome, With Comparable Outcomes to RASi
17:36 - 17:42	Single-nuclear transcriptomics identifies novel therapeutic targets in a translational model of chronic kidney disease in swine Speaker: Alejandro Chade (United States of America)
17:42 - 17:48	Endothelial-specific CDK12 knockdown potentiates cardiorenal injury through SPNS2-mediated cell apoptosis
17:48 - 17:54	Salvianolic acid C mitigates sepsis-induced kidney injury through promotion of renal gluconeogenesis Speaker: Ming Wu (P.R. China)
17:54 - 18:00	Nanoparticle-mediated Klotho Gene Therapy Prevents Kidney Disease Progression via PPARα Pathway



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

--	--

Thursday, 5. June 2025

Focussed Oral

Date: **05/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Focussed Oral Room 2**

16:30-18:00 CEST

Glomerular & tubulo-interstitial diseases

Chair:	
16:30 - 16:35	DAPAGLIFLOZIN IN INACTIVE LUPUS NEPHRITIS: A RANDOMIZED CROSS-OVER TRIAL
16:35 - 16:40	INVOLVEMENT OF THE COMPLEMENT SYSTEM IN IGA NEPHROPATHY: A DIFFERENT PERSPECTIVE
16:40 - 16:45	Association of Anti-Neutrophil Cytoplasmic Antibody (ANCA) Serology and Concentration with Incidence, Renal Trajectories and Mortality in ANCA-Associated Vasculitis
16:45 - 16:50	Targeted-Release Budesonide (TRB) treatment may have different effects on the inflammatory process in IgAN patients with recent and old diagnosis Speaker: CHRISTODOULOS KESKINIS (Greece)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:50 - 16:55	Prevalence and associated factors of sexual dysfunction in female patients with Lupus Nephritis: A cross-sectional study at AIIMS, New Delhi Speaker: Arpana Limbu (India)
16:55 - 17:00	Evaluation of Objective Nutritional Indexes as Predictors of Renal Progression in IgA Nephropathy Patients
17:00 - 17:05	Temporal trends of severe infections in patients with lupus nephritis and CKD: a nationwide study
17:05 - 17:10	Nine-year' experience of severe ANCA-associated glomerulonephritis treatment: a single-center retrospective study Speaker: Elena V. Zakharova (Russia)
17:10 - 17:15	Open label, single arm, multicenter, prospective study on oral enteric coated budesonide therapy for primary IgA nephropathy. An inter-rim report
17:15 - 17:20	Development and validation of nomograms for predicting the activity index of lupus nephritis
17:20 - 17:25	Single-cell RNA sequencing of circulating leukocytes from patients with IgA nephropathy and age- and kidney function-matched controls



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:25 - 17:30	Long-term efficacy and safety of telitaccept in the treatment of IgAN
17:30 - 17:35	Protein fragments predict venous thromboembolic events in ANCA-associated vasculitis Speaker: Cecilia Barnini (Austria)
17:35 - 17:40	Associations of systemic complement, kidney deposition and gene polymorphisms with patient and renal outcomes in ANCA-associated vasculitis – a systematic review Speaker: Yi-Ting Ong (Singapore)
17:40 - 17:45	Clinical and Pathological Significance of Exostosin1/Exostosin2 in Membranous Lupus Nephritis: A Retrospective Single-Center Study in China
17:45 - 17:50	Are there differences in the impact of induction immunosuppression on kidney outcomes according to ANCA Renal Risk Score in patients with ANCA-associated vasculitis?

Thursday, 5. June 2025

Symposium

Date: 05/06/2025



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Institutional

Room: **The Square**

16:30-17:45 CEST

The path for an environmental responsible (and sustainable) nephrology

Chair:	Ivo Laranjinha (Portugal)
16:30 - 16:55	How to green the Dialysis prescription? Speaker: Giorgina Piccoli (France)
16:55 - 17:20	Hemodialysis Unit – Let's look at it as a circular economy. Everything you throw out has its value Speaker: TARRASS FAISSAL (Morocco)
17:20 - 17:45	How do I evaluate the carbon footprint of my Unit? Speaker: Joachim Beige (Germany)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Chronic Kidney Disease

Room: **Hall E2**

16:30-18:00 CEST

Personalized approach in cardiometabolic kidney disease

Chair:	Julia Kerschbaum (Austria)
	Patrick Mark (United Kingdom)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:30 - 17:00	Metabolic communications by SGLT2 inhibition. Speaker: Markus Rinschen (Denmark)
17:00 - 17:30	Combination therapy for the treatment of kidney disease in people with type 2 diabetes. How, Who, when. Speaker: Hans-Joachim Anders (Germany)
17:30 - 18:00	Resistance to novel kidney protective agents: a concept to be developed. Speaker: Beatriz Fernandez Fernandez (Spain)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Institutional

Room: **Hall F1**

16:30-18:00 CEST

ERA Registry

Chair:	Vianda S. Stel (Netherlands) Alberto Ortiz Arduán (Spain)
16:30 - 17:00	The prevalence of reduced kidney function across Europe: a comparison of KDIGO and age-adapted definitions of CKD Speaker: Megan Astley (Netherlands)
17:00 - 17:30	Treatment trajectories of patients on kidney replacement therapy Speaker: Brittany Boerstra (Netherlands)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:30 - 18:00	Exploring the margins of survival benefit in kidney transplantation: an international target trial emulation study Speaker: Rachel Hellemans (Belgium)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Kidney Transplantation

Room: **Hall E1**

16:30-18:00 CEST

Pro/Con Machine perfusion

Chair:	Umberto Maggiore (Italy) Annemarie Weissenbacher (Austria)
16:30 - 17:15	Machine perfusion - PRO Speaker: Sarah Hosgood (United Kingdom)
17:15 - 18:00	Machine perfusion -CON Speaker: Orsolya Cseprenkal (Hungary)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

**Physiology, cell biology & genetic
diseases**

Room: **Hall C**

16:30-18:00 CEST

Hot Topics in ADPKD: PRO and CONS

Chair:	Lucile Figueres (France) Matias Simons (Germany)
16:30 - 17:15	Genetic Testing for all ADPKD adult patients: PRO Speaker: Emilie Cornec-Le Gall (France)
17:15 - 18:00	Genetic Testing for all ADPKD adult patients:CON Speaker: Albert Ong (United Kingdom)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Hypertension & Diabetes

Room: **Hall B**

16:30-18:00 CEST

Pro/Cons session: Inhibition of aldosterone synthase: are they an advantage over classical MRA?

Chair:	Matias Trillini (Italy) Amaryllis Van Craenenbroeck (Belgium)
16:30 - 17:15	Inhibition of aldosterone synthase: are they an advantage over classical MRA? PRO



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	Speaker: Maria Jose Soler Romeo (Spain)
17:15 - 18:00	Inhibition of aldosterone synthase: are they an advantage over classical MRA? CON Speaker: Ionut Nistor (Romania)

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

Dialysis

Room: **Hall D**

16:30-18:00 CEST

The fragile and the very old in dialysis

Chair:	Björn Meijers (Belgium) Giovambattista Capasso (Italy)
16:30 - 17:00	Dialysis versus conservative management Speaker: Mehmet Kanbay (Türkiye)
17:00 - 17:30	HD versus PD Speaker: Karlien François (Belgium)
17:30 - 18:00	Exercise and physical rehabilitation Speaker: Francesca Mallamaci (Italy)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Thursday, 5. June 2025

Symposium

Date: **05/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Hall A Plenary Room**

16:30-18:00 CEST

Pro-Cons: Membranous nephropathy

Chair:	Michael Rudnicki (Austria) Ingeborg Bajema (Netherlands)
16:30 - 17:15	Are the "new antigens" useful for the diagnosis and monitoring of patients with MN? PRO Speaker: Sanjeev Sethi (United States of America)
17:15 - 18:00	Are the "new antigens" useful for the diagnosis and monitoring of patients with MN? CON Speaker: Anne-Els van de Logt (Netherlands)

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Hall A Plenary Room**

08:15-09:45 CEST

Game changers in the diagnosis of podocytopathies



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chair:	Sophie Chauvet (France) Y.K.Onno Teng (Netherlands)
08:15 - 08:45	Serum assays for diagnosis of autoimmune podocytopathies: is it time? Speaker: Tobias B. Huber (Germany)
08:45 - 09:15	Autoimmunity in minimal change and FSGS: the same or different? Speaker: Valentina Raglianti (Italy)
09:15 - 09:45	Recurrence after transplant: a sign of autoimmune podocytopathy? Speaker: Marina Vivarelli (Italy)

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

Chronic Kidney Disease

Room: **Hall D**

08:15-09:45 CEST

Metabolic management in CKD

Chair:	William Herrington (United Kingdom) Evangelia Ntounousi (Greece)
08:15 - 08:45	Real world data evidence for cardiovascular and renal outcome in DKD Speaker: David C. Wheeler (United Kingdom)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:45 - 09:15	Lipid optimization in chronic kidney disease, overcoming statin era Speaker: Christoph Wanner (Germany)
09:15 - 09:45	Hyperuricemia: to treat or not treat Speaker: Stefanie Steiger (Germany)

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

Hypertension & Diabetes

Room: **Hall B**

08:15-09:45 CEST

New definitions in cardio – renal medicine

Chair:	Enrique Morales Ruiz (Spain) Beatriz Fernandez Fernandez (Spain)
08:15 - 08:45	Cardiovascular-kidney-metabolic (CKM) syndrome and its impacts on health. Speaker: Amaryllis Van Craenenbroeck (Belgium)
08:45 - 09:15	Selective glomerular hypofiltration syndrome: A critical appraisal. Speaker: Borja Quiroga (Spain)
09:15 - 09:45	Novel prediction risk equations for assessing CVD incorporating CKM health: now a reality Speaker: Morgan Grams (United States of America)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

--	--

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

Dialysis

Room: **Hall C**

08:15-09:45 CEST

Incremental PD and HD: a game changer? In which patients?

Chair:	Yuri Battaglia (Italy) Philip K.T. Li (Hong Kong, P.R. China)
08:15 - 08:45	Economic considerations of individualization of dialysis prescription Speaker: Maria Fernanda Slon Roblero (Spain)
08:45 - 09:15	Incremental hemodialysis and peritoneal dialysis: A promising and hallmark of individualized treatment Speaker: Michael Rudnicki (Austria)
09:15 - 09:45	Quality of life in dialysis patients: Its importance in deciding dialysis dose Speaker: Ellen Hoogeveen (Netherlands)

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

Kidney Transplantation

Room: **Hall E1**



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:15-09:45 CEST

Game Changers in alloimmune risk stratification and organ allocation

Chair:	Orsolya Cseprekal (Hungary) Shyam Bihari Bansal (India)
08:15 - 08:45	genome wide nonHLA vs HLA alloimmunity Speaker: Rainer Oberbauer (Austria)
08:45 - 09:15	AI, machine learning Speaker: Agathe Truchot (France)
09:15 - 09:45	Monitoring the immune response in viral infection vs rejection Speaker: Ana David (Austria)

Friday, 6. June 2025

Symposium

AKI & Critical Care Nephrology

Date: **06/06/2025**

Room: **Hall E2**

08:15-09:45 CEST

Game changers in prevention and treatment of AKI

Chair:	Danilo Fliser (Germany) Joana Gameiro (Portugal)
--------	-----------------------------------------------------



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:15 - 08:45	Amminoacids to prevent AKI Speaker: Martina Baiardo Redaelli (Italy)
08:45 - 09:15	Treatment of AKI related to disasters Speaker: Mehmet Sukru Sever (Türkiye)
09:15 - 09:45	Organoids for drugs screening in AKI Speaker: Ana NÚñez Nescolarde (Australia)

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Glomerular & tubulo-interstitial diseases

Room: **Focussed Oral Room 3**

08:15-09:45 CEST

Glomerular & tubulo-interstitial diseases

Chair:	
08:15 - 08:20	Rituximab for primary membranous nephropathy: a decade of experience Speaker: Fiona Chapman (United Kingdom)
08:20 - 08:25	Minimal Change Disease: A Novel Regimen of Glucocorticoids-induced Remission and then Rituximab as Maintenance Remission Therapy



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:25 - 08:30	An Observational Study of Treatment on IgA Nephropathy with Telitacicept and Immunosuppressive Regimens in a Single Center
08:30 - 08:35	Albuminuria predicts GFR-decline in patients with Alport syndrome
08:35 - 08:40	FEATURES OF LITHOGENIC AND ANTI-LITHOGENIC FACTORS IN URINE IN STONE FORMATION IN CHILDREN.
08:40 - 08:45	Efficacy and safety of low-dose Telitacicept in patients with primary IgA nephropathy: a retrospective cohort study
08:45 - 08:50	Efficacy and safety of endothelin receptor antagonists in IgA nephropathy: A systematic review and meta-analysis of randomized controlled trials
08:50 - 08:55	Renal cysts in ADPKD patients can be distinguished by low and high sodium concentrations in vivo using ²³Na magnetic resonance imaging Speaker: Christoph Kopp (Germany)
08:55 - 09:00	Physician-directed nudge for glycemic and lipid management in older patients with glomerulonephritis treated with immunosuppressants



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:00 - 09:05	Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors in Adults With IgA Nephropathy in the Phase 2 SPARTACUS Trial
09:05 - 09:10	Native kidney biopsy in lateral position compared to prone position: technical aspects, diagnostic yield and complications
09:10 - 09:15	Obinutuzumab alone may be an effective option for the initial therapy of adult minimal change disease
09:15 - 09:20	Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index.

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 4**

08:15-09:45 CEST

Chronic kidney disease

Chair:	
--------	--



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:15 - 08:21	The new era of glycomics for the identification of prognostic and diagnostic biomarkers of kidney disease: ExoGAG.
08:21 - 08:27	Distinctive Patterns of Trace elements in Chronic Kidney Disease of Uncertain Etiology: A Case Control Study
08:27 - 08:33	Estimation of kidney function in Graves' disease using creatinine and cystatin C Speaker: Sorena Abbaszadeh (Sweden)
08:33 - 08:39	Influence of metabolism-related comorbidities and insulin resistance (estimated glucose disposal rate) on the development of chronic kidney disease in a health-checkup population: a retrospective cohort study
08:39 - 08:45	Increased left ventricular mass is caused by extracellular not intracellular expansion in advanced CKD Speaker: Thomas Anderton (United Kingdom)
08:45 - 08:51	Multi-modal Fusion Models for Classification and Risk Prognosis in Diabetic Kidney Disease
08:51 - 08:57	Endothelin-1 and cardio-kidney events among patients with CKD, diabetes, and anemia Speaker: Finnian R. Mc Causland (United States of America)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:57 - 09:03	The Role of Trimethylamine N-oxide in Chronic Kidney Disease Progression and Mortality: Insights from the GCKD Study
09:03 - 09:09	A Positive Functional Modulator of ABCC6 Decreases Vascular Calcification and Improves Kidney Function in a Rat Adenine Diet Model of Chronic Kidney Disease
09:09 - 09:15	Development and validation of a prediction model for progression of CKD in European children
09:15 - 09:21	Elevated urine albumin-creatinine ratio associates with higher pulse-wave velocity in a population-based cohort
09:21 - 09:27	Indicators of Vaccination Status in Patients with Chronic Kidney Disease: Importance of Healthcare Providers' Recommendation
09:27 - 09:33	Burden of Chronic Kidney Disease and Related Urinary Disorders on Healthcare Utilisation in Ireland: A National Inpatient Analysis
09:33 - 09:39	Influence of Age and GFR Thresholds on Kidney Failure and Death in the Irish Health System



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:39 - 09:45	Impact of Adoption of European Kidney Consortium Equation (EKFC) equation compared to CKD-EPI Equations on CKD Prevalence and Staging in Irish Adults

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 5**

08:15-09:45 CEST

Chronic kidney disease

Chair:	
08:15 - 08:21	EXERCISE INTERVENTION IN PATIENTS WITH METABOLIC SYNDROME AND RENAL DISEASE: A PROSPECTIVE STUDY (EXRED)
08:21 - 08:27	Supplemented ketoanalogues (KAs) with plant versus animal based low protein diet (LPD) in non-dialysis CKD. Speaker: Naveen Medi (India)
08:27 - 08:33	Renal function assessment with point of care creatinine and potassium in diverse populations (RAPID study): An interim analysis Speaker: Rouvick Gama (United Kingdom)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:33 - 08:39	<p>IMPROVING MEDICATION SAFETY AND PRESCRIBING OF HIGH-RISK MEDICATIONS IN INDIVIDUALS WITH CHRONIC KIDNEY DISEASE: A VALIDATION STUDY Speaker: Jo-Anne Wilson (Canada)</p>
08:39 - 08:45	<p>The potential of Share Wave Elastography in renal imaging</p>
08:45 - 08:51	<p>Optimal Timing for Dialysis Preparation in CKD; Modeling with Multiple Linear Regression Speaker: Geo Neul Park (Korea, Rep. of South)</p>
08:51 - 08:57	<p>Natriuretic response to an acute oral potassium load in healthy individuals and patients with chronic kidney disease Speaker: Liffert Vogt (Netherlands)</p>
08:57 - 09:03	<p>Physical activity and incident chronic kidney disease: a systematic review and dose-response meta-analysis</p>
09:03 - 09:09	<p>The effects of empagliflozin on fluid and electrolyte balance Speaker: Steffen Flindt Nielsen (Denmark)</p>
09:09 - 09:15	<p>Zigakibart-treated patients with IgAN achieved high rates of proteinuria remission and stable eGFR over 76 weeks in a Phase 1/2 study</p>



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:15 - 09:21	Comparative Assessment of Endothelial Function in Patients with Chronic Kidney Disease Against the Background of Dyslipidemia
09:21 - 09:27	SMART Stone MDT and patient care recommendations: The Nephrologist's role in optimizing the adult high-risk kidney stone patient pathway Speaker: Pietro Manuel Ferraro (Italy)
09:27 - 09:33	SGLT2 Inhibitors as a Strategy for Obesity Control in Non-Diabetic CKD Patients: Insights from a One-Year Study Speaker: Mostafa Gamal (Egypt)
09:33 - 09:39	Long-term effect of semaglutide on the glomerular filtration rate slope in high-risk patients with diabetic nephropathy: analysis in real-world clinical practice.
09:39 - 09:45	Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent phase 2 studies Speaker: Frank Weber (Switzerland)

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Focussed Oral Room 2**



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:15-09:45 CEST

Glomerular & tubulo-interstitial diseases

Chair:	Kultigin Turkmen (Türkiye)
08:15 - 08:21	Phenotypic analysis of the oral and intestinal microbiome reveals microbial signatures for disease classification and potential drivers of autoantibody production in IgA nephropathy
08:21 - 08:27	Burden of illness in chronic primary glomerulonephritis: The patient perspective Speaker: Fernando Caravaca Fontan (Spain)
08:27 - 08:33	Characteristics of IgA Nephropathy patients treated with Mycophenolate Mofetil in the real world. Speaker: Efrain Tatis, (Spain)
08:33 - 08:39	Socioeconomic and Psycho-emotional Impact of C3 Glomerulopathy and Immune Complex Membranoproliferative Glomerulonephritis in Adult Patients in Spain Speaker: Fernando Caravaca Fontan (Spain)
08:39 - 08:45	EXPLORING THE INTERACTION BETWEEN THE COMPLEMENT SYSTEM AND ANCA VASCULITIS
08:45 - 08:51	The immunomodulatory role of neuroendothelial cells in lupus nephritis



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:51 - 08:57	Comparative Outcome of Monthly Intra Venous Cyclophosphamide versus Daily Oral Mycophenolate Mofetil at Induction for Patients of Class III & IV Lupus Nephritis in a Population of Asian Ethnicity
08:57 - 09:03	Long-term outcomes of patients with Primary FSGS treated with Rituximab
09:03 - 09:09	Biochemical Changes in γ-Glutamyl Cycle and Their Relevance in Systemic Lupus Erythematosus
09:09 - 09:15	Development of a multiple urinary biomarker model to predict the tubulointerstitial fibrosis area in patients with primary IgA Nephropathy
09:15 - 09:21	Frailty as a proxy measure for infection risk and mortality in ANCA Glomerulonephritis
09:21 - 09:27	Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand? Speaker: Valentina Querin (Netherlands)
09:27 - 09:33	Integrating Crescent Characteristics, Vascular Lesions, and Podocyte Injury into the MEST-C Framework: Enhanced Risk Stratification in IgA Nephropathy



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:33 - 09:39	Genetic Insights: delCFHR3-1 linked to de novo Thrombotic Microangiopathy in Kidney Transplant Recipients
09:39 - 09:45	Histological Patterns, Prognostic Factors, and Treatment Impact in Renal Sarcoidosis: Insights from a Spanish Multicenter Study
09:45 - 09:51	Ultrastructural Patterns in Membranous Nephropathy: A Scanning Electron Microscopy Study

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Dialysis

Room: **Focussed Oral Room 6**

08:15-09:45 CEST

Dialysis

Chair:	
08:15 - 08:21	Peritoneal Dialysis Modality and Outcomes in The Peritoneal Dialysis Outcomes and Practice Patterns Study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:21 - 08:27	ULTRASOUND GUIDED PERCUTANEOUS PERITONEAL DIALYSIS CATHETER INSERTION WITH MUSCULOFACIAL TUNNELING: AN INNOVATIVE AND SAFE TECHNIQUE Speaker: Xun Quan Sze (Malaysia)
08:27 - 08:33	Turning the Tide in Heart Failure Management: The Role of Peritoneal Ultrafiltration
08:33 - 08:39	Catheter cleaning brush manipulations in peritoneal dialysis
08:39 - 08:45	Comparison of Bacterial Culture Positivity Between Direct and Post-Centrifugation Inoculation into Blood Culture Bottles for Peritoneal Dialysis-Associated Peritonitis
08:45 - 08:51	Effect of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists on Peritoneal Dialysis-associated Peritonitis: A Territory-wide, Propensity-weighted Cohort in Hong Kong Speaker: Kit-Chung NG (Hong Kong, P.R. China)
08:51 - 08:57	"PD-PREDICT": A Machine Learning Tool to Predict Patient Survival in UK Peritoneal Dialysis Patients, with external Validation in Norway
08:57 - 09:03	Modifiable Factors Associated with Permanent Transfers from Peritoneal Dialysis: A Retrospective Study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:03 - 09:09	Peritoneal Protein Loss: how does it relate to Fluid Overload, Sarcopenia and Nutrition on Renal Disease
09:09 - 09:15	Evaluation of Peritoneal Dialysis Dropouts: A Single Centre Observational Study over 3-year follow-up
09:15 - 09:21	Clinical events and Patient-Reported Outcome Measures in Peritoneal Dialysis
09:21 - 09:27	Synbiotic Supplementation for Chronic Constipation in Patients under Peritoneal Dialysis: An Italian Multicenter Prospective Study Speaker: Silvio Borrelli (Italy)
09:27 - 09:33	Peritoneal immunometabolism links local inflammation to depressed immune cell function in peritoneal dialysis patients Speaker: Rebecca Herzog (Austria)

Friday, 6. June 2025

Focused Oral

Date: **06/06/2025**

Physiology, cell biology & genetic diseases, Focused Orals

Room: **Focused Oral Room 1**

08:15-09:45 CEST



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Physiology, cell biology & genetic diseases

Chair:	
08:15 - 08:21	Renal trajectories in the french RaDiCo Alport Syndrome cohort
08:21 - 08:27	Evolutionary Origins of Polycystic Kidney Disease Genes: Insights from Emerging Phylogenomic Methodologies
08:27 - 08:33	Dysregulated ion channel distribution promotes cyst formation in hereditary cystic kidney diseases Speaker: Susanne Hahnenstein
08:33 - 08:39	Mutant BCS1L patient urine derived renal epithelial cells: A Personalised Model of Mitochondrial Kidney Tubule dysfunction
08:39 - 08:45	Exploring the Role of Mitochondrial Genomic Variants and Haplogroups in Clinical Phenotypes of Polycystic Kidney Disease Speaker: Sophia Heneghan (Ireland)
08:45 - 08:51	SCREENING FOR PRIMARY HYPEROXALURIA TYPE 1 (PH1) IN CHRONIC KIDNEY DISEASE PATIENTS ELIGIBLE FOR KIDNEY TRANSPLANTATION – A BRAZILIAN MULTICENTER STUDY



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:51 - 08:57	<p>An external validation of polygenic risk scores in the general population using measured GFR – the Renal Iohexol Clearance Survey (RENIS) Speaker: Bjørn Eriksen (Norway)</p>
08:57 - 09:03	<p>Serological extracellular matrix fragments may serve as early kidney damage biomarkers in children with defects in Alport genes</p>
09:03 - 09:09	<p>Metabolic control affects growth in dRTA: findings from the ESPN - ERKNet dRTA sub-registry.</p>
09:09 - 09:15	<p>Incidence and outcomes of kidney replacement therapy for kidney failure due to inherited tubulopathies in Europe: findings from the ERA Registry</p>
09:15 - 09:21	<p>Autonomic Modulation in Normotensive ADPKD Patients</p>
09:21 - 09:27	<p>Prenatal ultrasound features and long-term prognosis of Very-Early-Onset Autosomal Dominant Polycystic Kidney Disease Speaker: Eleonora Superchi (Italy)</p>
09:27 - 09:33	<p>aHUS Brazilian Registry: Phenotypic and Genotypic Characteristics of an Admixed Population with Diverse Ancestry</p>



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:33 - 09:39	Effect of Female Sex Hormones on Liver Volume: Assessing the Safety of Preimplantation Genetic Diagnosis in Women with ADPKD
09:39 - 09:45	RENAL OUTCOMES OF KIDNEY-LIVER TRANSPLANTATION AND LIVER TRANSPLANTATION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE PATIENTS
09:45 - 09:51	FABRY OR NOT FABRY? THIS IS THE PROBLEM: A CLINICAL CASE.

Friday, 6. June 2025

Free Communication

Date: **06/06/2025**

Kidney Transplantation

Room: **Hall G2**

08:15-09:45 CEST

FC 17: Kidney transplantation: Interventions

Chair:	
08:15 - 08:33	Felzartamab in humoral rejection: an update
08:33 - 08:45	The Efficacy and Safety of SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: a multicentric study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:45 - 08:57	Effectiveness and Safety of Tocilizumab Treatment for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Speaker: Ha-Eun Lee (Korea, Rep. of South)
08:57 - 09:09	Outcomes of Standard versus CYP3A5 Genotype-adapted Dosing of Tacrolimus in Renal Transplant Recipients: A Randomized Control Study
09:09 - 09:21	Effect of felzartamab anti-CD38 treatment on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies
09:21 - 09:33	Targeting TNFα signalling in deceased donor kidneys: A path to improve graft outcomes
09:33 - 09:45	Monitoring Anti-CD38 Treatment with Felzartamab in Antibody-Mediated Kidney Allograft Rejection

Friday, 6. June 2025

Free Communication

Date: **06/06/2025**

AKI & Critical Care Nephrology

Room: **Hall G1**

08:15-09:45 CEST



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

FC 16: Acute Kidney Injury: Troubling our Minds

Chair:	
08:15 - 08:33	Hepatorenal syndrome and acute kidney injury (HRS-AKI) - what is new?
08:33 - 08:47	Nitazoxanide alleviates kidney damage and restores renal function in disease models of acute-on-chronic liver failure
08:47 - 09:01	Baseline Estimated GFR and the Prognostic Impact of Rapid Increases in Serum Creatinine After Major Elective Surgery: A Multicohort Study
09:01 - 09:15	Identification of heterogenous long-term kidney function trajectories after acute kidney injury reveals subgroups of patients at higher risk for long-term kidney dysfunction
09:15 - 09:29	Trajectories of Acute Kidney Injury Hospitalization Before and After Dementia Diagnosis: A Nationwide Cohort Study Speaker: Hong Xu (Sweden)
09:29 - 09:43	Association between Acute Kidney Injury and Dementia: A Multi-database Cohort Study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

--	--

Friday, 6. June 2025

Free Communication

Date: **06/06/2025**

Chronic Kidney Disease

Room: **Hall K**

08:15-09:45 CEST

FC 15: Novel CKD Treatments Beyond the Pillars

Chair:	
08:15 - 08:33	The nephropathy of sickle cell trait and sickle cell disease and CKD treatments
08:33 - 08:45	Iptacopan's rapid and sustained inhibition of overactive complement alternative pathway in C3G: Exploratory analysis from the Phase 3 APPEAR-C3G study
08:45 - 08:57	Long-Term Efficacy and Safety in the 60-Month, Phase 3 ILLUMINATE-B Trial of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 Speaker: Wesley Hayes
08:57 - 09:09	Changes in proteinuria and kidney function in subgroups of patients with IgAN defined by baseline Gd-IgA1 levels in a Phase 1/2 study of zigakibart



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:09 - 09:21	Hospitalization for Congestive Heart Failure (CHF) Following Treatment With Roxadustat in Patients With or Without a History of CHF: Pooled Post Hoc Analysis of Phase 3 Studies Speaker: Gabriel Choukroun (France)
09:21 - 09:33	A Win-Ratio Analysis of the Cardiovascular Safety of Vadadustat in Patients With CKD-Related Anemia Undergoing Dialysis
09:33 - 09:45	A multicenter, randomized, double-blind, placebo-controlled Phase 3 study in patients with idiopathic IC-MPGN: APPARENT protocol amendment

Friday, 6. June 2025

Free Communication

Date: **06/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Hall F1**

08:15-09:45 CEST

FC 14: About C3 and IgA Glomerulonephritis

Chair:	Pierre Marie Ronco (France) Jürgen Floege (Germany)
08:15 - 08:30	Pegcetacoplan Treatment Effect in Patients With Nephrotic Range Proteinuria: Results From the VALIANT Phase 3 Study in Patients With C3G or Primary (Idiopathic) IC-MPGN



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:30 - 08:45	Targeted Treatment With Pegcetacoplan for Adolescents With C3G or Primary (Idiopathic) IC-MPGN in the VALIANT Phase 3 Trial
08:45 - 09:00	Pegcetacoplan Demonstrates Clinically Significant Responses in C3G and Primary (Idiopathic) IC-MPGN Patients With or Without Concomitant Immunosuppression in VALIANT Speaker: David Kavanagh (United Kingdom)
09:00 - 09:15	The incidence and prevalence of IgAN from 2002-2023 in Denmark
09:15 - 09:30	Nefecon provides kidney benefit irrespective of baseline eGFR in patients with IgAN: a subanalysis of the NeflgArd study Speaker: Jonathan Barratt (United Kingdom)
09:30 - 09:45	Effect of iptacopan discontinuation on proteinuria and complement biomarkers in patients with immunoglobulin A nephropathy (IgAN): a post hoc analysis from a Phase II trial Speaker: Jonathan Barratt (United Kingdom)

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Kidney Transplantation

Room: **Focussed Oral Room 8**

08:15-09:45 CEST



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Kidney Transplantation

Chair:	
08:15 - 08:21	Elevated Soluble ST2 at Day 7 as a Prognostic Biomarker for Adverse Outcomes in Kidney Transplant Recipients
08:21 - 08:27	Incidence, Risk Factors, and Impact of Coronary artery disease Events after Kidney Transplantation
08:27 - 08:33	Predicting Graft Outcomes in Kidney Transplantation: The Strength of Standard Statistics Compared to Machine Learning Techniques
08:33 - 08:39	Association of Stigmatizing Language with Kidney Transplant Waitlisting Speaker: Lili Chan (United States of America)
08:39 - 08:45	Relationship between intra-abdominal pressure early after surgery and long-term kidney graft function
08:45 - 08:51	Sex differences in transplant outcomes and survival for children on kidney replacement therapy: data from the ESPN/ERA Registry



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:51 - 08:57	Impact of HLA-Sensitization on Patient and Graft Outcomes in ABO-incompatible Living Donor Kidney Transplants: Single decade experience from North India
08:57 - 09:03	Comparative outcomes of Preemptive and Non-Preemptive Living Kidney Transplantation
09:03 - 09:09	Biopsy-based transcript diagnostics improves prognostication along the AMR continuum
09:09 - 09:15	Are There Gender Differences in Access to Kidney Transplantation in the Basque Country?
09:15 - 09:21	Plasma Cadmium, Whole-Blood Cadmium and Late Graft Failure in Kidney Transplant Recipients
09:21 - 09:27	Glomerular Morphometry as a Predictor of Renal Graft Function
09:27 - 09:33	The Impact of Living Donor's Pretransplant Clinical Features on 1st and 3rd Year Allograft Functions



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:33 - 09:39	Comparative analysis of glomerular filtration rate obtained by different methods in kidney transplanted patients
---------------	-------------------------------------------------------------------------------------------------------------------------

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Dialysis

Room: **Focussed Oral Room 7**

08:15-09:45 CEST

Dialysis

Chair:	
08:15 - 08:21	Pre-operative Vascular Mapping and the Prognostic Value of Vascular Calcification in Advanced CKD Speaker: Tiago Assis Pereira (Portugal)
08:21 - 08:27	Kidney transplantation with a functional AV fistula is associated to long-term risk of de novo heart failure and atrial fibrillation
08:27 - 08:33	Beyond calipers: predictive value of pre operative Peak Systolic Velocity on Arteriovenous Fistula maturation
08:33 - 08:39	Fetuin-A as a Risk Factor for Arteriovenous Fistula (AFV) Failure in Chronic Kidney Disease Patients with Hemodialysis Through Vascular Calcification Mechanism: Systematic Review and Meta-Analysis



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	Speaker: Nyoman Paramita Ayu (Indonesia)
08:39 - 08:45	EFFECT OF EXCESSIVE SALT CONSUMPTION ON THE FUNCTIONAL STATE OF MICROVESSELS OF THE SKIN OF RATS WITH EXPERIMENTAL KIDNEY DYSFUNCTION
08:45 - 08:51	The Role of Vascular Access Choice in Hemodialysis Outcomes: A Nationwide Romanian Study
08:51 - 08:57	Are peripheral insertion catheters infrequent in hemodialysis patients?
08:57 - 09:03	Postoperative doppler surveillance as a tool for improving Arteriovenous Fistula patency and first use rates: a single center experience
09:03 - 09:09	Outcomes of endovascular AVF creation in a multiethnic Asian population Speaker: Mary Lim (Singapore)
09:09 - 09:15	A MULTICENTER STUDY ON TWO MAJOR CHALLENGES IN LATE REFERRAL PATIENTS: OUTCOMES OF AVFs AND TUNNELED CVC-RELATED INFECTIONS Speaker: Elettra Lomeo (Italy)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:15 - 09:21	Pre-Surgery Plasma Metabolites as Predictive Biomarkers of Arteriovenous Fistula Maturation Outcomes
09:21 - 09:27	Comparison of Standard versus High Dose Urokinase for Dysfunctional Tunneled Dialysis Catheters in Haemodialysis Patients: A Randomized Controlled Trial
09:27 - 09:33	Chemotherapy Administration Via Arteriovenous Fistula In Hemodialysed Patients: Too Daring Of An Option?
09:33 - 09:39	Obesity as a Predictor of Technique Survival in Peritoneal Dialysis

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 9**

08:15-09:45 CEST

Chronic kidney disease

Chair:	
08:15 - 08:21	Motor coordination disorders in patients with chronic kidney disease Speaker: Tomasz Gołębiowski (Poland)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:21 - 08:27	Study of the degree of change in the structural and functional state of the kidneys in patients with arterial hypertension
08:27 - 08:33	Empagliflozin Improves FMD in CKD: Modulation by the 786T>C Polymorphism of eNOS.
08:33 - 08:39	Efficacy and safety of HRS-5965 in patients with primary immunoglobulin A nephropathy (IgAN): a randomized, double-blind, parallel, placebo-controlled phase 2 trial Speaker: Jicheng Lv (P.R. China)
08:39 - 08:45	Self Management and Realisation of Target Blood Pressure in Chronic Kidney Disease (SMaRT BP CKD)
08:45 - 08:51	LOW RATE OF INFUSION-RELATED REACTIONS AND HIGH TREATMENT ADHERENCE WITH OBINUTUZUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: ANALYSIS OF THE NOBILITY AND REGENCY STUDIES
08:51 - 08:57	Design and baseline characteristics of MIRO-CKD: a Phase IIb, Randomised, Double-Blind Clinical Trial to Evaluate Effects of Balcinrenone in Combination with Dapagliflozin vs. Dapagliflozin in Patients with CKD Speaker: Patrick Mark (United Kingdom)
08:57 - 09:03	Finerenone as a Novel Non-Steroidal Mineralocorticoid Receptor Antagonist: A Potential Therapeutic Option for Lupus Nephritis



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:03 - 09:09	Monitoring of renal impairment in rheumatoid arthritis patients with different levels of disease activity the role of cystatin C
09:09 - 09:15	Treatment Patterns of Primary Immunoglobulin A Nephropathy (IgAN) in China: Evidence from a Real-World Study using Regional Electronic Health Record Data
09:15 - 09:21	Exogenous Ketosis increases Renal Function and Sodium Excretion in Healthy Subjects Speaker: Trine Züricho Lyksholm (Denmark)
09:21 - 09:27	AMPLITUDE, a Ph2/3 Adaptive Trial of Inaxaplin in APOL1-mediated Kidney Disease
09:27 - 09:33	Evaluation of Clinical Sensitivity and Limit of Detection for Neutrophils of the Homodimer Neutrophil Gelatinase-Associated Lipocalin (H-NGAL) Rapid Test in Patients with Peritoneal Dialysis-Related Peritonitis (PDRP)
09:33 - 09:39	An application of urinary peptidomics and in silico methods to guide multifactorial intervention in chronic kidney disease Speaker: Justyna Siwy (Germany)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:39 - 09:45	Optimal Timing for Dialysis Preparation in Diabetic Nephropathy Speaker: Geo Neul Park (Korea, Rep. of South)
---------------	-------------------------------------------------------------------------------------------------------------------------

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

AKI & Critical Care Nephrology

Room: **Focussed Oral Room 10**

08:15-09:45 CEST

AKI & Critical Care Nephrology

Chair:	
08:15 - 08:21	Longer time on polymyxin- B direct hemoperfusion for sepsis control prevents kidney injury on day 28; A multicenter retrospective observational study (PMX-OPTIC).
08:21 - 08:27	Concomitant use of renin-angiotensin system inhibitors and bortezomib were associated with a higher incidence of hyponatremia Speaker: Yuki Miyaguchi (Japan)
08:27 - 08:33	Urinary CXCL9 and renal outcome in Acute Kidney Injury Speaker: Ashok Kumar Yadav (India)
08:33 - 08:39	Acute Kidney Injury associated with immune-checkpoint inhibitors in cancer patients: a single centre retrospective study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:39 - 08:45	Time trends and Predictors of Acute Kidney Injury in the complete region of Stockholm, Sweden
08:45 - 08:51	Demographic variations in Acute kidney injury risk during Hot weather: A nationwide case-crossover analysis of a million AKI alerts
08:51 - 08:57	Demographic and Clinical Profile of Hospitalized Patients Requiring Dialysis: Insights from the DaVita Brazil Hospital Service 2023-2024
08:57 - 09:03	Continuous Renal Replacement Therapy (CRRT) in Critically Ill Patients: A Nationwide Analysis from DaVita Brazil
09:03 - 09:09	Histopathological and clinical characteristics of biopsy proven pregnancy related Acute kidney injury
09:09 - 09:15	Acute Kidney Injury and Renal Replacement Therapy after Heart Transplantation: epidemiology and short-term outcomes Speaker: Marco Fiorentino (Italy)
09:15 - 09:21	ACUTE KIDNEY INJURY IN CRITICAL CARE PATIENTS IN BRAZIL: A PROSPECTIVE COHORT STUDY



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:21 - 09:27	The alternative pathway of the Renin Angiotensin Aldosterone System is overactivated in severe COVID-19 at baseline
09:27 - 09:33	PULMONARY HYPERTENSION AND CHRONIC KIDNEY DISEASE: AN INTERGROUP VARIABILITY OF KIDNEY FUNCTION DETERMINANTS
09:33 - 09:39	Acute Kidney Injury and associated factors in people living with HIV/AIDS hospitalized for Disseminated Histoplasmosis in a referral hospital in Brazil
09:39 - 09:45	No Weekend Penalty: AKI Outcomes Remain Consistent Across Admission Days

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

Institutional

Room: **Hall A Plenary Room**

11:15-12:30 CEST

Late Breaking Clinical Trials

Chair:	Danilo Fliser (Germany) Ronald Gansevoort (Netherlands)
--------	------------------------------------------------------------



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Friday, 6. June 2025

Plenary Lecture

Date: **06/06/2025**

Institutional

Room: **Hall A Plenary Room**

14:15-15:00 CEST

Plenary Lecture 2

Chair:	Paola Romagnani (Italy) Ivan Rychlik (Czech Republic)
14:20 - 15:00	Cell and gene therapy in clinical practice: feasible, but available? Speaker: Michele De Luca (Italy)

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Hall A Plenary Room**

15:00-16:15 CEST

Game changers in IgA Nephropathy



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chair:	Hans-Joachim Anders (Germany) Eleni Frangou (Cyprus)
15:00 - 15:25	B cell targeting therapy Speaker: Jonathan Barratt (United Kingdom)
15:25 - 15:50	Dual RAS/endothelin inhibition Speaker: Hiddo J.L. Heerspink (Netherlands)
15:50 - 16:15	Complement inhibitors Speaker: Claudia Seikrit (Germany)

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

AKI & Critical Care Nephrology

Room: **Hall B**

15:00-16:15 CEST

Long term consequence of AKI

Chair:	Emanuel Zitt (Austria) Alexander Rosenkranz (Austria)
15:00 - 15:25	Quality over Creatinine Speaker: Khalil Chaibi (France)
15:25 - 15:50	Recovery after AKI in children Speaker: Ayse Akcan Arikan (United States of America)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:50 - 16:15	Recovery after AKI in obesity Speaker: Natacha Rodrigues (Portugal)

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

Dialysis

Room: **Hall D**

15:00-16:15 CEST

How to manage a greener dialysis program

Chair:	Giorgina Piccoli (France) Sanjin Racki (Croatia)
15:00 - 15:25	Water consumption Speaker: Mohamed Ben Hmida (Tunisia)
15:25 - 15:50	Waste reduction Speaker: Anna Julie Peired (Italy)
15:50 - 16:15	Green CRRT- is there a way? Speaker: Jolanta Malyszko (Poland)

Friday, 6. June 2025



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Free Communication

Date: **06/06/2025**

Kidney Transplantation

Room: **Hall E2**

15:00-16:15 CEST

FC 18: What a Graft Can Tell You

Chair:	
15:00 - 15:12	Correlation of activity, and chronicity indices derived from Banff lesion scores with injury dimension scores from biopsy-based transcript diagnostics
15:12 - 15:24	Urinary and blood mRNA biomarkers for detecting kidney allograft rejection (The KTD-Innov study: NCT03582436) Speaker: Evgenia Preka (France)
15:24 - 15:36	Detection of kidney allograft rejection using urinary chemokines: a prospective multicenter cohort study (KTD-Innov) Speaker: Valentin GOUTAUDIER (France)
15:36 - 15:48	Torque teno virus load in kidney transplantation: association with donor and recipient characteristics and clinical follow-up data
15:48 - 16:00	Torque Teno virus is associated with an increased risk for malignancies after kidney transplantation



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:00 - 16:12	Deep Learning Model for Predicting Delayed Graft Function Using Pre-Implantation Kidney Images: Interim Results from the DeepGraft Project
---------------	---------------------------------------------------------------------------------------------------------------------------------------------------

Friday, 6. June 2025

Free Communication

Date: **06/06/2025**

Hypertension & Diabetes

Room: **Hall F1**

15:00-16:15 CEST

FC 19: Hypertensive Derangements of Pregnancy and Volume Homeostasis

Chair:	
15:00 - 15:18	UMOD hypertension and the genetic of CKD
15:18 - 15:27	A KLOTHO GENE VARIANT (rs9536314) CORRELATES WITH DEVELOPMENT OF HYPERTENSIVE DISORDERS OF PREGNANCY AND HIGHER RATES OF MISCARRIAGE
15:27 - 15:36	Pregnancy and Kidney Outcomes for Individuals with Rare Kidney Diseases
15:36 - 15:45	Pregnancy and Kidney Outcomes for Individuals receiving Kidney



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	Replacement Therapy Speaker: Priscilla SMITH (United Kingdom)
15:45 - 15:54	Body water conservation increases blood pressure independently of Na⁺ balance
15:54 - 16:03	HETEROGENEITY OF CLINICAL RESPONSE TO LOW SALT DIET IN NAÏVE ESSENTIAL HYPERTENSIVE PATIENTS
16:03 - 16:12	Subclinical Kidney Remodeling and ACE-Inhibitor Resistance in Early Salt-Induced Hypertension Speaker: Max Schuller (Austria)

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

Physiology, cell biology & genetic diseases

Room: **Hall C**

15:00-16:15 CEST

Understanding ADPKD and its consequences

Chair:	Elena Levtchenko (Netherlands) John Sayer (United Kingdom)
15:00 - 15:25	Adult human organoids of PKD Speaker: Rafael Kramann (Germany)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:25 - 15:50	ADPKD in children Speaker: Djalila Mekahli (Belgium)
15:50 - 16:15	The primary cilium is a target for new ADPKD treatments Speaker: Alessandra Boletta (Italy)

Friday, 6. June 2025

Free Communication

Date: **06/06/2025**

Dialysis

Room: **Hall K**

15:00-16:15 CEST

FC 20: Peritoneal Dialysis: Epidemiological Insights

Chair:	
15:00 - 15:12	IRON DEFICIENCY and Mortality Risk in Patients STARTING Peritoneal Dialysis
15:12 - 15:24	The increase in ultrafiltration volume correlates strongly with an increase in sodium removal during steady concentration peritoneal dialysis with the Carry Life UF system Speaker: Olof Heimbürger (Sweden)
15:24 - 15:36	Prevalence and risk factors for low bone mineral density in peritoneal dialysis patients



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:36 - 15:48	Thirst in peritoneal dialysis patients.
15:48 - 16:00	Peritoneal Dialysis Outcomes in Relation to Ultrasonographic Peritoneal Thickness, IL-6, and MCP-1 Levels: A Prospective Study Speaker: Saliha Yıldırım (Türkiye)
16:00 - 16:12	The proinflammatory CD14++CD16+ monocytes and lymphocytes subsets are independently associated with technique failure in peritoneal dialysis patients.

Friday, 6. June 2025

Free Communication

Date: **06/06/2025**

Chronic Kidney Disease

Room: **Hall G1**

15:00-16:15 CEST

FC 21: What Cystatin C and Machines can teach us

Chair:	
15:00 - 15:12	Outcomes and risk factors of widened difference in estimated glomerular filtration rate by creatinine or cystatin C: adjust model development with > 300,000 UK Biobank participants



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:12 - 15:24	Estimated GFR in clinical practise: rolling the dice
15:24 - 15:36	Accuracy of GFR estimating equations based on creatinine, cystatin C or both in people with underweight or obesity: the Stockholm CREAtinine Measurements (SCREAM) project
15:36 - 15:48	Deep learning survival model to predict Renal Outcome for Chronic Kidney Disease (CKD) patients: a retrospective cohort study Speaker: Ka Chun Leung (Hong Kong, P.R. China)
15:48 - 16:00	Predicting absolute time to kidney failure in chronic kidney disease patients using machine learning
16:00 - 16:12	Machine learning identifies variables associated with risk of hospitalisation in a national in-centre hemodialysis patient cohort

Friday, 6. June 2025

Free Communication

Date: **06/06/2025**

Dialysis

Room: **Hall G2**

15:00-16:15 CEST

FC 22: Peritoneal Diaysis: Interventions



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chair:	
15:00 - 15:12	NOVEL INSIGHTS INTO PHARMACOKINETICS OF INTRAPERITONEAL CEFEPIME DURING AUTOMATED PERITONEAL DIALYSIS
15:12 - 15:24	The clinical evaluation of an antimicrobial impregnated catheter for the prevention of peritoneal dialysis catheter-related infections – initial results Speaker: Maarten Taal (United Kingdom)
15:24 - 15:36	Blood Pressure-Lowering Effects of Hydrochlorothiazide in Chronic Peritoneal Dialysis Patients with Residual Urine Output Speaker: Gordon Chun Kau CHAN (Hong Kong, P.R. China)
15:36 - 15:48	Role of Sildenafil and SB204741 in suppressing fibrotic potential of peritoneal fibroblasts obtained from PD patients
15:48 - 16:00	The protective effect of Xylocore in diabetes mellitus: pre-clinical and clinical evidences
16:00 - 16:12	INTEGRATED CONSERVATIVE THERAPY-LOW DOSE PERITONEAL DIALYSIS IN PATIENTS WITH SEVERE CKD (I-COPE CKD): MULTICENTRE PROSPECTIVE CONTROLLED STUDY IN ITALIAN NEPHROLOGY UNITS

Friday, 6. June 2025



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Focussed Oral

Date: **06/06/2025**

**Physiology, cell biology & genetic
diseases, Focussed Orals**

Room: **Focussed Oral Room 1**

15:00-16:15 CEST

Physiology, cell biology & genetic diseases

Chair:	Maria K. Svensson (Sweden)
15:00 - 15:05	Two novel heterozygous missense variants of CYP24A1 gene in families with kidney cysts and stones
15:05 - 15:10	Hydrogel embedding of iPSC-derived kidney organoids to enable imaging-based high-throughput screening
15:10 - 15:15	Syntaxin 3 regulates apical membrane integrity in proximal tubule epithelial cells and prevents Fanconi syndrome development Speaker: Hiroki Okushima (Japan)
15:15 - 15:20	Effect of Tyrosine Kinase Inhibitors on Hyperfiltration Response and Renal Functions in Nephrectomized Renal Cell Carcinoma Patients
15:20 - 15:25	How should we prioritise genetic testing for kidney stone disease?
15:25 - 15:30	Frequency of 24-hour urine test application in adult patients with kidney stone disease: a population-based study in primary care in



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	Italy
15:30 - 15:35	KDASDB: A Comprehensive and User-Friendly Database for Alternative Splicing in Kidney Diseases Speaker: Haopeng Yu (P.R. China)
15:35 - 15:40	Lanthanum carbonate does not reduce urinary oxalate excretion in hyperoxaluric kidney stone formers
15:40 - 15:45	Pharmacogenetic analysis from exome data and pharmaco-clinico-biological co-interpretation enable personalized care in nephrology and kidney transplantation
15:45 - 15:51	Impaired renal function in patients with spinal muscular atrophy: a longitudinal cohort study

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Dialysis

Room: **Focussed Oral Room 6**

15:00-16:15 CEST

Dialysis



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chair:	Silvio Borrelli (Italy)
15:00 - 15:06	Drop-out and mortality in peritoneal dialysis patients: a 18 years single center experience
15:06 - 15:12	Real costs of daily home hemodialysis compared to in-center hemodialysis in France
15:12 - 15:18	MOTS-c Levels and Sarcopenia Risk in Patients on Chronic Peritoneal Dialysis: A Pilot Study
15:18 - 15:24	Daily home hemodialysis is associated with a lower mortality rate compared with in-center hemodialysis in French patients.
15:24 - 15:30	Changes in Quality of Life and Caregiver Burden after Starting Peritoneal Dialysis: First Results from the SKIP-SH Cohort Study
15:30 - 15:36	A BIOMARKER-BASED PREDICTIVE MODEL FOR OVERHYDRATION IN PERITONEAL DIALYSIS
15:36 - 15:42	TRACING THE EVOLUTION OF PERITONEAL TRANSPORT: INSIGHTS FROM FOUR YEARS OF THERAPY



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:42 - 15:48	Ultrafiltration capacity on automated peritoneal dialysis: impact of prescription and real-world treatment response on clinical outcomes
15:48 - 15:54	URGENT START HEMODIALYSIS VERSUS IMMEDIATE-START AUTOMATED PERITONEAL DIALYSIS (APD-IS) IN CHRONIC KIDNEY DISEASE PATIENTS INITIATING UNPLANNED DIALYSIS
15:54 - 16:00	Experiences and health-related quality of life worsen over time in caregivers of dialysis patients, irrespective of home or in-centre dialysis: an observational cohort study Speaker: Esmee Driehuis (Netherlands)
16:00 - 16:06	THE THIOLOMIC PROFILE OF PERITONEAL MEMBRANE FIBROSIS: A HYPOTHESIS-DRIVEN RESEARCH
16:06 - 16:12	cofilin-1 modulates peritoneal dialysis-related fibrosis by targeting mitochondrial fragmentation

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Focussed Oral Room 2**



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:00-16:15 CEST

Glomerular & tubulo-interstitial diseases

Chair:	
15:00 - 15:06	Safety, Tolerability, and Efficacy of Mezagitamab (TAK-079) as Add-on to Standard of Care Therapy in Individuals with Primary IgA Nephropathy: Results from a Phase 1b Study
15:06 - 15:12	Real-world insights on the use of ACEi/ARB and SGLT2is and their impact on proteinuria levels in IgAN patients across five European countries Speaker: Philipp Csomor (Switzerland)
15:12 - 15:18	Novel Bruton's Tyrosine Kinase Inhibitor EVER001 in Chinese Patients With Primary Membranous Nephropathy: Preliminary Results From a Phase 1b/2a Study
15:18 - 15:24	Efficacy and safety of apixaban in patients with nephrotic syndrome: a prospective longitudinal cohort study
15:24 - 15:30	A mid-study update on the ACTION3 pivotal Phase 3 trial assessing DMX-200 in patients with focal segmental glomerulosclerosis (FSGS)
15:30 - 15:36	Evaluation of C3 deposition in patients with C3G: insights from the APPEAR-C3G Phase 3 study in patients treated with iptacopan



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:36 - 15:42	The Predictive Value of the Oxford Classification for the Effect of Glucocorticoid Therapy in IgA Nephropathy: A central Pathology Review from the TESTING Study in China
15:42 - 15:48	Predicting individual patient response to corticosteroids in IgA nephropathy: A secondary analysis from the TESTING cohort
15:48 - 15:54	Sex Differences across Treatment Response to Corticosteroids and Kidney Outcomes in IgA Nephropathy: Insights from the TESTING Trial
15:54 - 16:00	Plasma Apixaban Concentrations and their Effect on Thrombin Generation in Nephrotic Syndrome Speaker: Sarah Kelddal
16:00 - 16:06	Efficacy and Safety of Telitacicept in IgA Nephropathy: A Systematic Review and Meta-Analysis
16:06 - 16:12	Impact of SGLT2 inhibitors on kidney function and proteinuria in patients with membranous nephropathy Speaker: Bogdan Sorohan (Romania)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Dialysis

Room: **Focussed Oral Room 5**

15:00-16:15 CEST

Dialysis

Chair:	
15:00 - 15:06	Incremental hemodialysis is a cost-effective and patient-centered approach to renal replacement therapy for initiating outpatient dialysis. Speaker: TOSHIMASA TAKAHASHI (Japan)
15:06 - 15:12	The Emboless® venous chamber extensively reduce air contamination passing into HD patients blood
15:12 - 15:18	Comparison of the effect of nitric oxide gas supplied from the dialysate and from the replacement fluid on its antithrombotic effects during hemodialysis or hemodiafiltration
15:18 - 15:24	Evaluation of microcirculation by surface blood flow imaging of the tibialis anterior muscle in a rat dialysis model
15:24 - 15:30	IS A GREEN NEPHROLOGY POSSIBLE? A LOWER DIALYSATE FLOW COULD NOT AFFECT THERAPEUTIC EFFICACY IN SELECTED PATIENTS WHILE SAVING BILLIONS OF LITRES OF WATER



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:30 - 15:36	Predicting Fluid Overload Hospitalizations in Hemodialysis Patients Using a Foundational Model and Large Language Model Techniques
15:36 - 15:42	Achievement of hemodiafiltration (HDF) convective volumes (CV) > 23 L/session in a dialysis center without selection of "healthy" patients : is it really possible?
15:42 - 15:48	Rationalising the targets in Haemodiafiltration: Convection volume or β2-Microglobulin clearance?
15:48 - 15:54	Efficiency of haemodiafiltration in middle molecules clearance at different levels of residual kidney functions.
15:54 - 16:00	Perdialytic infusion of sodium octanoate improves the dialytic clearance of protein-bound uremic toxins in anephric pigs Speaker: Christophe Soulage (France)
16:00 - 16:06	Impact of Intradialytic Exercise on Cardiopulmonary Parameters Assessed by Cycle Ergometer Exercise Test. Speaker: Salvador Lopez Gil (Mexico)

Friday, 6. June 2025



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Focussed Oral

Date: **06/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 4**

15:00-16:15 CEST

Chronic kidney disease

Chair:	
15:00 - 15:06	Investigating the CKD Sex Paradox: Biomarkers and the Biological Basis of Sex Differences in CKD Progression and Mortality Speaker: Thomas McDonnell (United Kingdom)
15:06 - 15:12	Magnetic resonance imaging assessment of kidney morphometry in chronic kidney disease: baseline data from the AFIRM study
15:12 - 15:18	Plasma and Urinary KIM-1 in Chronic Kidney Disease: Prognostic Value and Implications for Kidney Failure and Mortality Speaker: Thomas McDonnell (United Kingdom)
15:18 - 15:24	SENTINEL CKD SCREENING IN AT-RISK PATIENTS: SIX-MONTH FOLLOW-UP AND IMPACT ON NEPHROPROTECTIVE TREATMENT
15:24 - 15:30	Clinical Practice Gaps in the Diagnosis and Management of Immunoglobulin A Nephropathy
15:30 - 15:36	Impact of Glomerular Hyperfiltration on Albuminuria in Populations with Obesity: An Analysis on NHANES (1999-2018)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:36 - 15:42	AARPRI is associated with chronic kidney disease (CKD) and the construction of risk prediction model based on AARPRI: Evidence from NHANES 2013-2018
15:42 - 15:48	Brain Changes in a Long-Term Rat Model of Chronic Kidney Disease (CKD)
15:48 - 15:54	CT coronary angiography to identify patients at increased risk of developing chronic kidney disease Speaker: Gavin Chapman (United Kingdom)
15:54 - 16:00	Targeted Plasma Proteomics Links Inflammation with Progression of Chronic Kidney Disease in a multi-national pediatric cohort
16:00 - 16:06	Association between nephrotoxic drugs and the development of chronic kidney disease based on french real-world data
16:06 - 16:12	Change in mGFR following bariatric surgery: A case-crossover study Speaker: Patrik Ene (Sweden)

Friday, 6. June 2025



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Focussed Oral

Date: **06/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Focussed Oral Room 3**

15:00-16:15 CEST

Glomerular & tubulo-interstitial diseases

Chair:	
15:00 - 15:06	A Phase 3, Open-Label, Multicenter Study of Ravulizumab in Pediatric Patients With IgA Nephropathy or IgA Vasculitis-Associated Nephritis
15:06 - 15:12	Suppression of complement alternative pathway by monthly dosing of sefaxersen, a novel antisense oligonucleotide therapy in development for IgAN Speaker: Nadine Schmit (Switzerland)
15:12 - 15:18	Nefecon provides kidney benefit irrespective of time since diagnosis in patients with IgAN: a subanalysis of the NeflgArd study
15:18 - 15:24	The NefXtend trial, investigating extended nefecon treatment beyond 9 months in patients with IgAN
15:24 - 15:30	Pegcetacoplan Treatment Appears to Halt Disease Progression in C3G and Primary (Idiopathic) IC-MPGN Patients: Results from the Phase 3 VALIANT Study Speaker: Daniel P. Gale (United Kingdom)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:30 - 15:36	COMPREHENSIVE TREATMENT PROGRAM FOR CHILDREN WITH UROLITHIASIS
15:36 - 15:42	FACTORS ASSOCIATED WITH INTRADIALYSIS HYPOTENSION
15:42 - 15:48	Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN) Speaker: Giulia Bassanese (Germany)
15:48 - 15:54	Real-world effectiveness of ravulizumab in adults with aHUS who switched to ravulizumab within 3 months of eculizumab treatment (aHUS IMPACT) Speaker: Yan Wang (United States of America)
15:54 - 16:00	Immunosuppression combined with tonsillectomy is effective in Caucasian patients with high-risk primary IgA-nephropathy
16:00 - 16:06	Targeted Treatment With Pegcetacoplan for Post-Transplant Recurrent C3G or Primary (idiopathic) IC-MPGN in the VALIANT Phase 3 Trial
16:06 - 16:12	Safety and mid-term efficacy of switching from Eculizumab to Ravulizumab in a cohort of adult patients with atypical hemolytic uremic syndrome



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

--	--

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 10**

15:00-16:15 CEST

Chronic kidney disease

Chair:	
15:00 - 15:06	The effect of GLP-1 receptor agonists on renal outcomes: A systematic review and meta-analysis
15:06 - 15:12	Novel Therapeutic for Diabetic Kidney Disease through Targeting Lp-PLA2 in Immune Cells and Damaged Renal Parenchymal Cell
15:12 - 15:18	Efficacy of β-lactams versus fluoroquinolones for empirical antibiotic treatment of kidney cyst infections in polycystic kidney disease Speaker: Yuta Nakano (Japan)
15:18 - 15:24	Impact of Systemic Glucocorticoids on Gd-IgA1 Levels in Immunoglobulin A Nephropathy: Insights from the TESTING Trial



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:24 - 15:30	Effect of SGLT2 Inhibitor (Dapagliflozin) on Coronary Calcification and Cardiac Parameters in Non-Diabetic CKD Patients: A Randomized Controlled Trial. Speaker: Mostafa Gamal (Egypt)
15:30 - 15:36	A cross-sectional, multinational, survey on current practices and patterns in telenephrology among nephrologists
15:36 - 15:42	Impact of a plant-based food basket on uremic toxins, dietary patterns and carbon footprint in patients with chronic kidney disease
15:42 - 15:48	Exploring the second line agent of choice in the management of Chronic Kidney Disease-associated Pruritus: A global cross-sectional study of clinician experience and preference
15:48 - 15:54	Impact of Synbiotics on Chronic Kidney Disease Patients: A Randomized, Placebo-Controlled Study.
15:54 - 16:00	Effects of a nutrition education program on quality of life and morphofunctional status in patients with advanced chronic kidney disease: ERCANUT Randomized Clinical Trial
16:00 - 16:06	Effect of Mediterranean Diet and Exercise on Patients with Chronic Kidney Disease



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

--	--

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Hypertension & Diabetes

Room: **Focussed Oral Room 9**

15:00-16:15 CEST

Hypertension & Diabetes

Chair:	
15:00 - 15:06	The association between analogue compared to human insulin, prescribed dialysate glucose load, body mass index and mortality in people with kidney failure and type 2 diabetes on peritoneal dialysis
15:06 - 15:12	Comparative Effectiveness of Angiotensin-converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers: Multi-database Target Trial Emulation Studies
15:12 - 15:18	MAJOR RISK FACTORS FOR CARDIOVASCULAR DISEASE IN YOUNG CHILDREN
15:18 - 15:24	Continuous Glucose Monitoring (CGM) Use in People with Diabetes (PwD) on Dialysis: A Retrospective, Cross-Sectional, Observational Study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:24 - 15:30	How to screen for diabetes mellitus before kidney transplantation?- the Norwegian experience
15:30 - 15:36	Effect of Reducing Dialysate Sodium Concentration on Blood Pressure Variability in Hemodialysis Patients: A Randomized Controlled Trial
15:36 - 15:42	Research kidney biopsies in type 2 diabetes: clinical and laboratory parameters alone are not enough to identify candidates for kidney biopsy Speaker: Signe Kjærgaard Jakobsen (Denmark)
15:42 - 15:48	Assessing the neutrophil to lymphocyte ratio as a marker for diabetic nephropathy in type 2 diabetes mellitus patients
15:48 - 15:54	Effect of Dapagliflozin and Empagliflozin on Phosphate-FGF23 Homeostasis in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
15:54 - 16:00	The effects of self-performed dietary sodium reduction on blood pressure and the renin-angiotensin-aldosterone system



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:00 - 16:06	Early clinical experience of finerenone in patient with chronic kidney disease and type 2 diabetes in real life. Comparison with FIDELITY Pooled
---------------	---------------------------------------------------------------------------------------------------------------------------------------------------------

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Dialysis

Room: **Focussed Oral Room 7**

15:00-16:15 CEST

Dialysis

Chair:	
15:00 - 15:06	In Vitro Evaluation of the Antithrombotic Properties of a Urokinase-Coated Indwelling Hemodialysis Catheter
15:06 - 15:12	Evaluation of Vascular Access via a TRIAGE System for Hemodialysis: A Tool to Assess Clinical Risk in Hemodialysis Patients
15:12 - 15:18	Antibacterial and anticoagulant strategies on catheter surfaces for preventing catheter-related bloodstream infection and catheter thrombosis during hemodialysis
15:18 - 15:24	A Safe Guidewire-Assisted Exchange Technique for the Management of CRBSIs in Hemodialysis Patients: A Single-Center



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	<p>Study Speaker: Elettra Lomeo (Italy)</p>
15:24 - 15:30	<p>Comparison Of 70% Ethanol Versus Heparin Lock In Treating Tunnelled Jugular Catheter-Related Bloodstream Infections In Hemodialysis Patients-A Randomized Controlled Trial</p>
15:30 - 15:36	<p>Effect of Arteriovenous fistula creation and maturation on chronic kidney disease patients' microcirculation</p>
15:36 - 15:42	<p>Early Outcomes of KiteLock (EDTA 4%): A New CVC Locking Solution</p>
15:42 - 15:48	<p>"Radiocephalic fistulas and Vascular doppler ultrasound (DUS): Beyond Conventional Limits"</p>
15:48 - 15:54	<p>Gender disparity in autologous arteriovenous access for hemodialysis</p>
15:54 - 16:00	<p>Optimizing Timing for Vascular Access Creation: The Role of Kidney Failure Risk Equation and eGFR in Predicting Dialysis Initiation</p>



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Kidney Transplantation

Room: **Focussed Oral Room 8**

15:00-16:15 CEST

Kidney Transplantation

Chair:	
15:00 - 15:06	Deep phenotyping of urinary cells with cytometry by time of flight reveals CD8+CD38+ T cells as biomarker to detect T cell-mediated rejection Speaker: Nina Görlich (Germany)
15:06 - 15:12	Multimodal spatial profiling of microvascular inflammation in kidney allografts Speaker: Valentin GOUTAUDIER (France)
15:12 - 15:18	PCSK9 inhibitors protect kidney from ischemia-reperfusion injury reducing oxidative stress and enhancing tissue resistance: a metabolomics analysis Speaker: Maria Antonietta Grignano (Italy)
15:18 - 15:24	Complement system evaluation in blood group incompatible living donor kidney transplantation
15:24 - 15:30	Gut microbiome alterations precede graft rejection in kidney transplantation patients Speaker: Hendrik Bartolomaeus (Germany)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

15:30 - 15:36	HUMAN LEUKOCYTE ANTIGEN ALLELES ASSOCIATED WITH ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION IN A MEXICAN POPULATION.
15:36 - 15:42	PRE-TRANSPLANT ANTI-HLA IgM ANTIBODIES AND KIDNEY TRANSPLANT OUTCOMES
15:42 - 15:48	Reprogramming innate immune memory using tacrolimus-loaded nanobiologics promotes organ transplant acceptance
15:48 - 15:54	Hypothermic Oxygenated Perfusion of Marginal Kidneys with Extracellular Vesicles from Mesenchymal Stromal Cells: A Proteomic Analysis
15:54 - 16:00	Engineered ATP-Loaded Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Novel Strategy to Counteract Cell ATP Depletion in an In Vitro Model Speaker: Maria Antonietta Grignano (Italy)
16:00 - 16:06	Plasma Uromodulin dynamics in deceased kidney donors and the association with transplant outcomes
16:06 - 16:12	Health-Related Quality of Life in the First Year Post Kidney Transplantation – a Cohort Study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:12 - 16:18	Longitudinal analysis of the urinary Dickkopf-related protein 3 and its association with kidney function following kidney transplantation
16:18 - 16:24	Automated Segmentation and Quantification of Arterial Intimal Fibrosis for Remuzzi Score Calculation in Kidney Transplant Process
16:24 - 16:30	The Impact of First Year eGFR and Subsequent eGFR decline on Kidney Transplant Outcomes – a single centre experience
16:30 - 16:36	Physician Communication and the Patient-Provider Relationship as Factors for Non-Adherence in Kidney Transplant Recipients

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Kidney Transplantation

Room: **Focussed Oral Room 8**

16:30-18:00 CEST

Kidney Transplantation

Chair:

--	--



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:30 - 16:36	The Impact of Early vs Delayed Immunosuppressive Agents on Delayed Graft Function and Rejection: A Meta-Analysis
16:36 - 16:42	EXERCISE AND PREDIABETES AFTER RENAL TRANSPLANTATION: EXPRED-II
16:42 - 16:48	Telitacicept Therapy in Recurrent IgA Nephropathy Post-Kidney Transplantation: A Case Series and Literature Review
16:48 - 16:54	Kidney Transplant Outcomes in Highly Sensitized Patients with Preformed Donor-Specific Antibodies Using a DELISTING Strategy
16:54 - 17:00	Role of high plasma levels of VWF and Ristocetin Cofactor in Kidney Transplant Recipients Speaker: Carmela Caputo (Italy)
17:00 - 17:06	Basiliximab Induction Alone vs. a Dual ATG-Basiliximab Approach in First Living Non-Sensitized Renal Transplant Recipients with Reduced HLA Matching Speaker: Tamar Hod (Israel)
17:06 - 17:12	Higher daily protein intake can reduce the risk of infections in kidney transplant recipients during the early post-transplant period



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:12 - 17:18	Comparative Efficacy of Therapeutic Hypothermia versus Normothermia in Kidney Transplantation: A Meta-Analysis and Trial Sequential Analysis
17:18 - 17:24	Who Says No? Profiles of Participants and Nonparticipants in an Exercise and Physical Activity Intervention Study After Kidney Transplantation Speaker: Jasmine De Beir (Belgium)
17:24 - 17:30	Dapagliflozin in kidney transplant recipients with diabetes mellitus and urine metabolomics analysis
17:30 - 17:36	Immunosuppression reduction in kidney transplantation: can we rest assured?
17:36 - 17:42	Shall We Go For a Walk? A Comparative Study of the Six-Minute Walk Test and Cardiopulmonary Exercise Test in De Novo Kidney Transplant Recipients
17:42 - 17:48	Recombinant zoster vaccine (RZV) confers persistent immune responses with no safety concerns 4 to 8 years after vaccination of adults with renal transplant Speaker: Melinda Hutton (United States of America)
17:48 - 17:54	Molecular Profiling of Renal Function after Liver Transplantation



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:54 - 18:00	Immunosuppression Management After Kidney Transplant Failure and Its Impact on Sensitization: Where Do We Stand in 2025? A Systematic Review with Meta-Analysis
18:00 - 18:06	THE ROLE OF PROTOCOL BIOPSIES IN KIDNEY TRANSPLANTATION: CLINICAL IMPACT AND PROGNOSTIC VALUE OF BANFF CRITERIA

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Kidney Transplantation , Focussed Orals

Room: **Focussed Oral Room 7**

16:30-18:06 CEST

Kidney Transplantation

Chair:	
16:30 - 16:36	Temporal trends in the risk of fractures in adult kidney transplant recipients
16:36 - 16:42	Increase in the use of expanded criteria living donors to facilitate preemptive kidney transplantation for our patients



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:42 - 16:48	Long-term outcomes of renal transplantation from expanded criteria living donors
16:48 - 16:54	Living Kidney Donation Practices in Europe: A Survey of DESCaRTES and EKITA Transplantation Working Groups
16:54 - 17:00	Is Preemptive Kidney Transplantation Beneficial in Elderly Kidney Recipients?: A Comparative, Multicentre National Study Speaker: Hamad Dheir (Türkiye)
17:00 - 17:06	Dialysis After Graft Failure: Clinical Patterns and One-Year Outcomes
17:06 - 17:12	Post-transplant metabolomics: Early prediction of renal function and possible therapeutic target discovery
17:12 - 17:18	Factors affecting senescent and regulatory T-cell numbers within the first year following kidney transplantation
17:18 - 17:24	Monitoring of Adherence to Immunosuppressive Drugs by Electronic Healthcare Data in Kidney Transplant Recipients



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:24 - 17:30	Prognosis of the kidney transplant patient: the role of "traditional" risk
17:30 - 17:36	Prevalence and Correlates of Hepatic Steatosis and Fibrosis in Chronic Kidney Disease Patients Prior of Kidney Transplantation: A Retrospective Cohort Study
17:36 - 17:42	Impact of low dose thymoglobulin-basiliximab induction therapy on acute rejection and post-transplant neoplasia in kidney transplant recipients
17:42 - 17:48	Identifying Risk Factors for Bone Fractures in Kidney Trasplant Recipients: A Clinical Data Perspective
17:48 - 17:54	Maternal kidney disease and Offspring Neurodevelopmental Outcomes: A Nationwide Population-based Study
17:54 - 18:00	Uremic burden as a predictor of preemptive kidney transplant outcome: Insight from a decision tree analysis in France

Friday, 6. June 2025



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Focussed Oral

Date: **06/06/2025**

AKI & Critical Care Nephrology

Room: **Focussed Oral Room 9**

16:30-18:00 CEST

AKI & Critical Care Nephrology

Chair:	
16:30 - 16:36	The impact of an Acute Kidney Injury Service on patient outcomes at a large district general hospital in the United Kingdom
16:36 - 16:42	Renoprotective Effect of Intravenous Amino Acid Infusion in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis Speaker: Ramon Jr Larrazabal (Philippines, The)
16:42 - 16:48	Associations between Lymphopenia and the Development/Recovery of Acute Kidney Injury among Patients Hospitalized with Respiratory Virus Infections
16:48 - 16:54	Plasma Free Hemoglobin, Haptoglobin, and Risk of CSA-AKI. A Translational Systematic Review and Meta-Analysis.
16:54 - 17:00	Clinical performance of the new Plasma Filter PX2 in Therapeutic Plasma Exchange: An interventional Multicenter Study



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:00 - 17:06	The generalized application of VExUS does not provide clinically relevant information for the treatment of hospitalized patients with hyponatremia: an observational study
17:06 - 17:12	Reducing the incidence and severity of acute kidney injury in people with ileostomies - a nurse-led trifecta approach in a district general hospital in the United Kingdom
17:12 - 17:18	Targeting M2b Macrophages by Selenium Nanomedicine for the Treatment of Lupus Nephritis
17:18 - 17:24	Regional Citrate Anticoagulation is a safe and effective strategy for treating critically ill patients undergoing Kidney Replacement Therapy for Metformin-Associated Lactic Acidosis (MALA): definitive documentation through serum citrate measurements Speaker: Maria Chiara Pacchiarini (Italy)
17:24 - 17:30	Ravulizumab in atypical haemolytic uraemic syndrome: analysis of quality of life outcomes in adult and paediatric phase 3 trials Speaker: David Kavanagh (United Kingdom)
17:30 - 17:36	Rechallenge of Immune Checkpoint Inhibitors in cancer patients with biopsy-confirmed renal injury: a case series. Speaker: Stavros Fokas (Greece)
17:36 - 17:42	Contrast-Induced Nephropathy: A Prospective Comparative Study Using Capillary Blood Sampling with Point of care Creatinine Measurement



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	Speaker: TAE WON LEE (Korea, Rep. of South)
17:42 - 17:48	Results of the COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter (COSA) registry
17:48 - 17:54	Clinical Response and Refractoriness in Immune Thrombotic Thrombocytopenic Purpura

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 10**

16:30-18:00 CEST

Chronic kidney disease

Chair:	
16:30 - 16:36	Developing a Risk Prediction Model for Progression Events in Chronic Kidney Disease Patients
16:36 - 16:42	Dapagliflozin's effect on kidney oxygenation: analysis of functional MRI data from the Randomized GLUTREPRO Trial Speaker: Elisa Russo (Italy)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:42 - 16:48	The effect of prophylactic anticoagulation on major bleeding events in hospitalized chronic kidney disease and lower limb fracture patients. A phase 2, Randomized, Double Blind, Control Trial.
16:48 - 16:54	ALIGN post-hoc analyses: Reduction in proteinuria with atrasentan across subgroups by MEST-C score, baseline hematuria and baseline UPCR
16:54 - 17:00	Changes in albuminuria and the effect of finerenone on cardiovascular outcomes: Insights from FINEARTS-HF Speaker: Finnian R. Mc Causland (United States of America)
17:00 - 17:06	Real-world impact of finerenone on albuminuria in patients with diabetes and CKD
17:06 - 17:12	Implementation of quadruple therapy in heart failure with reduce ejection fraction in patients with advance chronic kidney disease: Challenges and experience in our Cardiorenal Unit
17:12 - 17:18	Effects of vicaurostat with and without empagliflozin in people with chronic kidney disease by baseline BMI Speaker: Peter Rossing (Denmark)
17:18 - 17:24	Guideline adherence in primary and nephrology care for older patients with advanced chronic kidney disease and the association with social and clinical characteristics



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:24 - 17:30	BRINGING KIDNEY DISEASE PREVENTION INTO SCHOOLS: IMPACT OF A PILOT HEALTH EDUCATION PROGRAMME TO IMPROVE KIDNEY HEALTH
17:30 - 17:36	HOW DOES INTRADIALYTIC EXERCISE INFLUENCE EMOTIONAL WELL-BEING AND QUALITY OF LIFE IN RENAL DIALYSIS PATIENTS?
17:36 - 17:42	Safety and Tolerability of ABBV-CLS-628: Results From a Phase 1 First-in-Human Study Speaker: Maureen Horton (United States of America)
17:42 - 17:48	Demographics and Comorbidities of Dialysis Patients Using SGLT2 Inhibitors and GLP-1 Agonists
17:48 - 17:54	Ketogenic Diet as a Therapeutic Approach in ADPKD

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 3**

16:30-18:00 CEST



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chronic kidney disease

Chair:	
16:30 - 16:36	Association between Healthy Dietary Patterns and Chronic Kidney Disease: Findings from the Korean National Health and Nutrition Examination Survey (KNHANES) 2019-2021 Speaker: Yaerim Kim (Korea, Rep. of South)
16:36 - 16:42	Diagnosis Challenges for Chronic Kidney Disease in Irish Primary Care: A Real-world Study Comparing eGFR, uACR and Diagnosis Coding in 66 Irish General Practices Speaker: Danyao Jin (United Kingdom)
16:42 - 16:48	High urinary TFF3 is a significant risk factor for rapid age-related loss of GFR in the general population Speaker: Jon Viljar Norvik (Norway)
16:48 - 16:54	PROGRAM FOR EARLY DETECTION AND MANAGEMENT OF CHRONIC KIDNEY DISEASE IN CROATIA – FIRST RESULTS Speaker: Mario Laganović (Croatia)
16:54 - 17:00	Implications of Integrating the Kidney Failure Risk Equation into Nephrology Referrals from Primary Care
17:00 - 17:06	Influenza Vaccination Uptake and Determinants Among Korean Chronic Kidney Disease Patients: A Nationwide Cohort Analysis Speaker: Hyunjeong Cho (Korea, Rep. of South)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:06 - 17:12	The associations of cardiac and stress bio-markers NT-proBNP and growth differentiation factor 15 (GDF-15), with incidence and progression of CKD among people, living in war-affected region (Kharkiv, Ukraine). Save Kidneys Study, granted by Clinical Research Program of the ISN.
17:12 - 17:18	Geriatric Assessment use to frailty prediction in older CKD patients
17:18 - 17:24	Integrated Proteomic and Radiomic Signatures to Predict Ejection Fraction Improvement in CKD Patients Listed for Kidney Transplantation Speaker: Mirela Dobre (United States of America)
17:24 - 17:30	Real-world performance of two mortality scores designed for elderly patients with advanced CKD
17:30 - 17:36	CKD Stage 3 Patient Monitoring: Evaluating Current Practices in General Practice
17:36 - 17:42	The association between dexa-measured visceral fat and age-related iohexol-clearance decline - a population-based cohort study- Speaker: Karl Brobak (Norway)
17:42 - 17:48	The SPIRIT study : A multicenter prospective observational study of patients with CKD to assess therapeutic algorithms,disease



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

	<p>management and quality of life in Greece Speaker: EMELINA STAMBOLLIU (Greece)</p>
17:48 - 17:54	<p>Capturing Service Users' Experience of the Integrated Community Conservative Palliative Renal Care Services</p>

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Chronic Kidney Disease

Room: **Focussed Oral Room 4**

16:30-18:00 CEST

Chronic kidney disease

Chair:	
16:30 - 16:36	<p>Albuminuria A3 in a central district of Madrid: current situation Speaker: Cristina Riaza Ortiz (Spain)</p>
16:36 - 16:42	<p>Effect of CKD and hemodialysis on the epigenetic clock: implications for the reverse epidemiology</p>
16:42 - 16:48	<p>Etiological Analysis of Early-Onset Chronic Kidney Disease: A Study on Dent Disease in Chinese Pediatric Patients</p>



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:48 - 16:54	Validation of a new simplified method for quick and easy quantification of iohexol as part of precise kidney function measurement
16:54 - 17:00	Implementation of an iohexol-based GFR-measurement in clinical routine
17:00 - 17:06	MEASURED GFR IN ONCOLOGICAL SOLITARY KIDNEY: A CRITICAL PARAMETER FOR PRECISION MANAGEMENT IN ONCONEPHROLOGY
17:06 - 17:12	Cerebrovascular changes, cognitive functioning, depressive symptoms and apathy in older adults with advanced CKD
17:12 - 17:18	Inflammatory cytokine clusters are associated with adverse outcomes in patients with CKD
17:18 - 17:24	Adjustment of glomerular filtration rate by BSA: an unnecessary error in estimating renal function
17:24 - 17:30	Evaluating the Clinical Applicability of KFRE in Advanced Chronic Kidney Disease: Insights from a Spanish Cohort



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:30 - 17:36	Precision Medicine in Onco-Nephrology: Unveiling the Gap Between Measured and Estimated GFR
17:36 - 17:42	Comparative Analysis of GFR Estimation Equations in Oncologic Patients
17:42 - 17:48	#BloodyAmazingKidneys - A national awareness campaign to alert the general public about the risks of CKD
17:48 - 17:54	Hemostasis abnormalities in patients across different stages of chronic kidney disease, after evaluating a wide spectrum of coagulation parameters. Speaker: EMELINA STAMBOLLIU (Greece)
17:54 - 18:00	Size-selective glomerular filtration is a hallmark of premature kidney ageing
18:00 - 18:06	Obstructive sleep apnea accelerates CKD progression in type 2 diabetes

Friday, 6. June 2025

Symposium

Date: **06/06/2025**



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Institutional

Room: **The Square**

16:30-17:45 CEST

Women of ERA

Chair:	Lucia Del Vecchio (Italy)
16:30 - 16:45	Welcome and introducing remarks Speaker: Lucia Del Vecchio (Italy)
16:45 - 17:00	Sex differences in the epidemiology, management and outcomes of kidney disease Speaker: Kitty J Jager (Netherlands)
17:00 - 17:15	Gender balance in artificial intelligence: hidden barriers to overcome Speaker: Loretta Falcone (United States of America)
17:15 - 17:30	Exploring Gender Equity in Nephrology: The WERA survey Speaker: Magdalena Jankowska (Poland)

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Dialysis

Room: **Focussed Oral Room 5**

16:30-18:00 CEST



Discover the ERA25 Scientific Programme.
 Please note that the information below is constantly being updated.

Dialysis

Chair:	
16:30 - 16:36	Clinical impact of catheter insertion method: a single-center retrospective study using propensity score analysis
16:36 - 16:42	Relationship Between Tissue Hydration and Peritoneal Membrane Transport
16:42 - 16:48	Association between healthcare expenditure per capita and adoption of early home dialysis and kidney transplantation Speaker: Jan Dominik Kampmann (Denmark)
16:48 - 16:54	Long-term impact of peritoneal dialysis ultrafiltration on cardiorenal patients
16:54 - 17:00	Development of a Support System for Patients on Dialysis: Examining the Implementation and Continuation of Exercise Therapy
17:00 - 17:06	PD-peritonitis diagnosis using novel, rapid diagnostic assay RenoTact®: a study on pre-clinical performance and usability.



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:06 - 17:12	The Risk Factors and Outcomes of Peritoneal Dialysis-Associated Culture-Negative Peritonitis: A 10-Year Single Center Experience
17:12 - 17:18	Novel Tidal, Steady-Concentration Sorbent-Based PD (Viva Kompact) Reduces Glucose Exposure and Maintains Target Weight: A Comparative Pilot Study vs. Conventional PD
17:18 - 17:24	A PRACTICAL APPROACH FOR PERFORMING REMOTE MONITORING IN THE CARE OF PATIENTS WITH AUTOMATED PERITONEAL DIALYSIS USING SHARESOURCE ANALYTICS 1.0
17:24 - 17:30	Design of a prospective, multicenter, randomized, crossover study of the Carry Life UF system in continuous ambulatory peritoneal dialysis (CAPD) patients in the home setting Speaker: Martin Wilkie (United Kingdom)
17:30 - 17:36	Evaluating Leukocyte Test Strips for Peritonitis Diagnosis in Peritoneal Dialysis Patients
17:36 - 17:42	MSC exosomes inhibit peritoneal fibroblast transdifferentiation by entering fibroblasts via CD44-EGFR binding Speaker: Fang Yu (P.R. China)
17:42 - 17:48	IMPORTANCE OF CHARACTERIZING INTRADIALYTIC HEMODYNAMIC CHANGES USING BIOREACTANCE AND ECHOCARDIOGRAPHY METHODS Speaker: Ana Alicia Astroña Rojas (Spain)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:48 - 17:54	Evaluation of regional citrate anticoagulation in 230 intermittent dialysis, 165 plasma exchange treatments and 95 liver replacement procedures
17:54 - 18:00	Efficacy and Safety of an Innovative Polymethylmethacrylate Membrane Used for Post Dilution On-Line Hemodiafiltration. A Crossover Randomised Controlled Study.

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Glomerular & tubulo-interstitial diseases

Room: **Focussed Oral Room 2**

16:30-18:00 CEST

Glomerular & tubulo-interstitial diseases

Chair:	
16:30 - 16:35	Imlifidase a new treatment for severe minimal change disease?
16:35 - 16:40	Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:40 - 16:45	Patients With Focal Segmental Glomerulosclerosis (FSGS) Achieved Low Proteinuria Targets Earlier and More Often With Sparsentan (SPAR) vs Irbesartan (IRB) in DUPLEX
16:45 - 16:50	Long-term stabilization of kidney function (estimated glomerular filtration rate) in patients with native C3 glomerulopathy (C3G) Speaker: David Kavanagh (United Kingdom)
16:50 - 16:55	Reduction of hematuria and albuminuria with iptacopan in C3G: Findings from APPEAR-C3G study Speaker: Fernando Caravaca Fontan (Spain)
16:55 - 17:00	Effects of nefecon on Hits 1, 2, and 3 of the pathogenic cascade of IgA nephropathy: a full NeflgArd analysis Speaker: Ishika Khan (United Kingdom)
17:00 - 17:05	Exploring the gut-targeted mechanism of nefecon: effects on GALT-associated and systemic IgA markers in IgA nephropathy
17:05 - 17:10	Sustainability and depth of UPCR reduction in patients with primary IgAN treated with nefecon: a secondary analysis of the Phase 3 NeflgArd trial Speaker: Jonathan Barratt (United Kingdom)
17:10 - 17:15	Rituximab in treating steroid-sensitive nephrotic syndrome in children—experience from Uzbekistan.



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:15 - 17:20	Clinical and histological response of proliferative, crescentic IgA nephropathy to 6-month methylprednisolone course: a repeat biopsy study
17:20 - 17:25	ORIGIN 2b: Changes in Gd-IgA1 and eGFR After Discontinuation of Atacicept Treatment in IgA Nephropathy Speaker: Jonathan Barratt (United Kingdom)
17:25 - 17:30	Efficacy and safety of Telitacicept treatment for proliferative sclerosis IgA nephropathy: A real-world retrospective study
17:30 - 17:35	A PK/PD Analysis and Population PK Modeling of Ravulizumab Using Data from the Phase 2 Trial in Adults with IgA Nephropathy (SANCTUARY)

Friday, 6. June 2025

Focussed Oral

Date: **06/06/2025**

Dialysis

Room: **Focussed Oral Room 6**

16:30-18:00 CEST

Dialysis



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chair:	Silvio Borrelli (Italy)
16:30 - 16:36	VASCULAR ACCESS OF INCIDENT DIALYSIS PATIENTS WITH POLYCYSTIC KIDNEY DISEASE. A REGISTRY-BASED STUDY USING PROPENSITY SCORE MATCHING METHODOLOGY Speaker: Ramon Roca-Tey (Spain)
16:36 - 16:42	Arteriovenous fistula and pulmonary hypertension in patients on hemodialysis
16:42 - 16:48	Vascular Access-Associated Excess Mortality Speaker: Amun Hofmann (Austria)
16:48 - 16:54	Prediction of Fistula Maturation Using Central Venous Oxygen Saturation and Upper Body Blood Flow Speaker: Andrea Nandorine Ban (United States of America)
16:54 - 17:00	Critchley-Critchley Analysis of DBB-EXA™ vs. Transonic® HD02: Accuracy, Reproducibility, and Clinical Implications in Vascular Access Flow Measurement
17:00 - 17:06	Dialysis with a permanent catheter is associated with higher levels of IL-6 and myostatin compared to dialysis fistula.
17:06 - 17:12	AVF ELECTIVE LIGATION IN KIDNEY TRANSPLANT RECIPIENTS IS NOT ASSOCIATED WITH AN ACCELERATION OF KIDNEY FUNCTION DECLINE



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:12 - 17:18	Clinical Impact of Teledialysis in Automated Peritoneal Dialysis vs. Hemodialysis: A Retrospective Comparison
17:18 - 17:24	Personalizing Peritoneal Dialysis Prescriptions Using Q-Learning: An AI-Based Approach to Optimize Renal Replacement Therapy
17:24 - 17:30	Peritoneal dialysis induced hepatic glucotoxicity results in metabolic inflammation and oxidative stress
17:30 - 17:36	Peritoneal Infusion of Microplastics Induces Over-Expression of GDF-15 in Kidney and Heart in Mice
17:36 - 17:42	VALUE OF THE NUTRITIONAL PROGNOSTIC INDEX AS AN INDICATOR OF CARDIOVASCULAR RISK IN PERITONEAL DIALYSIS
17:42 - 17:48	Rationale and study design of EXCITE, a pilot study to evaluate safety and efficacy of PolyCore, a ternary combination of xylitol, L-carnitine and polydextrln, to treat end-stage kidney disease patients starting peritoneal dialysis. Speaker: Silvio Borrelli (Italy)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Focussed Oral

Date: **06/06/2025**

**Glomerular & tubulo-interstitial
diseases, Focussed Orals**

Room: **Focussed Oral Room 1**

16:30-18:00 CEST

Glomerular & tubulo-interstitial diseases

Chair:	
16:30 - 16:36	Uromodulin p.His36Tyr mutation actuates kidney injury by activating ferroptosis via down-regulating FoxO3a expression
16:36 - 16:42	Dose-dependent NSAID effects on autophagy and fibrosis pathways in renal tubular epithelial cells Speaker: Gabor Kokeny (Hungary)
16:42 - 16:48	An Expanded Proteomic Workflow Using Data-Independent Acquisition Mass Spectrometry for the Identification of Target Antigens in Membranous Nephropathy
16:48 - 16:54	The protective effects of a ketogenic diet in experimental glomerulonephritis are independent of the Hca2 receptor. Speaker: Sebastian Göhring (Austria)
16:54 - 17:00	Exploring A Novel Renoprotective Protein TMEM52B: Insights into Its Role and Mechanisms in Renal Fibrosis



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:00 - 17:06	Decoding Podocyte Effacement: A High-Resolution Approach Using STED Microscopy and Spatial Transcriptomics Speaker: Tobias Bohnenpoll (Germany)
17:06 - 17:12	Effect of Desmopressin on Post-Kidney Biopsy Bleeding: A Randomized, Double-Blind, Placebo-Controlled Study
17:12 - 17:18	Adult renal progenitor cells can decrease the inflammatory and immunological triggering in IgA Nephropathy patients at renal tissue level.
17:18 - 17:24	Investigation of the Rac1-SGK1 Pathway and Therapeutic Effects of Finerenone and Rac1 Inhibition in a Fabry Disease Podocyte Model Speaker: Kultigin Turkmen (Türkiye)
17:24 - 17:30	Characterizing the NIH Activity and Chronicity Indices in Two Independent Lupus Nephritis Cohorts: A Critical Analysis Speaker: Valentina Querin (Netherlands)
17:30 - 17:36	Free Light Chains in Light Chain Proximal Tubulopathy: De Novo Sequencing and Resistance to Lysosomal Proteases Speaker: Xin Wang (P.R. China)
17:36 - 17:42	Podocyte-specific YAP activation triggers crescentic glomerulonephritis through a crosstalk with parietal epithelial cells



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:42 - 17:48	Specific Urinary Peptidomic Profiling in Patients with Post-COVID-19: a Case-Control Study (UriCoV) Speaker: Dilara Gülmez (Austria)
17:48 - 17:54	Repurposing Disulfiram to target neutrophil extracellular traps in experimental ANCA associated vasculitits
17:54 - 18:00	URINARY METABOLOMICS IN NEPHROTIC SYNDROME: THE EXPERIENCE OF "FONDAZIONE POLICLINICO UNIVERSITARIO A. GEMELLI"
18:00 - 18:06	Macula Densa Cell Targeting Kidney Tissue Regenerative Therapeutic Approaches

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

Institutional

Room: **Hall G2**

16:30-18:00 CEST

Young Awardees

Chair:	Jennifer Lees (United Kingdom) Mario Gennaro Cozzolino (Italy)
--------	-----------------------------------------------------------------------



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:30 - 16:48	Basic science Speaker: Florian Siegerist (Germany)
16:48 - 17:06	Translational science Speaker: Markus Rinschen (Denmark)
17:06 - 17:24	Translational science Speaker: Eleni Stamellou (Greece)
17:24 - 17:42	Clinical science Speaker: Robin WM Vernooij (Netherlands)
17:42 - 18:00	Clinical science Speaker: Dearbhla Kelly (United Kingdom)

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

Institutional

Room: **Hall G1**

16:30-18:00 CEST

ERAC symposium: Improving patient care with the Real world data insights

Chair:	Dimitrios Goumenos (Greece) Jaquie Finn (United Kingdom)
--------	-------------------------------------------------------------



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

16:30 - 17:00	Current landscape in nephrology Speaker: Samira Bell (United Kingdom)
17:00 - 17:30	Ethical and Regulatory Considerations Speaker: Hrefna Gudmundsdottir (Iceland)
17:30 - 18:00	Future Directions Speaker: Christoph Wanner (Germany)

Friday, 6. June 2025

Free Communication

Date: **06/06/2025**

Chronic Kidney Disease

Room: **Hall K**

16:30-18:00 CEST

FC 24: CKD and Public Health: Part 1

Chair:	
16:30 - 16:48	Latin America: From Early Detection to Access to Treatment of Kidney Disease Speaker: Ricardo Correa-Rotter (Mexico)
16:48 - 17:00	Comparison of healthcare utilization between CKD and non-CKD patients: an observational study in the West region of France.



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:00 - 17:12	Impact of targeted screening in high-risk individuals and guideline-directed medical therapy on CKD burden in Europe: projections from IMPACT CKD
17:12 - 17:24	Care processes and clinical reactions to newly detected albuminuria; the Stockholm CREATinine Measurements (SCREAM) project Speaker: Antoine Creon (Sweden)
17:24 - 17:36	Insights from CDC NHANES survey among self-reported Chronic Kidney Disease patients and their outcomes: A National database mortality analysis of United States Population from 2001-2020.
17:36 - 17:48	Patient and Carer Treatment Preferences for Chronic Kidney Disease (CKD): A Discrete Choice Experiment (DCE) across Eight Countries
17:48 - 18:00	Clinical utility of a risk-based referral model to nephrologist-specialist care; the Stockholm CREATinine Measurements (SCREAM) project Speaker: Aurora Caldinelli (Sweden)

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

Chronic Kidney Disease

Room: **Hall C**

16:30-18:00 CEST



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Pro/Cons Should we screen the population for albuminuria?

Chair:	Alberto Ortiz Arduán (Spain) Siren Sezer (Türkiye)
16:30 - 17:15	Should we screen the population for albuminuria? PRO Speaker: Ronald Gansevoort (Netherlands)
17:15 - 18:00	Should we screen the population for albuminuria? CON Speaker: Joseph Vassalotti (United States of America)

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

AKI & Critical Care Nephrology

Room: **Hall E1**

16:30-18:00 CEST

Pro and Cons: Shock and AKI- is citrate safe?

Chair:	Bairbre McNicholas (Ireland) Greet De Vlieger (Belgium)
16:30 - 17:15	Shock and AKI- is citrate safe? PRO Speaker: Andrew Davenport (United Kingdom)
17:15 - 18:00	Shock and AKI- is citrate safe? CON Speaker: Nuttha Lumlertgul (Thailand)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

--	--

Friday, 6. June 2025

Free Communication

Date: **06/06/2025**

Dialysis

Room: **Hall F1**

16:30-18:00 CEST

FC 23: Hemodialysis: Interventions

Chair:	
16:30 - 16:48	Antiplatelet and antithrombotic agent use in advanced CKD, dialysis and renal transplantation: a consensus approach
16:48 - 17:00	Hemodiafiltration versus high-flux Hemodialysis on mortality of dialysis patients: A systematic review and meta-analysis
17:00 - 17:12	ASSOCIATION OF INCIDENT DIALYSIS MODALITY WITH PATIENT SURVIVAL: A SYSTEMATIC REVIEW AND META-ANALYSIS
17:12 - 17:24	Gallic acid carbon dot-supported heparin-like polymer as an optimized membrane-anchored antioxidant and anticoagulant for hemodialysis treatment



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:24 - 17:36	Stronger Together: Sodium and chemical displacers combine to improve uremic toxin clearance beyond individual effects Speaker: João Brás (Netherlands)
17:36 - 17:48	Effect of Remote Ischemic Preconditioning on Hemodialysis Adequacy, Hematological, and Cardiovascular Parameters in Hemodialysis Patients: A Randomized Controlled Trial
17:48 - 18:00	Oral sucrosomal iron versus intravenous iron sucrose in participants on hemodialysis: a randomized, single-blind, placebo-controlled, crossover study.

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

Hypertension & Diabetes

Room: **Hall E2**

16:30-18:00 CEST

Hypertension diagnosis and treatment in specific populations

Chair:	Francesca Mallamaci (Italy) Pantelis Sarafidis (Greece)
16:30 - 17:00	2025 update on resistant hypertension in CKD: where do we stand and where do we go? Speaker: Roland E. Schmieder (Germany)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

17:00 - 17:30	BP Control in Patients with Advanced CKD Speaker: Cheol Ho Park (Korea, Rep. of South)
17:30 - 18:00	Intradialytic hypertension: newer insights into epidemiology and management Speaker: Fotini Iatrudi (Greece)

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

Kidney Transplantation

Room: **Hall B**

16:30-18:00 CEST

Pro/Con HLA-i desensitization

Chair:	Luuk Hilbrands (Netherlands) Ivana Dedinska (Slovakia)
16:30 - 17:00	Predicting the clinical efficacy of desensitisation Speaker: Nithya Krishnan (United Kingdom)
17:00 - 17:30	Pro - what protocols? Speaker: Umberto Maggiore (Italy)
17:30 - 18:00	Con - international KPD program (STEP) Speaker: Rainer Oberbauer (Austria)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

**Glomerular & tubulo-interstitial
diseases**

Room: **Hall A Plenary Room**

16:30-18:00 CEST

Pro-Cons: Can advanced microscopies help in clinical routine?

Chair:	Jürgen Floege (Germany) Miriam Zacchia (Italy)
16:30 - 17:15	Pro: High resolution microscopy in daily clinics Speaker: Valentina Raglianti (Italy)
17:15 - 18:00	Cons: Problems and pitfalls for advanced microscopies in daily clinics Speaker: Laura Barisoni (United States of America)

Friday, 6. June 2025

Symposium

Date: **06/06/2025**

Dialysis

Room: **Hall D**

16:30-18:00 CEST

Potassium Dietary Restrictions for Dialysis Patients: pro and cons dabate



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Chair:	Liliana Garneata (Romania) Stephan J. L. Bakker (Netherlands)
16:30 - 17:00	Potassium Dietary Restrictions for Dialysis Patients: CON Speaker: Liffert Vogt (Netherlands)
17:00 - 17:30	Potassium Dietary Restrictions for Dialysis Patients: PRO Speaker: Björn Meijers (Belgium)

Saturday, 7. June 2025

Symposium

Date: **07/06/2025**

Chronic Kidney Disease

Room: **Hall D**

08:30-09:45 CEST

Cardiovascular Outcomes in CKD: Focus on Sex Differences and Dietary Solutions

Chair:	Valerie A. Luyckx (Switzerland) Andrew Davenport (United Kingdom)
08:30 - 08:55	Sex disparities in cardiovascular disease outcomes in chronic kidney disease Speaker: Olga Balafa (Greece)
08:55 - 09:20	Diet therapy Speaker: Carla Maria Avesani (Sweden)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

09:20 - 09:45	Low salt diet Speaker: Gert Mayer (Austria)
---------------	-------------------------------------------------------

Saturday, 7. June 2025

Symposium

Date: **07/06/2025**

Institutional

Room: **Hall A Plenary Room**

08:30-09:45 CEST

Navigating IgA Nephropathy Management in the Era of New KDIGO Guidance

Chair:	Christoph Wanner (Germany)
08:30 - 08:55	Mechanistic and Therapeutic Advances in IgAN: New and Upcoming Agents Speaker: Jonathan Barratt (United Kingdom)
08:55 - 09:20	Case-based illustrations of key concepts and applications of KDIGO guidance Speaker: Jürgen Floege (Germany)
09:20 - 09:45	Special considerations: Different patient populations call for different approaches



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

Saturday, 7. June 2025

Symposium

Date: **07/06/2025**

Dialysis

Room: **Hall B**

08:30-09:45 CEST

Game changers for managing hypertension and diabetes in dialysis in 2025

Chair:	Mehmet Kanbay (Türkiye) Ana Elena Rodríguez-Rodríguez (Spain)
08:30 - 08:55	Choosing the right antihypertensive drug to avoid intrahemodialysis hypotension Speaker: Carmine Zoccali (Italy)
08:55 - 09:20	GLP-1 agonists in diabetes management in dialysis patients: Can it be a solution for obesity, blood pressure control? Speaker: Marieta P. Theodorakopoulou (Greece)
09:20 - 09:45	Evaluation of glycemic control in dialysis patients Speaker: Andrew Frankel (United Kingdom)

Saturday, 7. June 2025

Symposium

Date: **07/06/2025**

Institutional

Room: **Hall C**

08:30-09:45 CEST



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

How to raise kidney disease awareness

Chair:	Kate Stevens (United Kingdom) Manfred Eugen Grieger (Germany)
08:30 - 08:55	Social Media as a new tool for spreading kidney health. Speaker: Hugo Diniz (Portugal)
08:55 - 09:20	Strong kidneys campaigns: understanding unmet needs for a better kidney health. Speaker: Charles J. Ferro (United Kingdom)
09:20 - 09:45	Kidney Data sharing and discussion: open, but how much? Speaker: Emma Horton-Wright (United Kingdom)

Saturday, 7. June 2025

Symposium

Date: **07/06/2025**

Kidney Transplantation

Room: **Hall F1**

08:30-09:45 CEST

Game changers in cAMR

Chair:	Christophe Mariat (France) Rainer Oberbauer (Austria)
08:30 - 08:55	Complement inhibitors Speaker: Dela Golshayan (Switzerland)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

08:55 - 09:20	anti-CD38 sufficient? Speaker: Tristan de Nattes (France)
09:20 - 09:45	NK Cells in AMR – A Therapeutic Target? Speaker: Matthias Diebold (Switzerland)

Saturday, 7. June 2025

Symposium

Date: **07/06/2025**

Glomerular & tubulo-interstitial diseases

Room: **Hall K**

08:30-09:45 CEST

Tubulopathy and Interstitial Nephritis

Chair:	Francesco Trepiccione (Italy) Dominique Eladari (France)
08:30 - 08:55	RNAinterference for Primary Hyperoxaluria Speaker: Justine Bacchetta (France)
08:55 - 09:20	IgG4-Related Kidney Disease: targeting B cells makes the difference Speaker: Augusto Vaglio (Italy)
09:20 - 09:45	The changing spectrum of acute interstitial nephritis Speaker: Beatriz Sanchez Alamo (Spain)



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

--	--

Saturday, 7. June 2025

Symposium

Date: **07/06/2025**

AKI & Critical Care Nephrology

Room: **Hall E1**

08:30-09:45 CEST

What's new in CRRT

Chair:	Jolanta Malyszko (Poland) Raymond Vanholder (Belgium)
08:30 - 08:55	Extracorporeal strategies/therapy for cast-induced AKI Speaker: Silvia De Rosa
08:55 - 09:20	CRRT vs IDH in critically ill patients with AKI Speaker: Stephane Gaudry (France)
09:20 - 09:45	Inequalities in CRRT access and practice around the world Speaker: Raymond Vanholder (Belgium)

Saturday, 7. June 2025

Symposium

Date: **07/06/2025**

Physiology, cell biology & genetic

Room: **Hall E2**



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

diseases

08:30-09:45 CEST

Use of common drugs in rare kidney diseases

Chair:	Emilie Cornec-Le Gall (France) Tom Nijenhuis (Netherlands)
08:30 - 08:55	SGLT2i and RAS blockade in ADPKD Speaker: Roland Schmitt (Germany)
08:55 - 09:20	SGLT2i and RAS blockade in Alport syndrome Speaker: Oliver Gross (Germany)
09:20 - 09:45	Treatment of tubulopathies with cheap drugs Speaker: Lucile Figueres (France)

Saturday, 7. June 2025

Plenary Lecture

Date: **07/06/2025**

Institutional

Room: **Hall A Plenary Room**

10:00-10:45 CEST

Plenary Lecture 3

Chair:	Roser Torra (Spain) Dimitrios Goumenos (Greece)
--------	----------------------------------------------------



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

10:05 - 10:45	Obesity: now a treatable disease Speaker: Ruben Nogueiras (Spain)
---------------	-----------------------------------------------------------------------------

Saturday, 7. June 2025

Symposium

Date: **07/06/2025**

Institutional

Room: **Hall A Plenary Room**

11:00-12:30 CEST

Nephrology Pearls

Chair:	Roser Torra (Spain) Dimitrios Goumenos (Greece)
11:00 - 11:22	Introduction Speaker: Roser Torra (Spain)
11:22 - 11:44	Congress Passage Ceremony Speaker: Roser Torra (Spain)
11:44 - 12:06	Take home message introduction Speaker: Dimitrios Goumenos (Greece)
12:06 - 12:28	Where to go in the future: the cutting edge message from the president Speaker: Roser Torra (Spain)

**62nd ERA
CONGRESS**
VIENNA & VIRTUAL
JUNE 4-7, 2025

www.era-online.org

in collaboration with
 ÖGN
Österreichische
Gesellschaft für
Nephrologie



Discover the ERA25 Scientific Programme.

Please note that the information below is constantly being updated.

--	--